DE112008001076T5 - System for a controlled application of an injectable fluid - Google Patents

Abstract

A human or animal implantable drug delivery device having at least one deformable reservoir adapted to receive, store and dispense at least one drug having at least one outlet through which the at least one drug may exit the at least one deformable reservoir; and at least one controllable dispensing mechanism operatively connected to the at least one outlet for controlling delivery of the at least one portion of the at least one active agent from the at least one deformable reservoir.

Description

BACKGROUND

at The in vivo administration of a drug today is a number of Technologies including actuator pumps, osmotic Pumps and the release of high-tech materials used. Implantable controlled application agents for drug application was developed. Some remedies are based on the gradual application a drug from a polymeric carrier the time due to the degradation of the carrier. On a polymer based drug delivery agents have been developed that include a drug in an iron polymer that is derived from an external Applied magnetic field is manipulated so as to the drug application to control. MEMS-based drug delivery agents that have an integrated electrical circuit are further in development, as well as MEMS-based systems for execution chemical reactions in development. Implantable osmotic Pumps were developed for the purpose of drug application.

SUMMARY

The This invention relates generally to the field of drug delivery Means and systems for applying active substances in the human or animal body. In particular, the invention relates including smart-controlled, drug-delivery systems Means capable to do so, transcutaneously, percutaneously or subdermally in a natural or artificial body cavity to be used by a human or animal. The remedy is for that able to deliver a drug in vivo in the long run and may be arranged to deliver one from the outside Absorb active ingredient. That is, the agent can be delivered with one Drug can be loaded when the agent is used in vivo. The means may be self-propelled, it may have a programmable processor or may be activated by external means. embodiments a system including a remote controlled drug delivery agent and an associated controller will be described. method the use and control of the agent are also disclosed. Corresponding Various embodiments may include an agent delivery agent placed in an in vivo environment of a human or an animal be to inject a drug into the in vivo environment or to release in this. Embodiments are for described an application system including at least a deformable reservoir configured to receive, Including and dispensing at least one active ingredient including at least one outlet through which the active ingredient of a deformable Reservoir exits and at least one controllable output mechanism, the operational with the at least one issue connected to control the application of at least one part at least one active ingredient consisting of the at least one deformable Reservoir exits. The agent may be a processor or a memory or activate another independent structure the controllable output mechanism. It further describes a system in which the means and the remote control for generating and transmitting a control signal are formed, which for the drug delivery agent is sufficient. The control signal may itself be the controllable output mechanism or it may issue commands to enable the controllable output mechanism give the funds. Other embodiments will be including methods for applying a Active ingredient in humans or the animal. Further embodiments have the percutaneously used drug delivery agent on with Sensors that sense environmental conditions and generate a signal for activating the at least one controllable dispensing mechanism can be used to control the exit of the drug the deformable reservoir. Other embodiments are taken into account, wherein the drug delivery agent operated independently, d. h., a voltage source or a power recovery device, for example, such, the power in response to electromagnetic signal or wins in response to a local acceleration. Such a local acceleration can be shared with the movement of the environment in the respective human or animal. In some embodiments, the body may of the object as a power source for operating the means be used.

Various "energy harvesting" or "energy harvesting" agents are known or may be developed (see, for example, US Pat U.S. Patents 6,615,074 . 6,655,035 and 6,768,246 and US Published Patent Applications 20030014091 and 20030165648, each of which, as far as they are compatible, are incorporated herein by reference). For example, means can be used to use energy from body movements of the subject (e.g. inertial devices such as self-charging wristwatches) to power the device. Pressure and chemical gradients in the body can further create energy for delivering performance to the agent. For example, energy may be derived from the systolic-diastolic cycle or the pulsating inflow of the subject, or may be a microturbine placed in the subject's breath stream. Power generating means can gain energy from the environment of the subject. An exemplary embodiment of a drug delivery agent has a performance-binding structure that is designed to obtain power or energy from the environment. The means may be configured to store the received energy or to use the received energy immediately to supply the agent.

Other Embodiments are considered, the use a micropump or nanopump to remove the drug from the to pump at least one reservoir. The revelation takes into account that the reservoir can be a flexible elastomeric material, that is able to shape it at least in one dimension to change when filled with the active substance, which is to inject into the human or the animal. The reservoir can be a geometrically reconfigurable element with a Lumen of the human or animal is placed and containing an active substance is loaded for application in humans or in the animal. Of the Approach also takes into account the use of a remote control, which either inside or outside of man or Animal that is capable of producing a control signal to transmit that activates the controllable output mechanism, to cause the application of the drug from the reservoir. The remote control may be programmed to provide a control signal create, based on a measured state either in or outside the human or animal and / or accordingly a specific schedule. The remote control can be used to create be formed programmable commands for the means. The rate of application of the active ingredient from the at least one programmable reservoir can be constant or variable and can be done at controllable intervals.

One Embodiment relates to the percutaneous use of a Drug delivery agent using an application mechanism. at other applications, the execution can be a simple and involve faster application with a syringe-like agent instead of a surgical procedure. In some cases the introduction of the agent is completely under local Anesthesia and possibly without anesthesia at the time of the initial operation, leave only a puncture site instead of an incision. Such percutaneous injection is less painful and leads less likely to cause complications such as wound infection and a violation of the surrounding tissue.

The The preceding summary is illustrative only and is intended to be in no way limit. In addition to the illustrative Aspects, embodiments and described above Features arise further aspects, embodiments and features from the following own description with reference on the drawings.

BRIEF DESCRIPTION OF THE FIGURES

1 shows an embodiment of an application system for use in a human,

2 shows an embodiment of an application system with a remote control;

3 shows a further embodiment of an application system with a remote control;

4 shows in schematic form an embodiment of an application means using a positive pressure to deliver drug from the reservoir;

5 shows an electromagnetically responsive control including a polymer and magnetically or electrically active components;

6 shows the example of an application agent with an osmotic pump;

7A and 7B show an embodiment in which the design or shape of a controllable dispensing mechanism changes in response to a control signal;

8A and 8B show an embodiment in which the design or form of a controllable application mechanism changes in response to a control signal;

9A and 9B show an embodiment in which the shape or geometry of a controllable application mechanism changes in response to a control signal;

10A and 10B show an embodiment in which the controllable application mechanism changes in shape in response to a control signal;

11 shows an example of an embodiment with a power receiving structure;

12 shows an example of an embodiment with an RFID structure;

13 shows a control signal generated from stored pattern data;

14 shows a control signal calculated from a model based on stored parameters;

15 is a schematic diagram of a remote control;

16 shows an example of an electromagnetic waveform;

17 shows an example of an electromagnetic waveform;

18 shows an example of an electromagnetic waveform;

19 shows an embodiment of an application means with a downstream, the fluid influencing structure;

20 shows a further embodiment of an application means with an upstream, the fluid influencing structure;

21 shows an embodiment of the application means with an environment interface;

22 shows a drug delivery agent with an extraction mechanism;

23 FIG. 3 is a flowchart of a method of applying an active agent; FIG.

24 is a flowchart of another method of applying a fluid;

25 Fig. 12 is a schematic diagram of an embodiment of a system having a remote control and an application means;

26 is a diagram of an embodiment of an application system with an application means with an RFID.

27 Fig. 10 is a schematic diagram of an embodiment of a system including a remote controller, an application means, and a sensor;

28 Fig. 10 is a schematic diagram of an embodiment of a system having a remote control and an application means with a sensor;

29 Fig. 10 is a schematic diagram of another embodiment of a system having a remote control and an application means;

30 is an embodiment of a system with a remote control and a plurality of application means in an environment;

31 is a diagram of an embodiment of an application means;

32 is a schematic of another embodiment of an application system;

33 is a schematic of another embodiment of an application system;

34 shows an embodiment of an application system with an encryption;

35 shows an embodiment of an application system that uses an authentication process;

36 is a flowchart of a method for applying a drug;

37 is a flowchart of a method for applying a drug;

38 FIG. 10 is a flowchart of a portion of a method of applying a drug; FIG.

39 FIG. 10 is a flowchart of another method of applying a drug; FIG.

40 FIG. 10 is a flowchart of another method of applying a drug; FIG.

41 is an extension of the procedure of 40 ;

42 Fig. 10 is a flow chart of additional steps for controlling an application agent;

43A Figure 3 is a schematic representation of a drug delivery kit with a syringe and a drug delivery agent;

43B is a schematic representation of the kit in use;

44A Figure 3 is a schematic representation of a drug delivery agent following injection in an in vivo environment; and

44B Figure 12 is a schematic representation of a drug delivery agent that receives drug from an external source.

DETAILED DESCRIPTION

In the following detailed Be The description is made to the attached drawings, which form a part of the description. In the drawings, similar symbols typically indicate components similar to one another, unless the context dictates otherwise. The exemplary embodiments given in the detailed description, the drawings and the claims are not meant to be limiting. Other embodiments may be used and other changes may be made without departing from the scope and spirit of the subject matter presented herein. The term "percutaneously useable" and similar terms such as "percutaneously used", "percutaneous use", "transcutaneously useable" means that the use of an agent-delivery agent is through the skin or a hidden layer of an animal. The percutaneous introduction of the drug delivery agent may be in any in vivo lumen or any body cavity z. For example, the perituneal cavity, a torax cavity, sinus cavity, nasal cavity, or the like, or may be subdermal, for example, in an ad hoc cavity. The term "human" or "animal" as used herein means vertebrates such as mammals, birds, reptiles, amphibians and fish. Further, the term "mammal" as used herein means warmbloods of higher vertebrates (such as placentals, marsupials, or cloacal animals) that provide milk to mammals via mammary glands, whose skin is usually more or less covered with hair, and includes humans. Other mammals include, but are not limited to, cattle and pets.

Embodiments are described herein which include an agent delivery agent useful in a human or animal having at least one deformable reservoir adapted to receive, contain, and deliver at least one agent having at least one outlet through which the at least one agent from the at least one definable reservoir and with at least one controllable dispensing mechanism operatively connected to the at least one outlet for controlling the application of the at least one portion of the at least one active agent from the at least one deformable reservoir. Further embodiments are described with a Wirkstoffapplikationssstem comprising at least one drug delivery agent that is applicable to a human or an animal, with at least one deformable reservoir which is adapted to receive, retaining and dispensing at least one drug, with at least one outlet through which at least one active substance can escape from the at least one deformable reservoir and at least one controllable application mechanism is operatively connected to the at least one outlet for controlling the application of at least a portion of the at least one active substance from the at least one deformable reservoir and at least one remote control for generating and transmitting at least one control signal to the at least one active agent application means is formed. Further embodiments are described which comprise an active substance application kit with at least one application mechanism; at least one drug delivery agent useful in a human or animal having at least one definable reservoir configured to receive, retain, and controllably deliver at least one drug including at least one outlet through which the at least one drug is released from the at least one definable reservoir and at least one controllable dispensing mechanism operatively connected to the at least one outlet and configured to control application of the at least one material from the at least one deformable reservoir. Further described are the embodiments comprising a method of delivering at least one drug to a human or an animal using at least one drug delivery agent in an in vivo environment of the human or animal, wherein the at least one drug delivery agent has at least one definable reservoir associated with Receiving, maintaining and controllably discharging the at least one active ingredient and having at least one outlet and at least one controllable application mechanism, which is operatively connected to the at least one outlet and dispensing a quantity of the at least one active substance in the at least one definable reservoir, wherein the at least a controllable application mechanism delivering the at least one active agent in response to at least one control signal. 1 shows an example of an embodiment of a drug delivery system 10 ,

The term "substance" as used herein means a substance which is a solid, a liquid or a liquefiable form or gaseous. A patch may be any of a variety of agents, including a single agent, two or more different agents, or a mixture of agents. For example, an active ingredient may include a compound exhibiting a physiological effect, a therapeutic agent, a pharmaceutical agent or a pharmaceutically acceptable salt, an adduct or derivative, a biological compound, a chemical compound, a peptide or nucleotide or glycopeptide or lipopeptide, a nutrient or micronutrient, a medically effective nutrient or any combination it. The drug to be administered may be an active drug including a cell, a cell component, a virus, a provirus, or a microscopic life form. In some embodiments, the application agent may include at least one nutrient, hormones, growth factor, medication, therapeutic compound, enzymes, genetic material, vaccine, vitamin, neurotransmitter, cytokine, cell-signaling agent, pro- or anti-apoptotic agent, an imaging agent Labeling agent, a diagnostic agent, a drug or drug, a nanomaterial, an inhibitor or blocker. In some embodiments, the drug to be administered may be a component or precursor of a biologically active material, for example, the drug to be administered may include at least one precursor or component of a nutrient, hormone, growth factor, medication, therapeutic compound, enzyme, genetic material , a vaccine, vitamin, neurotransmitter, cytokine, cell-signaling agent, a pro- or anti-apoptotic agent, an imaging agent, a labeling agent, a diagnostic agent, a nanomaterial, an inhibitor or a blocker. Such precursors may include, for example, prodrugs (see, for example, US Pat. "Liver-Targeted Drug Delivery Using HepDirect® Prodrugs," Erion et al., Journal of Pharmacology and Experimental Therapeutics Fast Forward, JPET 312: 554-560, 2005 (claiming a date of first publication of Aug. 31, 2004) and "LEAPT: lectin-directed enzyme activated prodrug therapy", Robinson et al., PNAS October 5, 2004 vol. 101, No. 40, 14527-14532 , claiming an online publication on September 24, 2004 ( http://www.pnas.org/cgi/content/full/101/40/14527 Useful materials may be generated, for example, by converting a premediate into a drug by enzymatic reaction of an agent in the bloodstream or a tissue or organ (CYP450, cholesterol metabolism, for example, with cholesterol monooxygenase, cholesterol). Reductase, cholesterol oxidase).

therapeutic Active ingredients that are known in the art can with the Applicants as described herein may be used. Therapeutic agents can, for example, agents for the treatment of autoimmune diseases, osteoporosis, cancer, diabetes of Type I or Type II, mental disorders such as depression, bipolar disorder or schizophrenia and infectious diseases and consequences of these diseases.

Dependent of the intended application or use environment for the application agent, the application material at least one antibiotic, microbicidal, antiviral, fungicidal, transfection agent or a nanomaterial. In some embodiments For example, the active agent may be a tissue-specific marker or a targeting molecule include, for example, a tissue specific edothelial homing protein. A tissue-specific marker or a target molecule can in targeting the application material to a specific location or tissue in the body of a human or an animal support.

The drug delivery agent described herein may be used to controllably administer a medicament for the purpose of prevention or treatment of diseases commonly found in third world countries. Such diseases are known to those skilled in the art and include, but are not limited to, those described herein. Embodiments of the drug delivery agent may include programming the agent, for example, either prior to use in vivo or subsequent to incorporation in vivo, to deliver at least one drug into the in vivo environment. Programming may include the steps of long-term delivery of the drug, for example daily administration over a period of days or weeks or months. The application may be scheduled in a constant manner using an agent as described herein to allow for a consistent and sustained blood level of the drug. Some application regimens may take into account the pharmacokinetic properties of the drug to maintain the desired blood concentration of the drug. As described herein, some embodiments of the drug delivery device may include sensors configured to detect a biological condition or other parameter of the environment. The means may be programmed to respond to the measured state or parameter. Some diseases or infections may require the delivery of the therapeutic agent over the course of months to prevent the recurrence of the disease or to create immunity to a delivered vaccine. It will be understood by those skilled in the art that the drug delivery agent as described herein permits a wide variety of variations in the drug to be delivered to the human or animal, and particularly to humans. Each aspect of the function of the drug delivery agent includes, but is not limited to, the timing or amount or constellation of the drug delivery, may be programmed into the agent, or may be controlled by remote control as desired by the user becomes. The immunization can be accomplished using a vaccine delivered by the drug delivery agent according to pulsed or highly objectionable time intervals.

Examples of delivery materials comprise, but are not limited to, at least one of efavirenz, Lamivudine and Zidovudine, Tenofovir (Viread ^®), and Emtricitabine (Emtriva ^®) individually for application or in any combination or sequence for the treatment of HIV-I Infections, or first-line (for example, isoniazid and rifampicin) or second-line drugs (for example, fluoroquinoleines, thioamides, macrolides) for the treatment of tuberculosis infections. Other embodiments exclude the application of at least one drug to be administered, which is an antiviral or antimicrobial agent. Other embodiments comprise the application of at least two active substances to be applied, wherein the at least one active substance to be administered is a vaccine.

Vaccines, whether administered separately or in combination with another excipient, such as viral or bacterial vaccines. Examples or diseases for which vaccines can be administered include, but are not limited to, malaria, HFV, tuberculosis, burial, influenza, hepatitis A, hepatitis B, hepatitis C, hepatitis E, hepatitis G, HPV, schistosomiasis, leishmaniasis, Smallpox (variola), pneumonia, diphtheria and cancer. Treatments for a malaria infection are well known in the art and may involve the use of at least one of the following active ingredients include: chloroquine, Sulfadoxinepryrimethamin (Fansidar ^®), Mefloquine (Laram ^®), atovaquone-proguanil (Malarone ^®), quinine, doxycycline, artemisin derivatives and / or primaquine. Treatments of tuberculosis are well known to those skilled in the art and may include isoniazid, rifampin, pyrazinamide, rifapentin and / or ethambutol.

vaccines for maser infection are well known to those skilled in the art. treatments a Leischmaniasisinfektion are well known in the art and can include antimony-containing components, including Meglumine antimonite, sodium stibogluconate, pentamidine and / or amphotericin B. Treatments of a smallpox infection are well known to those skilled in the art and can be anti-infective and / anti-viral agents include. Treatment of bacterial pneumonia are well known to those skilled found at least one of the following active ingredients: Macrolides such as Ery-Tab, Biaxin, Biaxin XL and Zithromax, tetracycline such as doxycycline (bibramycin, Doryx); Fluoroquinolones such as Levaquin and Avelox; cephalosporins such as Ceclor, Duricef, Ceftin and Lorabid; Penicillins like Amoxil, Biomox, Omnipen, Augmentin, Veetids and Timentin, Vancomycin (Vancocin) and / or ketolides (telithromycin). Treatments of diphtheria infections are well known to those skilled in the art and may include antitoxin. Treatments of hepatitis C infection are well known to those skilled in the art and may, for example, pegylated interferon alfa-2a, Ribavirin and telaprevir or any combination thereof.

vaccines for HIV-I are well known to the skilled person and can a fragment or portion of an HIV-1 envelope protein gp120 include, in particular, the area of the gp120 attached to the Antibody b 12 is bound. Other application substances can include an immune system modulator, or a vaccine adjuvant. A vaccine adjuvant is a component that immunoresplies potentiated to an antigen and / or this towards the desired Immune responses modulated.

Examples of the vaccine adjuvant include mineral salts such as, for example, aluminum hydroxide and aluminum or calcium phosphate gels, oil emulsions and surfactant based formulations such as MF59 (microfluidized detergent stabilized oil-in-water emulsion), QS21 (purified saponin), AS02 [SBAS2] ( Oil-in-water emulsion + MPL + QS-21), montanide ISA-51 and ISA 720 (stabilized water-in-oil emulsion); particulate adjuvants, such as virosomes (unilamellar liposomal carriers with influenza haemagglutinin), AS04 ([SBAS4] Al salt with MPL), ISCOMS (structured complex of saponins and lipids), polylactide-co-glycolide (PLG); Microbial derivatives (natural and synthetic), such as monophosphoryl lipid A (MPL), detox (MPL + M. Phlei cell wall scaffold), AGP [RC-529] (synthetically acylated monosaccharides), DC Chol (lipoid immunostimulators that self-assemble into liposomes OM-174 (Lipid A derivative), CpG Motifs (synthetic oligonucleotides with immunostimulatory CpG motifs), modified LT and CT (genetically modified bacterial toxins to effect non-toxic adjuvant effects); endogenous human immunomodulators such as hGM-CSF or hIL-12 (cytokines that can be given either as a protein or as a coded plasmid), immudaptin (C3d tundem array); and inert carriers, such as gold particles.

Other Embodiments have the use of to be applied Active ingredients that are supplied if necessary and / or as necessary, for example, insulin or a pain medication.

One or more of the drug delivery agents described herein may be used for Controlling the therapeutic application of a controlled substance in vivo and / or can prevent abuse or addiction by the patient. For example, prescribed analgesics or other potential addictive substances may be administered in amounts and, accordingly, in a schedule or schedule that prevents the likelihood of addiction training or abuse. Examples of the most commonly misused controlled substances include opioids, also known as narcotic analgesics. Opioids used for pain relief are the most commonly used prescribed medications. Examples of opioids include morphine, codeine, oxycontin (oxycodone), vicodin (hydrocodone) and demerol (meperidine). Other controlled substances include central nervous system soothing agents that are commonly used to treat anxiety, panic attacks and sleep disorders. Examples are Nembutal (pentobarbital sodium), Valium (diazepam), and Xanax (alprazolam). Other controlled substances include central nervous system stimulants that are commonly used to treat sleep disorder, narcolepsy and attention / hyperactivity disorder. Examples include Ritalin (methylphenidate) and Dexedrine (dextroamphetamine). These drugs, which can be addictive, increase brain activity and increase alertness and energy. Similar means may thus be terminated to eliminate or minimize the likelihood of overdose, particularly relative to the individual or then given characteristics of the subject.

One Plan suitable for using the drug delivery agent, which has been described and claimed herein may include such for example, have been given by a doctor or the Patients according to a model or given guidelines. In addition, a plan can be created according to a special one Measurement, for example, a measurement that performed has been from a physiological sensor as described here becomes.

A or more drug delivery agents as described herein can be used to control the therapeutic regimen an antidepressant or psychotherapeutic agent in vivo or to prevent its use or misuse the patient or the search engine. For example, you can prescribed psychotherapeutic agents or others in quantities and be fed according to a plan that determines the likelihood of Avoiding addiction or abuse. Often the compliance an antipsychotic medication a challenge. This one described and claimed application agent can be used Be used for delivering psychotherapeutic drugs to ensure the compliance of the patient. For example, can in patients whose future compliance with the medical Council on medication is important, adherence to medication through use the plan of the substance delivery agent as described herein and claimed to be ensured.

Drug delivery schedules suitable for use with the drug delivery agent may be those that have been presented, for example, by a physician, or by the patient according to a model or guidelines. In addition, a drug delivery schedule may be created according to a particular measurement, for example, a measurement made by a physiological sensor as described herein. Examples of the best known psychotherapeutic drugs described a shoot: escitalopram (brand name: Lexapro ^®) citalopram (brand name: Celexa ^®), fluoxetine (brand name: Prozac ^®), Paroxetine (brand name: Paxil ^®) and sertraline (brand name: Zoloft ^®). Therapeutic agents for the treatment of anxiety disorders such as generalized anxiety disorders, obsessive-compulsive disorder (OCD), panic disorders, post-traumatic stress disorder (PTSD), and social phobia (or social anxiety disorder) are examples of such disorders that can be treated using a drug delivery agent as described herein and is claimed. Other psychotherapeutic agents for use with the disclosed and claimed device include, but are not limited to Clozaril ^® (Clozapine), Haldol ^® (haloperidol), Loxitane ^® (Loxapine), Mellaril ^® (Thioridazine), Moban ^® (Molin your) Navane ^® (Thiothixene), Prolixin ^® (Fluphenazine), Risperdal ^® (Risperideine) SERENTIL® ^® (Mesoridazine), Stelazine ^® (trifluoperazine), Thorazine ^® (Chlorpromazine), Trilafon ^® (Peohenazine), and Zyprexa ^® (Olanzapine).

As Described here, the system can be used to deliver each to be administered drug individually or in combination with at least another application substance. A combination therapy with several can be provided for delivering the drugs to be administered Fabrics sequentially or simultaneously or individually according to different time plans.

As used herein, the term "fluid to be applied" refers to agents to be administered which may have any shape that exhibits fluidic or fluid-like behavior, including liquids or other solid particles in a liquid carrier. The fluid to be applied may be a solution, a suspension / gel, a fluidized powder or an emulsion.

In the embodiment of 1 has the application system 10 a drug delivery agent 12 on that in an environment 14 is arranged (in this particular embodiment a human body) and a remote control 16 , The term "remote control" as used herein means the transmission of information (e.g., data or control signals) or power signals or other interactions between remote or separate devices or devices such as a remote control or drug delivery system, without a direct connector such as a wire or cable that controls the remote and the application system interconnects and does not imply any particular distance relationship between the remote control and the application means which, in various embodiments, may be distant over a relatively large distance (e.g., miles or kilometers) or relatively small distances (eg, inches or millimeters).

The drug delivery agent 12 has a responsive output mechanism 18 which responds to a control signal from the remote control 16 is produced. The device may operate without a remote control to enable the controllable output mechanism. The means may comprise a processor mechanism for generating and transmitting at least one control signal to the controllable output mechanism 18 configured to control the delivery of at least one substance from the controllable dispensing mechanism 18 , The processor mechanism may include a memory and may be programmed in vivo by remote control and may be programmed in vivo prior to deployment. All functions described herein which may be performed by the remote control may be programmed in the processor of the device. The programming of such a processor is known to the person skilled in the art. The device also has a timer or a counter. The device may further include a mechanism that determines its internal state and may include a transmission mechanism for communicating information regarding its internal state. In addition, an embodiment may include an external device or a remote controller that has the ability to determine the internal state of the drug delivery agent. The remote control may include a display for presenting any desired information regarding at least one drug delivery agent, including, but not limited to, its function, material delivery history and schedule, substance status, host physiological data, etc. Other embodiments of this drug delivery agent include aspects such as: wherein the control signal activating the controllable output mechanism may be generated and transmitted by a remote controller or by a processor mechanism included in the apparatus and programmed to generate and transmit a control signal.

2 shows a drug delivery system 20 with a drug delivery agent 21 that from a remote control 22 is controlled. In the embodiment of 2 indicates the drug delivery agent 21 a controllable dispensing mechanism 23 and a deformable reservoir 24 on, the one substance to be delivered 25 includes. The remote control 22 transmits a control signal 26 to the addressable output mechanism 23 to control the delivery of the material 25 from the deformable reservoir 24 , The delivery substance 25 exits the deformable reservoir 24 over the outlet 27 out. The drug delivery agent 21 may further have a body structure as further described herein.

3 shows a further embodiment of an application system 30 with an application agent 31 that from a remote control 32 is controlled. In the embodiment of 3 indicates the application agent 31 a pump 33 and an application reservoir 34 on, the one substance to be delivered 35 includes. The remote control 32 transmits a control signal to the at least one controllable output mechanism 37 for controlling the rate of delivery of the material to be dispensed 35 from the reservoir. The remote control 32 continues to transmit control signals 36 to a receiving element 38 in the pump 33 for controlling the pumping of the substance to be dispensed from the application reservoir 35 , The exit 35 and the controllable output mechanism 37 are further in the application agent 31 locked in. In various embodiments, the control signal may be electromagnetic, mechanical / acoustic or ultrasonic.

4 shows in schematic form a drug delivery device with an application reservoir 41 formed for containing a substance to be dispensed, the application reservoir has at least one outlet 42 , through which the substance to be dispensed can emerge from the application reservoir, a material to be dispensed 43 that in the application reservoir 41 is included and at least one controllable output mechanism 44 for controlling the discharge of the substance from the reservoir into the environment, for example a valve is arranged. The material to be dispensed can from the reservoir 41 by controlled diffusion escape or is from the application reservoir 41 through a positive pressure moves to the application reservoir 41 is discharged (for example by a pump or by a pressure caused by the contraction forces 45 is applied, which is generated by the expanded deformable reservoir or by a pressure medium, which is provided in the reservoir, such as a gas-filled bladder or an osmotic mechanism).

To the Modulating or varying the rate of exit or release of the substance to be dispensed is the at least one controllable dispensing mechanism, in this and in the other embodiments is used, operable with at least one outlet of at least connected to an application reservoir. In some embodiments For example, the controllable dispensing mechanism may be fixed to or scanned be at the reservoir by any of the usual, not biological degradable agents such as, for example, a biocompatible adhesive. The at least one controllable output mechanism is in communication with the at least one outlet such that the output of at least a substance from the at least one reservoir of the controllable Output mechanism can be controlled. The process of operational Connection of the controllable output mechanism with the output The reservoir can take place before the arrangement of the device in the application means, for example a hypodermic needle, as will be further described here. The term "variable Control "as it is sometimes used here in relation on the controllable output mechanism has the ability for determining and setting various parameters associated with the Delivery of the material from the at least one reservoir connected are. In one embodiment, "variable Control "mean that a substantially constant steady delivery is maintained. In other words, variable Control means that the exit or release of the material from the at least one reservoir for a time interval is interrupted during the exit of the material the at least one reservoir during other time intervals is allowed. In still other embodiments, " variable Control "mean that the rate of material leakage from the at least one reservoir over a period of time is adjusted. The rate of leakage of the material can be dependent vary from measured states (as described here) is) or according to a control signal from an external Source is received.

Of the At least one controllable output mechanism may be different have functional properties. Embodiments, For example, the controllable dispensing mechanism may include a heating element or form (for example, a resistive element) or a cooling element (which may be, for example, a thermoelectric device). at In some embodiments, the controllable dispensing mechanism a receiving element such as an antenna or other geometric reinforcing structure have to increase the reception of an electromagnetic Control signal generated by a remote control signal generator becomes. The term "electromagnetic control signal", as used here has electrical properties, magnetic Properties or has both properties. The answer of the controllable output mechanism on an electromagnetic field can be on the absorption of energy are based on the electrical signal or due to a torque or pulling on all or part of the controllable dispensing mechanism due to the electric field. The answer depends on the Intensity, relative orientation and frequency electric field and geometry, composition and the nature of the material of the controllable dispensing mechanism from. An answer can be on a macro level, on a microscopic level Level or a nanoscopic or molecular level. In some embodiments, the controllable output mechanism may be to the control signal by changing the form responses. at In some embodiments, the controllable dispensing mechanism to the control signal by changing in at least one dimension reply. The answer to the controllable output mechanism can include one or more of the following. Heat cool, Vibrate, Expand, Stretch, Unfold, Contract, Deform, Soothing or wrinkles globally or locally. In some embodiments For example, the controllable dispensing mechanism may be designed to be selective Responses to an electric field with a specific frequency and / or Orientation. The frequency selectivity can be compared by a suitable selection of the controllable dispensing mechanism in size and shape relative to the frequency of the electromagnetic signal, while the directional selectivity can be compared by the design and the orientation the controllable output mechanism.

The controllable dispensing mechanism used in various embodiments of the application means and system as described herein may include one or more electromagnetically active materials. The controllable output mechanism may include a magnetically or electrically active material. Examples of magnetically active materials include, but are not limited to, permanent magnetizable materials, ferromagnetic materials such as iron, nickel, cobalt and alloys thereof, ferromagnetic materials such as magnetite, ferrous materials, irony materials, diamagnetic materials such as Quartz, paramagnetic materials such as silicate or sulfides, antiferromagnetic materials such as tilted antiferromagnetic materials that have behavior similar to ferromagnetic materials. Examples of electrically active materials include, but are not limited to, ferroelectric, piezoelectric, and dielectric materials, including permanently poled dielectrics and dielectrics that have both positive and negative permittivities, and metallic materials.

Of the controllable output mechanism may include materials that their Change size and shape when thermal Energy is applied. By combining materials As in polymer gels, one can see the different properties use the individual components to bring about the whole thing. thermal attractive materials have thermally attractive gels (hydrogels) such as thermosensitive N-alkyl-acrylamide polymers, poly (N-isopropylacrylamides) (PNIPAAm), biopolymers, entangled elastin-based networks, Materials that undergo a thermally triggered hydrogelation undergo memory foam, resin components, thermochromic materials, Proteins, shape memory alloys, plastics and thermoplastic Materials. Materials that contract in response to heating or can fold thermally-responsive gels (hydrogels) which undergo a thermally triggered hydrogelation (For example, poloxamer, non-entangled PNIPAAm Derivative, chitosan / glycerol compounds, elastin-based polymers), thermosetting resins (for example, phenolic Melamines, urea and polyester resins), dental composites (e.g. Monomethyl acrylates), and thermoplastics.

at In some embodiments, the controllable dispensing mechanism a polymer, a ceramic, a dielectric or a metal include. The controllable dispensing mechanism may be different materials such as polymers, ceramics, plastics, dielectrics or metal or Combinations of these include.

at In some embodiments, the controllable dispensing mechanism a polymer and a magnetically or electrically active component exhibit. In some embodiments, the controllable Output mechanism, a shape memory material such as a shape memory polymer, a shape memory metal or a composite structure as a bimetallic structure.

In some embodiments, the controllable output mechanism may include a polymer and an electrically active component (including highly polarizable dielectrics) or a magnetically active component (including ferro polymers and the like). In embodiments where the controllable dispensing mechanism includes one or more electrically or magnetically active components, the electrically or magnetically active component may respond to an electrical control signal in a first manner (eg, by heating) and the response of the controllable dispensing mechanism may be responsive to that electrically or magnetically active component (e.g., expansion or change in shape in response to heating of the electrically or magnetically active component). The controllable output mechanism may have a composite structure in some embodiments. Controllable dispensing mechanisms may in some embodiments have microfluidic devices that have been produced by microfabrication. In addition, a reversible valve based on an "artificial muscle" may be used to control the flow of material to be delivered from the expandable reservoir to the environment. Such valves are described and known, see for example Low, L., Seetharaman, S., He, K., Madou, MJ, 2000, Microactuators Towards Microvalves for Responsive Controlled Drug Delivery, Sens. Actuators B 67, 149-160 , which is incorporated herein by reference. The term "artificial muscle" refers to a chemo-mechanical actuator consisting of a mixture of a hydrogel and an electronically conductive redox polymer, for example polyaniline and polypyrrole or their derivatives. Alternatively, other embodiments include an electroactive polymer actuator based on an acrylic acid, acrylamide, and polypyrrole / carbon composition. This polymeric actuator acts as an artificial muscle bends with the application of a low voltage with a fast response time. See for example "Responsive Drug Delivery Systems" Sapna Deo, Patricia Eisenhardt, Elizabeth Moschou, Serban Peteu, Leonidas Bachas, Marc Madou, Sylvia Daunert, Analytical Chemistry, 2003, 75 (9) 206A-213A ; and Madou, MJ, Florkey, J., 2000, "From batch to continuous manufacturing of microbiomedical agent", Chem. Rev. 100, 2679-2692; and US Patent Publication 2004/0182704 ; each of which is incorporated by reference. Induced by an increase in electrical bias, the polymer is controllable and therefore the polymer can swell and shrink to close and open a valve using electrical control. In other embodiments, microvalves and micropumps having an electrically responsive hydrogel system for actuation may be used. See for example Beebe, DJ, Moore, JS, Bauer, JM, Vu, Q., Liu, RH, Devadoss, C, Jo, B., 2000, "Functional hydrogel structures for autonomous flow cont rol inside microfluidic channels ", Nature 404, 588-590 ; and US Pat. 6,663,821 entitled "Bistable Microvalve", all of which are incorporated by reference. The micropumps and microvalves discussed above may be used in the drug delivery system described herein to control the flow of the delivery material from the expandable application reservoir to the environment.

5 shows an example of a controllable output mechanism 50 having a composite structure formed from a polymer 51 and a plurality of electrically or magnetically active components in the form of a plurality of particles 52 that over the polymer 51 are distributed. In some embodiments, the electrically or magnetically active components may also be heatable by the electrical control signal, and the heating of the electrically or magnetically active components may cause a change in the configuration of the polymer. An example of a magnetically responsive polymer is that described, for example, in US Pat Neto, et al, "Optical, Magnetic and Dielectric Properties of Non-Liquid Crystalline Elastomers Doped with Magnetic Colloids"; Brazilian Journal of Physics; which bears the date of March 2005; Pp. 184-189; Volume 35, Number 1 , which is incorporated herein by reference. Other examples of materials and structures are presented in Agarwal et al., "Magnetic-driven temperature-controlled microfluidic actuators"; Pp. 1-5 ; to find at: Error! Hyperfink reference invalid.
_papers / OralPresentations / C2.pdf or U.S. Patent 6,607,553 both of which are incorporated by reference.

An exemplary embodiment of an active substance application device may have at least one controllable dispensing mechanism which has a pump for pumping the substance to be supplied, for example a fluid, from the application reservoir and in particular when the reservoir is not under pressure. Alternatively, the substance to be supplied, for example the fluid, can easily diffuse out of the application agent. Various types of pumps can be used without limitation. Suitable pumps may include, for example, a micropump (nanopump), microosmotic, mechanical, displacement, centrifugal, and peristaltic pumps. 6 shows an embodiment of an application agent that includes an osmotic pump. The application agent 60 has an application reservoir 61 on, the substance to be supplied 272 includes and a controllable output mechanism 63 with an outlet can have. The controllable output mechanism 63 is operative with the application reservoir 61 connected to control the flow of the material to be supplied from the reservoir. An osmotic pump 64 has an osmotic chamber 65 on which an osmotic pressure generating substance 66 having. The semi-permeable membrane 67 is for the osmotic fluid 68 Permeable, but not on the osmotic pressure generating substance 66 , The osmotic fluid 68 flows into the osmotic chamber 65 , This causes the impermeable barrier 69 (which may be a fixed movable barrier or a flexible membrane) into the application reservoir 61 to go and so the substance to be supplied 272 from the outlet, in the controllable dispensing mechanism 63 is intended to pump. An activation of the controllable output mechanism 63 may cause leakage of the feed from the reservoir.

Various different osmotic pressure producing substances can be used in the application system as described herein. For example, the osmotic pressure generating agent may use an ionic and a nonionic water attracting or water absorbing agent, nonvolatile water soluble species, salts, sugars, polysaccharides, polymers, hydrogels, osmopolymers, hydrophilic polymers and absorbent polymers, and others. Water attractants may include nonvolatile water soluble species such as magnesium sulfate, magnesium chloride, sodium sulfate, sodium phosphate, sodium sulfate, lithium sulfate, sodium phosphate, potassium phosphate, D-mannitol, sorbitol, inositol, uric acid, magnesium succinate, tartaric acid, raffinose, various monosaccharides, oligosaccharides and polysaccharides such as sucrose. Glucose, lactose, fructose, dextran and mixtures thereof. Water-absorbing active substances include osmopolymers, for example hydrophilic polymers, which swell on contact with water. Examples of such water-absorbing agents include poly (hydroxyalkylmethacrylate) MW 30,000-5,000,000, polyvinylpyrrolidone MW 10,000-360,000, anionic and cationic hydrogels, polyelectrolyte complex, poly (vinyl alcohol) with a low acetoacetate, optionally interlocked with glyoxal, formaldehyde or glutaraldehyde and with polymerization of 200 to 30,000, mixtures of, for example, methylcellulose, entangled agar and carboxymethylcellulose or hydroxypropylmethycellulose and sodium carboxymethylcellulose; Polymers of N-vinyllactams, polyoxyethylene polyoxypropylene gels, polyoxybutylene-polyoxyethylene block copolymer gels, Johannesbaum resin, polyacrylic gels, polyester gels, polyuria gels, polyether gels, polyamide gels, polypeptide gels, polyamino acid gels, polycellulose gels, rosin acid carboxy polymer MW 250,000-4,000,000, cyanameric polyacrylamides, entangled indene-maleic anhydride polymers, Starch graft copolymers, acrylate polymerolysaccharides. Other water-attracting and / or water-absorbing agents have absorbent polymers such as poly (acrylic acid) potassium salt, poly (acrylic acid) sodium salt, poly (acrylic acid-o-acrylamide) potassium salt, poly (acrylic acid) sodium salt graft poly (ethylene oxide), poly (2-hydroxyethyl methacrylate) and / or poly (2-hydroxypropyl methacrylate) and poly (isobutylene-co-maleic acid). A variety of osmotic pressure-generating agents and / or water-absorbing agents are disclosed in U.S. Pat US Patent Publications 2004/0106914 and US 2004/0015154 both of which are fully incorporated by reference. The ability to produce an osmotic pressure of the osmotic pressure generating material may depend on the solubility of the osmotic pressure generating material in the osmotic fluid and / or on the concentration of the osmotic pressure generating material in the osmotic fluid and a change in either concentration or the solubility may modify the ability to produce an osmotic pressure of the osmotic pressure generating material. The concentration of the osmotic pressure generating material in the osmotic pressure may be modifiable by changing the solubility of the osmotic pressure generating material in response to an electric field controlling signal or by a change in the osmotic fluid in response to the electric field controlling signal.

The 7A and 7B show an embodiment of an application agent 70 in which at least one controllable dispensing mechanism 71 a responsive to an electromagnetic field control 72 which can respond to a control signal by generating heat. The active ingredient to be applied 73 is from the application reservoir 74 in the application medium 75 includes. The controllable output mechanism 71 has an initial temperature Ti. Subsequent heating of the controllable output mechanism 71 in response to an electromagnetic control signal has the controllable output mechanism 71 then a temperature T ₂ , as in 7B (Ti <T ₂ ). The change in temperature of the controllable dispensing mechanism 71 may modify the shape, design, or geometry of the controllable dispensing mechanism, resulting in leakage of the dispensing material 73 from the application reservoir 74 causes. The electromagnetic field responsive control 72 may include a metallic, metal-containing or ferromagnetic material, or another material having a significant electromagnetic loss tangent or resistivity. As previously described, the application means may further include a pump and an outlet.

8A and 8B show a further embodiment of an application means 80 in which at least one controllable dispensing mechanism 81 on an electric field responsive control 82 Has. The electromagnetic field responsive control 82 may lower the temperature (from Ti to T ₂ , where Ti> T ₂ ) in response to an electromagnetic control signal and may cause the controllable dispensing mechanism to change its shape or geometry to produce an output and cause the dispensing material 83 from the reservoir 84 withdraw. The electromagnetic field responsive control 82 may for example have a thermoelectric element. Methods and / or mechanisms for generating refrigeration may include, but are not limited to, a thermoelectric device (fur animal effect) and a liquid-gas evaporation device (Joule-Thomson) or devices having the phase-changing materials or systems which include significant enthalpies to transition. In some embodiments of the application means, the at least one controllable output mechanism having a shape changing structure that changes in at least one dimension in response to an electromagnetic control signal. The 9A and 9B show a application substance 92 receiving control unit 90 that has a controllable output mechanism 91 has, which has a structure changing in shape. Other embodiments having the shape changing materials are also considered. A shape changing structure may include a polymeric material, an iron polymer, a hydrogel, a bimetallic structure, or a shape memory material. In some embodiments, the shape changing structure may be an expanding or contracting structure, wherein the change in at least one dimension includes expansion or contraction in at least one dimension.

10A and 10B show a controllable output mechanism 100 which in response to an electromagnetic control signal with a corresponding increase in the size of the pores 101 in 10B relative to the size of the pores 101 in 10A expanded.

In these and other embodiments, the application means may include at least one biocompatible sensor for detecting at least one parameter of the at least one application reservoir. For example, the sensor can detect the amount or concentration of the fluid to be applied in the application reservoir. In other embodiments, the application means may include at least one biocompatible sensor for detecting at least one parameter of the environment. For example, the sensor may detect the presence of or the constellation or detect the activity of chemical or biological molecules or cells within at least a portion of the region surrounding the delivery agent.

Examples of such sensors are in the US Patent 6,935,165 , and the US Patent Publications 2004/0007051 and 2005/0208469 described, all of which are incorporated by reference herein. Further examples of sensors are described in "Easy-to-Hake Nano Sensors: Tiny electronics-based detectors could provide simple tests for cancer or bioterror drugs." By Kevin Bullis , to find under http: //www.technologyreview.eom/Nanotech/18127/ This disclosure is incorporated by reference. Further examples of sensors are described at Gruner, G., "Carbon Nanotube Transistors for Biosensing Applications"; Anal. Bioanal. Chem. (2006) 384: 322-335 Also, this disclosure is incorporated by reference. Carbon nanotube transistors are suitable for mass production as described at Gabriel, JC, Mat. Res. Soc. Symp. Proc, (2003) Vol. 776, Q.12.7.1-12.7.7 Also, this disclosure is incorporated by reference. 11 shows in schematic form an embodiment of an application means 110 with a controllable dispensing mechanism 111 who has an active section 112 and a power receiving structure 113 Has. The application agent further has an application reservoir 114 and an outlet 115 on. The power absorbing structure 113 may have any structure having a size, a shape, and a material suitable for receiving and transmitting electromagnetic energy of a particular frequency or frequency band. The power receiving structure may include an antenna. The power receiving structure may have a resonant structure.

The resonant structure may be a resonant circuit, a resonant electromagnetic structure, a molecular bond or a mechanical resonant structure. In some embodiments, the power receiving structure may be 113 a high frequency selective while in other embodiments it can operate over a wide frequency band or across multiple frequency bands. The power absorbing structure 113 may consist of various metallic or electrical or magnetically active materials. The active section 112 may include various materials that are mechanically, thermally or chemically responsive to received electromagnetic energy and the power receiving structure 113 be transferred to affect the effective concentration of the primary drug in the application reservoir. The power receiving structure may have a mechanism that converts the mechanical energy (ie, kinetics) into electrical energy. The energy extraction from vibrations is based on the movement of a "spring" mounted mass relative to its support frame. The mechanical acceleration is caused by vibrations, which in turn causes the mass component to move and vibrate (generating kinetic energy). This relative displacement causes opposite frictional and damping forces exerted against the mass, which reduces the vibrations and eventually extinguishes them. The damping forces absorb the kinetic energy of the initial vibration. This energy can be converted into electrical energy via an electric field (electrostatic) or a magnetic field (electromagnetic). While this may be the mechanical design, correspondences such as MEMS resonators, resonant piezoelectric structures or the like that operate with similar physical phenomena are possible. In addition, non-resonant mechanical energy extraction can be accomplished in a variety of ways, including a winding mechanism such as those used in self-winding watches, ratcheting mechanisms, or other approaches to converting input energy into either dynamic energy, potential energy, heat, or other useful forms.

12 shows an embodiment of an application device 120 with an RFID 121 , The application device 120 has an application reservoir 122 , an outlet 1123 and a controllable dispensing mechanism 124 on. The RFID 121 can store a unique identification code that identifies the application means 120 from a remote control (not shown) having an RFID detection circuit. This allows, for example, a selective control for certain application means. Similar means may be used to validate the identity of a remote controller over the control circuitry of the at least one application means.

Applicants as described may be used for use in a variety of in vivo environments. An application agent of this kind as disclosed herein may have a biocompatible body structure adapted to function in the body of a human or animal or to receive the application agent as described in U.S. Pat 1 is shown. The body structure can be inserted prior to introduction of the drug delivery device, followed by introduction of the drug delivery device into it, or else the body structure can be introduced in conjunction with the introduction of the drug delivery device. A body structure may contain a biocompatible material and may be of any shape suitable for receiving the drug delivery device. The body structure may be flexible or rigid and may be of any shape to define a demarcation between the drug delivery device and the surrounding tissue. The optional removal of the drug delivery device from the in vivo environment, as will be further described herein, may allow the body structure to receive a new delivery agent or may be degraded by incorporation into the body structure of a particular biocompatible degradation agent (eg, a fluid borne degradation material) Of course, it can be degraded biocompatible after a period of time.

The Drug delivery device can be in the body of a human or an animal and would be used then typically have suitable biocompatible properties. Furthermore, the application means may have features that require a placement or positioning at a desired location in the area allowed or targeted in a desired location in the area. These features may be size and shape features have tie or gripping structures to prevent movement the body structure in the environment (in the case that the Device is placed at the desired location) or Target features (surface chemistry, shape, etc.) that the device in the direction of the place or the desired Cause a place. The body structures can include a tissue-specific marker or target molecules (For example, the tissue specific markers or the target molecules are a tissue specific endothetic Have protein. The application means, as it is to be arranged in the Body of a human or an animal can be used can be constructed using methods known to those skilled in the art The micro creation are known what the device is suitable makes, for a transcutaneous introduction over a hypodermic needle.

at In some embodiments, the application means a MEMS (micro-electro-mechanical system) or NEMS (nano-electromechanical system) System) or another microfabricated electromechanical Device. The term "MEMS" as he is here can be used on either MEMS devices or Refer to MEMS devices or both. The MEMS or the NEMS device can of at least one metal, polymer, ceramic, glass, semiconductor material, Nanotube material or other known materials, which are commonly used to be constructed In some embodiments, the device may be a battery-free device, which through power input, inductive coupling or an ambient power source is supplied. In other embodiments, the device may have a battery or other built-in power source. In some embodiments, the application agent an electromagnetic control signal generator, which in Substantially in, on or adjacent to the at least one application reservoir is arranged. In other embodiments, the electromagnetic control signal generator in a location away from be arranged the application reservoir.

As described herein, the drug delivery system may include remote control. The remote control can be any device that is capable of selectively controlling the operation or activation of the drug delivery device while the device is deployed in vivo. A remote control may have an electromagnetic signal generator capable of generating an electromagnetic signal sufficient to activate a controllable output mechanism of the dispenser located in a human or animal to control delivery of the dispenser To control the drug to be supplied from the application reservoir of the application agent; and an electromagnetic signal transmitter capable of wirelessly transmitting the electromagnetic signal to the controllable dispensing mechanism. Various types and frequencies of electromagnetic control signals may be used in the application systems as described herein. For example, in some embodiments, the application system may include a remote controller configured to generate a control signal of a static or quasi-static electrical command or a control of a static or quasi-static magnetic field used to activate the controllable dispensing mechanism to control the release of the effective Mass or concentration of the primary drug in a desired manner is sufficient. In other embodiments, the remote controller may be configured to generate a radio frequency microwave infrared millimeter wave, optical or ultraviolet electromagnetic field control signal sufficient to activate the controllable dispensing mechanism to control the effective concentration of the primary drug in a desired manner. In another embodiment, the remote controller may be configured to display information to the users via a read or transfer of data or information to another device which may then print information or data or display the information or data. The control signal may be generated based at least in part on a predetermined activation pattern. As in 13 a given activation pattern may store a set of data 1002a . 1002b . 1002c . 1002d , ... 1002e with values f (t1), f (t2), f (t3), f (t4), .... f (t _N ) that are in the storage mechanism 1000 or the location 1000 is stored. The activation pattern on which the electromagnetic signal is based is in a plot 1004 in 13 shown. In the plot 1004 is the time t _n on the axis 1006 and a signal amplitude f (t _n ) that is a function of t _n , is on the axis 1008 specified. The value of the electromagnetic signal over time is through the track 1010 shown. The default activation pattern given by the data 1002a . 1002b . 1002c . 1002d , ... 1002e may be based on calculations, measurements, or other method that may be used to generate an activation pattern suitable for activating the controllable output mechanism. The storage mechanism 1000 may be a location in a remote control or located in the drug delivery device. As an example, a simple remote control may include a stored activation pattern in the memory and may include an electrical circuit configured to generate an electromagnetic control signal corresponding to the pattern for a predetermined duration or at predetermined intervals without further input of either feedback information or user data , In a more complex embodiment, a predetermined activation pattern may be generated in response to particular feedback or user input conditions.

In some embodiments, a signal may be generated based on a model-based calculation. As in 14 an activation pattern f (t _n ) may be a function not only of time (t _n ) but also of model parameters Pi, P ₂ , ... P k, as by the equation 1050 specified. dates 1052a . 1052b , .... 1052c have values P ₁ , P ₂ , ... P _k can in the memory 1054 get saved. A control signal can be calculated from the stored model parameters and time information. For example, as in the plot 1056 indicated the time on the axis 1058 indicated and the strength or amplitude of the electromagnetic control signal is on the axis 1060 indicated, so that the curve 1068f (t _n) represents. The memory 1054 can be a location in a remote control. The remote control may generate a control signal based on the stored function and corresponding parameters. In some embodiments, the control signal may also be a function of one or more feedback signals (from the dispenser or environment, for example) or some user input or data or commands.

15 shows a remote control with a memory 1104 capable of storing predetermined data values or parameters used in the model-based calculation as described herein. The remote control 1100 can continue an electrical circuit 1102 , a signal generator 1112 and a signal transmitter 1114 for transmitting a control signal 1116 include. The memory 1104 can be a location 1106 to include a stored activation pattern or model parameters include portions of the memory 1104 can continue to store the operating system, program code, etc. for use by the electrical circuit 1102 be used. The remote control 1100 can continue a beam aligner 1118 Such as an antenna, an optical element, a mirror, a transducer or other structure that can control the electromagnetic signaling. The remote control 1100 may be configured to generate a control signal having different characteristics, depending on the intended application of the system. Embodiments and features of the electrical circuit, the signal generator and the signal transmitter depend on the type of electromagnetic control signal. The formation of the circuit and associated structures for generating and transmitting signals (eg, electromagnets) may be implemented using Tools and techniques such as those skilled in the art from Electrodynamics of Continuous Media, 2nd Edition, by LD Landau, EM Lifshitz and LP Pitaevskii, Elsevier Butterworth-Heinemann, Oxford, but especially not exclusively pp. 1-13- and 199-222 This reference will be hereby incorporated by reference for discussion of the theory underlying the generation and propagation of electrical, magnetic and electromagnetic signals.

The remote control 1100 may be configured to generate a control signal having different characteristics, depending on the intended application of the system. In some embodiments, a particular remote control may be configured to generate only a particular type of signal (a specific frequency or a frequency band, while in other embodiments a particular remote control may be tunable to generate a variable frequency signal Cause DC bias or offset as well as AC frequencies The generation of radio frequency electromagnetic signals is described, for example, in US Pat The ARRL Handbook for Radio Communications 2006, R. Dean Straw, Editor, published by ARRL, Newington, CT , a disclosure which is incorporated herein by reference. The electromagnetic signal generator 1112 can do this be able to provide an electromagnetic control signal sufficient to control a controllable dispensing mechanism of the application means disposed in an environment, the flow of application fluid from the application reservoir to the environment, and an electromagnetic signal transmitter capable of doing so by wirelessly transmitting the electromagnetic control signal to the controllable dispensing mechanism of the application means in an environment. The signal transmitter 1114 may comprise a transmitter unit, for example an antenna or waveguide suitable for use with an electromagnetic signal.

static and quasi-static electric fields, for example generated by charged metallic surfaces while static and quasi-static magnetic fields, for example by passing a current through one or more wires or coils can be generated, or by the Use of one or more permanent magnets, as those skilled in the art is known. The terms "send" "sender" and "transfer" used here are not just for sending in the sense of a radio wave transmission and reception of electromagnetic signals limited, but also stands for wireless coupling and / or transmission of magnetic signals from one or more sources to one or more remote locations.

The Remote control can be modified as it is intended Use is suitable. For example, it can be designed to be wearable on the body of a human (or an animal) to be in which the application agent has been used, for example on a belt, a belt or the like or to be attached to the human body. alternative This can be designed to be placed in the environment of an animal to be, for example, as a tabletop device for use in a house or a clinical environment.

at According to various embodiments, the dispenser a remote control having a control signal of a static or a quasi-static electric field or one static or quasi-static magnetic field, an electromagnetic Radio frequency signal, an electromagnetic control signal in the Microwave range, an infrared electromagnetic control signal, an electromagnetic control signal in the millimeter range, one optical electromagnetic control signal or an electromagnetic Control signal in the ultraviolet range sufficient for activation the controllable dispensing mechanism for controlling the total amount or the rate of exit of the dispensed from the supply reservoir Active ingredient. Different types of electromagnetic control signals can be used to enable the controllable output mechanism. The controllable output mechanism may be static or on quasi-static electric field or a static or quasi-static one respond to magnetic field. It can be done in different ways non-ionizing electromagnetic radiation or in some cases, respond to ionizing electromagnetic radiation. control signals It electromagnetic field, in various embodiments can be used, have electromagnetic radio frequency radiation, electromagnetic microwave radiation, electromagnetic infrared radiation, electromagnetic millimeter wave radiation, electromagnetic optical radiation or electromagnetic ultraviolet radiation one.

Of the Signal generator can be an electrical circuit or a microprocessor In some embodiments, the generated electromagnetic Signal generated at least partially according to a predetermined activation pattern become. The circuit and / or the microprocessor can in a drug delivery device or in the remote control be arranged. The remote control or the drug delivery device can have a memory that is capable of a given Save activation pattern. In some embodiments, can the electromagnetic signal based on a model-based Calculation are generated; the remote control can store which is capable of modeling parameters that are model-based Calculation have been used to save.

In some embodiments, the signal generator may generate an electromagnetic signal having a defined magnetic field strength and / or a defined electric field strength. In general, the term field strength, as used for either a magnetic or an electric field, may refer to the amplitude, the square of the amplitude, or the time average of the quadratic amplitude. The electromagnetic signal may have signal characteristics that are effective to produce a change in the dimension of at least one controllable dispensing mechanism, a change in temperature of at least one controllable dispensing mechanism, a change in the shape of the at least one controllable dispensing mechanism, or a change in the orientation or position of at least one controllable dispensing mechanism are sufficient. In some embodiments, the electromagnetic signal generator may be an electro comprise magnets or an electrically polarized element or at least one permanent magnet or an electret. The electromagnetic signal may be generated at least partially according to a programmed pattern. The electromagnetic signal may have signal characteristics for producing a change in dimension of at least one controllable output mechanism, the change in dimension causing the agent to exit the at least one supply reservoir of the application agent. In some embodiments, it may have signal properties sufficient to produce a change in shape, volume, area, and / or configuration of at least one controllable output mechanism, the change in dimension being that of shape, volume, area, and / or. or the formation of at least one controllable dispensing mechanism causes the feed material to exit the supply reservoir of the application agent. The electromagnetic signal may have signal characteristics sufficient to produce a change in the form of a controllable dispensing mechanism including a shape memory material, a bimetallic structure or a polymeric material, causing the feed material to exit the feed reservoir of the application agent. The electrical signal may have a defined magnetic field strength or location, or a defined electric field strength or location. In some embodiments, the remote control or process may be configured to generate and transmit an electromagnetic control signal having a frequency and / or orientation that may be selectively received by the at least one controllable output mechanism. In some embodiments, the remote control may include at least hardware, software or firmware configured to encrypt the electromagnetic control signal to generate an encrypted electromagnetic control signal.

16 Figure 12 shows an example of an electromagnetic waveform of the type that may be used to activate at least one controllable output mechanism. In the plot 1150 is the time on the axis 1152 arranged and the electromagnetic field strength is on the axis 1154 arranged. The curve 1156 is in the form of a rectangular wave that toggles between the zero amplitude and the non-zero amplitude A.

17 shows another embodiment of an electromagnetic waveform. In the plot 1200 is time on the axis 1202 reproduced and the electromagnetic field strength is on the axis 1204 played. The curve 1206 includes bursts 208 and 1210 while the field strength varies between A and -A at a certain frequency and interval 1212 while the field strength is zero.

18 shows another example of an electromagnetic waveform. In the plot 1250 is the time on the axis 1252 reproduced and the electromagnetic field strength is on the axis 1254 played. The curve 1256 has bursts 1258 and 1262 while the field strength varies between A and -A at a first frequency and burst 1260 while the field strength alternates between B and -B at a second (lower) frequency. Different limits may be selectively received by different individual or classes of controllable output mechanisms in a device or system having multiple controllable output mechanisms. An electromagnetic control signal may be characterized by one or more frequencies, phases, amplitudes or polarizations. An electromagnetic control signal may have a typical temporary profile and direction and characteristic spatial dependencies.

The magnetic or electric field control signal generated by the processor in the drug delivery device or the remote control is generated, can be a defined field strength and / or have a defined electric field strength. At lower frequencies are the electrical and magnetic components of the electric field separable when the field reaches a medium. at a static and quasi-static field application, the control signal of the electromagnetic field are considered as an electric field or a magnetic field. A quasi-static field is one, that is slowly changing, d. h., with one wavelength, which is great in terms of the physically interesting Range or a frequency that is low compared with the characteristic response frequency of the object or medium, the Frequency over which the field is no longer considered "quasi-static" is dependent on the dimensions of the electrodynamic Properties of the medium or structure (s) coming from the field to be influenced.

As shown in various embodiments, the at least one feedstock reservoir may include at least one outlet through which the material to be delivered moves into the environment, such as by pumping or diffusion. In other embodiments, as in FIG 19 shown, an application agent 190 a downstream active agent treatment structure 191 that is in communication with the delivery reservoir 192 is and is adapted to receive material from the supply reservoir 192 emitted in response to a control signal becomes. The downstream material treatment structure 191 may have a chamber as in 19 is shown. The application agent 190 may further include a pump (eg, osmotic pump) and at least one controllable dispensing mechanism 194 , In other embodiments, for example, the application means 200 , this in 2 may be a downstream active agent treatment structure 201 one or more channels 202 , Chambers 203 , Cleaver 204 , Mixer 205 or other drug-treatment structures, or various combinations thereof. The application agent 200 further has a supply reservoir 206 and an outlet 207 on. With regard to the active substances, which are fluids or can be fluidized, typical examples of fluid treatment structures which are suitable in certain embodiments are described in US Pat U.S. Patents 6,146,103 and 6,802,489 , and in Krauss et al., "Fluid pumped by magnetic stress", which bears the date of 1 July 2004, p. 1-3 ; to find under: http://arxiv.org/PS_cache/physics/pdf/0405/0405025.pdf , which are each incorporated herein by reference. Fluid treatment structures may include, but are not limited to, channels, chambers, valves, mixers, splitters, accumulators, pulse flow generators and suction suppressors, and others.

One drug to be applied could be in the deformable Feedstock reservoir structures that take different forms and Configurations have to be introduced. The term "deformable", like he used here means that the reservoir the ability to change a shape in at least one dimension. A deformable reservoir may, for example, be volumetric expandable, radially expandable or volumetrically constant but geometrically reconfigurable. In some embodiments The deformable reservoir may be an expanding or contracting one Structure, with the change in at least one Direction an expansion or contraction in at least one dimension includes. Another embodiment is a deformable Reservoir folded along its longitudinal axis and at apex angle and shrouded like a screen for a compact storage or transport to a minimum diameter for insertion (eg, injection) when used to be realized. A non-limiting example a volumetrically expandable reservoir is a balloon-like Structure. A non-limiting example of a longitudinally-configurable Reservoirs is a microcatheter that is capable of doing so to bend and occupy a lumen of a human or an animal. Examples of microcatheters are known to the person skilled in the art. Like here described in embodiments, the deformable Reservoir have at least one outlet through which an active ingredient from the supply reservoir can leak into the external environment or to a downstream location. In another embodiment can chemically or biologically inertise the deformable reservoir have inner or outer surfaces. such inert surfaces, in particular the outer surface, can be the chemical or biological interaction between minimize the device itself and the environment. Inert materials, which are suitable for the deformable reservoir are known in the art.

The deformable reservoir can at least one inlet structure, a Mechanism or port for taking active substance from outside the environment is supplied, to the filling to allow the reservoir during this in which human or animal remains employed. The inlet mechanism may be a self-sealing material that is in the body the reservoir is enclosed, so no permanent hole is formed in this. The inlet mechanism can be configured be to introduce the drug into the deformable reservoir but allow the material to escape from the deformable Reservoir to prevent through the same mechanism. The inlet mechanism of the deformable reservoirs may be a one-way valve or another Be a mechanism capable of supporting a vehicle for the drug to be administered to the reservoir, for example a syringe needle to pick up. Such an inlet mechanism can be passive or active. An active inlet mechanism can to accept a delivery of the material from outside be formed if necessary and therefore can be controlled and therefore be formed using the materials described herein for the controllable output mechanism. Such a At least one controllable inlet mechanism can be used a control signal that is different from the at least one control signal used to activate and controlling the at least one controllable dispensing mechanism. The inlet mechanism may further comprise means for decontaminating the Carrier containing the additional active ingredient supplies. Such decontamination methods and mechanisms are the person skilled in the art can and the transmission of UV light and / or a chemical decontaminant.

As previously mentioned, application agents as described herein may include various types of micropumps or nanopumps that are suitable for injection. A micropump or nanopump suitable for use in a drug delivery device may include a positive displacement micropump, a centrifugal pump, or a peristaltic pump. The choice of pump and method of construction may be dependent upon the intended use of the drug delivery device, the site of application, the dimensions of the drug delivery device, among other things, as understood by one skilled in the art. In some embodiments, the downstream location may be an animal environment. In some embodiments, the downstream location may be a downstream drug treatment structure, in some embodiments, the downstream location may include a downstream environmental interface. An environmental interface may be a function to facilitate the distribution of the drug to be administered in an environment.

21 shows an example of a drug delivery device 210 with an environment interface 211 , In the embodiment of 21 creates the environment interface 211 the application of the material 212 into the blood, through capillaries 213 flows. The drug delivery device 210 has a pump 214 and a drug-containing structure 215 on (shown here as an application reservoir), the drug to be administered 212 includes.

In other embodiments, the drug delivery device 223 as it is schematic in 22 is shown, an extraction mechanism 221 to remove the entire device 220 from the in vivo environment. A removal tool may include a syringe including a hollow tube capable of receiving the drug delivery device. As described above, a body structure may be disposed about the drug delivery device, the body structure may facilitate removal of the drug delivery device. The drug delivery device 223 can be an extraction mechanism 212 comprising coupling the drug delivery device 223 to the extraction tool 222 facilitated. The extraction mechanism 221 may be a magnetic portion on the drug delivery device 223 which is attracted to the magnetic end of an extraction tool 212 and fits together with this. In certain circumstances, removal of the drug delivery device from the in vivo environment may be required prior to emptying the at least one deformable reservoir. In this case, it may be necessary to remove all or part of the active ingredient to be applied from the application reservoir before or during the extraction of the device from the environment. Removal of the active agent from the reservoir can be achieved in a variety of ways and includes the use of a syringe-like device or needle that can access the reservoir contents or the controllable inlet mechanism.

Another embodiment includes an active agent application kit having at least one delivery mechanism provided with a drug delivery device insertable into a human or animal. The at least one injectable drug delivery device is disposed in the delivery mechanism and provided with at least one deformable reservoir adapted to receive, store, and controllably dispense at least one drug, including at least one outlet through which the at least one drug is selected from the at least one definable drug Reservoir can be released and at least one controllable export mechanism, which is operatively connected to the at least one outlet and configured to control the release of the at least one active substance from the at least one deformable reservoir. The delivery mechanism may include a syringe or syringe-like device or any other device known to those skilled in the art, as far as it is adapted to deliver the drug delivery device into the in vivo environment. The drug delivery kit may further comprise a remote control configured to generate and transmit at least one control signal sufficient to activate the controllable dispensing mechanism. The kit may further comprise, in one embodiment, at least one active agent to be administered, as described herein. The at least one active substance to be administered can be completed in an ampoule or arranged in the application mechanism itself. Another example includes a method of applying an agent to a human or animal by incorporating an agent delivery device as described herein into an in vivo environment of a human or animal. The drug delivery device has at least one deformable reservoir adapted to receive and dispense at least one drug to be delivered, and at least one outlet, at least one controllable dispensing mechanism, operatively connected to the at least one outlet; and apply an amount of at least one active agent in the at least one deformable reservoir subsequent to insertion of the device into the in vivo environment, and transmit an electromagnetic control signal to the in vivo environment comprising the device applying the drug, the electromagnetic controller having signal characteristics which are receivable by the drug delivery device and are sufficient to provide the at least one controllable delivery mechanism for causing the delivery of at least a portion of the at least one drug from the at least one drug delivery device to activate at least one reservoir.

One Embodiment may be a method of applying of a therapeutic agent in a human or animal with introduction of the drug delivery device into a in vivo environment of the human or animal, wherein the drug delivery device has at least one deformable reservoir for receiving and for storing the drug to be supplied and with is formed at least one outlet, wherein the at least one controllable output mechanism operatively with the at least one Outlet is connected; Applying a quantity of the at least one to be administered drug into the at least one deformable Reservoir following the introduction of the at least a reservoir in vivo, sealing the at least one deformable Reservoir, the at least one active ingredient to be applied includes, and transmitting an electromagnetic control signal to the in vivo environment containing the drug delivery device includes, wherein the electromagnetic control signal signal characteristics received by the drug delivery device can and are sufficient to the at least one output mechanism for effecting delivery of a portion of the at least one active agent from the at least one deformable reservoir to activate.

23 schematically shows a method for feeding a material through the use of the application device described here. A basic procedure 1500 - 1506 includes receiving a control signal from a remote control 1502 , and the response to the electromagnetic control signal, which is the delivery of the drug to be applied from the application reservoir at step 1504 caused, a.

In 24 is shown schematically that an extended version of the procedure 155 - 1508 receiving an electromagnetic control signal from a remote controller at step 1552 and, responding to the electromagnetic control signal, causing a deformation ( 1554 ) of the controllable dispensing mechanism and thereby causing leakage of the material from the deformable drug reservoir at step 1556 ,

One Methods, as described herein, may include receiving the control signal with an appealing material (for example an electromagnetically-responsive material), which, in turn, for example, a hydrogel, a permanently magnetizable Material, a ferromagnetic material, an iron-like material, an iron-containing material, a dielectric or ferroelectric or piezoelectric material, a diamagnetic material paramagnetic material, a metal and an antiferromagnetic material can have. The method may include the step of delivering the have substance to be applied in an external environment, what, for example, the body of a human or an animal may include, in particular, the body of a People. Alternatively, the method may include dispensing the one to be administered Active ingredient in a downstream environmental interface or a downstream material treatment structure have what a channel, a chamber, a mixer, a separator or a combination thereof.

25 schematically shows a drug delivery system 1650 , which is a drug delivery device 1652 and a remote control 1654 having. In this embodiment, the drug delivery device 1652 a pump 1678 , a deformable reservoir 1656 , the one to be administered drug 1662 includes, with at least one outlet 1658 through which an active ingredient from the deformable reservoir structure 1656 can escape; and an agent to be administered in the medium 1660 that of the deformable material 1656 is received and at least one controllable output mechanism 1664 which is adapted or configured to control the output of the drug from the reservoir in response to an impinging electromagnetic control signal 1672 or in response to a sensed condition of a sensor.

The remote control 1654 has an electromagnetic signal generator 1668 which is capable of producing an electromagnetic signal 1672 sufficient to generate the controllable output mechanism 1664 of the drug delivery device 1652 in the area 1653 is arranged to control. An electromagnetic signal transmitter 1670 is capable of the electromagnetic control signal 167 wirelessly to the controllable output mechanism 1664 of the application device in the environment to cause the discharge of the material into the environment. The remote control can be an electrical circuit 1674 comprising at least one hardware, firmware and / or software configured to generate the electromagnetic control signal. The remote control 1654 can be an electromagnetic signal generator 1668 which is capable of generating a control signal of a static or a quasi-static electric field, a control signal of a static or quasi-static magnetic field, an electromagnetic control signal in the radio frequency range sufficient, an electromagnetic control signal in the microwave range, a infrared electromagnetic control signal, an electromagnetic Millimeter-wave control signal, an optical electromagnetic control signal (which may include ultraviolet and / or infrared wavelengths) sufficient to activate the controllable output mechanism for controlling the delivery of the drug from the drug-receiving structure. The remote control may include an electromagnetic signal generator configured to generate a rotating electromagnetic control signal.

The at least one controllable output mechanism 1664 may include a magnetically or electrically active material that is at least one of the following materials: a hydrogel, a permanent magnetizable material, a ferromagnetic material, a ferrimagnetic material, a ferrous material, an irony material, a dielectric material, a ferroelectric material, a piezoelectric material Material, a diamagnetic material, a paramagnetic material, a metallic material, an antiferromagnetic material or a combination of said materials. In some embodiments, the controllable output mechanism may include a polymer, a ceramic, a dielectric, a metal, a shape memory metal, or a combination of a polymer and a magnetically or electrically active component.

Another, in 26 schematically illustrated embodiment is a variation of the embodiment of 25 in which the drug delivery device 1704 continue an RFID 1700 can have. The remote control 1720 can be an RF interrogation signal generator 1706 for generating an RF interrogation signal can be tuned to the RFID. The remote control further has an electromagnetic signal generator 1668 , an electromagnetic signal transmitter 1670 , an electrical circuit 1674 which are essentially like in 25 is described, works. The remote control may further include an interrogation signal transmitter for transmitting a transmittable RFID interrogation signal and an interrogation signal receiver for receiving a returned RFID interrogation signal from an RFID in an application device. An RFID detection circuit is configured to detect the presence of a selected RFID from a returned RFID interrogation signal. Upon detecting the presence of a particular RFID, the remote controller may generate and transmit a control signal configured to be received by the application device having the particular RFID.

27 schematically shows an application system with a remote control 1850 , which is an electromagnetic control signal 1856 generated to the application device in an in vivo environment 1856 is sent. The electromagnetic control signal 1852 is received by or indirectly activated by at least one controllable output mechanism 1858 in the application device 1854 , The remote control 1850 can be a signal input 1851 arranged to receive at least one signal 1860 that of an environment 1856 from at least one sensor 1862 is sensed, with the electromagnetic signal 1852 based at least in part on the at least one signal 1860 that is measured by the environment is generated. For example, the signal 1860 the presence or absence of a particular molecule or substance, the temperature of the environment, or any other measured state or signal. The remote control can be an electrical circuit 1864 , a signal generator 1866 , a signal transmitter 1868 and a memory 1860 include. The signal, for example a feedback signal from the sensor 1862 , can be transmitted wirelessly. The remote control may include a signal input adapted to receive a feedback signal in accordance with one or more parameters measured by the environment, wherein the electromagnetic control signal is generated based at least in part on the feedback signal sensed by the environment. For example, the feedback signal may correspond to the activity of at least one controllable output mechanism or to the presence, concentration or chemical activity of chemical or biological substances in the environment. 28 schematically shows another embodiment of an application system with a remote control 1900 which is an electromagnetic control signal 1902 to the application device 1904 in the neighborhood 1906 sends.

The remote control 1900 can be a signal input 1908 which is for receiving a signal 1912 from at least one sensor 1910 in the application device 1904 is set up. The electromagnetic control signal 1902 can at least partially on the signal 1912 based on one or more parameters sensed by the application device. In some embodiments, the signal from the application device may indicate the presence or absence of a particular molecule or substance, the concentration or chemical activity of a chemical in or around the delivery device, a temperature in or around the delivery device, the pumping or delivery rate of the delivery device, or others Address the parameters that have been measured by the application device. For others, the signal may correspond to the pumping rate of the application device, for example, from the pump 1922 has been generated. In some embodiments, the sensor 1910 for recognizing at least one parameter from the at least one region of the environment surrounding the application device. The electromagnetic control signal 1902 may be at least partially based on the signal point 1912 be determined. Examples of sensors are in the US Patent 6,935,165 , and the US Patent Publication 2004/0007051 , and 2005/0208469 both of which are incorporated by reference. Further examples of sensors will be found in the article "Easy-to-hake Nano Sensors: Tiny electron-based detectors could provide simple tests for cancer or bioterror drugs." By Kevin Bullis , described on the internet below http://www.technologyreview.com/Nanotech/18127/ can be found. This article is incorporated by reference. Other examples of sensors are from Gruner, G., "Carbon Nanotube Transistors for Biosensing Applications"; Anal. Bioanal. Chem. (2006) 384: 322-335 This publication is also incorporated by reference. Carbonnanotube transistors are designed for mass production, as is required by Gabriel, JC, Mat. Res. Soc. Symp. Proc, (2003) Vol. 776, Q.12.7.1-12.7.7 , this paper is incorporated by reference. The application device 1904 has a controllable dispensing mechanism 1920 on. The signal 1912 can be wirelessly retransmitted to the remote control 1900 , The remote control 1900 can be a processor 1914 , a signal generator 1916 , a signal transmitter 1918 and a memory 1924 include. In 29 schematically illustrates that in some embodiments, the remote control may be configured to receive receiver inputs from control parameters. The remote control 1950 has an entrance 1960 for receiving input signals of information or commands from one of such as, for example, commands, variables, durations, amplitudes, frequencies, waveforms, data storage and recovery commands, body data, etc. As in the other embodiments, the remote control transmits 1950 an electromagnetic control signal 1952 to the drug delivery agent 1954 in the neighborhood 1956 where there is the taxable spending mechanism 1958 activated. The input 1960 may include one or more input devices such as a keyboard, a miniature keyboard, a microphone, a mouse, etc. for directing input information from a used or input 1960 of any type of different analog or digital data inputs or ports, including data readers such as disk drives, storage device readers, etc., to obtain information or data in digital or electronic form. Data or commands through the input 1960 can be entered with the electrical circuit 1962 used to the operation of the remote control 1950 to modify and for modulated generation of an electromagnetic control signal from the signal generator 1964 and the transmission of the electromagnetic control signal 1952 from the transmitter 1966 , In some embodiments, the remote control may be configured with a storage mechanism or location to record the user's input according to the user's physical state. For example, the user may enter the time and date and nature of his / her state. For example, the remote controller may be configured to receive alphanumerically inputted characters as well as whether the user feels good or bad, has a headache or fever, is suffering from insomnia or loss of appetite, drowsy, dizzy, irritable, and so on. Such recorded information may be useful to the attending physician and may, for example, allow the physician to input the user with the recorded information from the application means regarding the time and amount of material supplied to program the plan and / or the amount of material supply , In some embodiments, the remote control may be configured with a learning function responsive to the user's inputs. The remote control may be programmed to respond to certain predetermined user inputs in any manner dictated by the physician, such as with a programmed setting of drug dosing and schedule. 30 schematically shows an application system having a plurality of application means, wherein two or more of the plurality of application means are controlled by the remote control. The remote control may include a plurality of selectively activatable output mechanisms, each associated with a material treatment element, which allows multiple material treatment steps to be performed in a predetermined sequence. It is contemplated that an application system may include a plurality of application means, which may be the same or different in nature. As in 30 can be shown an application system 2000 a plurality of identical application means 2002 exhibit in an in vivo environment 2004 have been distributed to effect a drug delivery in a plurality of locations in the environment and controlled by a remote control 2006 , Alternatively, an application system may comprise a plurality of different application means at different locations in an environment, each of which performs or controls an agent application suitable for the particular location. The embodiments described herein are not limited to means, systems or methods having a particular number or configuration of the controlled dispensing mechanism within an application means or a specific number or configuration of Application means or remote controls within an application system. Depending on the particular application of a system, the controllable dispensing mechanism and / or the application means may be controlled in a particular pattern to produce a desired distribution of an agent to be administered to a human or animal. Such systems may be formed using appropriate hardware, firmware, software, or by a plurality of remote controls.

The remote control in the in 30 1, it may include an electromagnetic signal generator capable of generating an electromagnetic control signal sufficient to activate at least one controllable output mechanism in a plurality of application means located in a human or animal, to control the rate of application of the drug to be administered from the at least one deformable reservoir of each of the agents. In a related embodiment, the remote control may include a plurality of signal inputs configured to receive signals from a plurality of application means, the plurality of signal inputs, coupled to a processor configured to generate the electromagnetic control signals based on a plurality of signals , are adjusted. Selective activation or control of the controllable output mechanism may be accomplished by configuring the controllable output mechanism to be activated by the control signals having certain signal characteristics including, for example, an electromagnetic control signal, a particular frequency, phase, amplitude, temporal profile, polarization, and / or directional properties and spatial variations thereof. For example, different controllable output mechanisms may be responsive to different frequency components of a control signal, thereby enabling selective activation of the different controllable output mechanisms. The remote control or a microprocessor mechanism included in the drug delivery agent may be configured to generate a rotating electric field, wherein the rotating electromagnetic signal is capable of independently controlling two or more application means as a function of the orientation of the rotating electromagnetic signal to activate.

As schematically in 31 can be shown an application system 2101 in some embodiments, a plurality of application means 2102 . 2104 . 2106 and 2108 and a plurality of remote controls 2100a . 2100b . 2100c exhibit. 31 shows that each application means can be controlled by one or more control signals distributed in a distributed manner by two or more of the plurality of remote controls 2100a - 2100c be generated.

As schematically in 32 can be shown, an application system 2151 a plurality of application means 2151A . 2152b and 2152c and a plurality of remote controls 2151A . 2151B and 2152c Each application means can be controlled by a separate remote control. For example, the application agent 2151A through the remote control 2150a controlled, the application means 2152b from the remote control 2150b and the application agent 2152c from the remote control 2150c , In other embodiments, as exemplified in 33 can be represented, a remote control 2200 a plurality of broadcast channels 2204a . 2204b . 2204c and 2204d (more or fewer channels can be used without restriction). The remote control 2200 may be a channel allocation hardware or software 2206 formed to be the plurality of transmission channels 2204a - 2204d for transmitting the electromagnetic control signal from the signal transmitter 2208 to selected application means from the plurality of application means 2202a - 2202f to distribute. In another embodiment of the application agent 2250 as shown schematically in 34 is shown, the remote control 2252 an encryption hardware or software 2262 which is selected for encrypting one or more control signal components, wherein the encryption of one or more control signal components from an application means 2254 can be received, including a corresponding decryption component 2262 which includes hardware, firmware, or software necessary to perform a decryption protocol combination with the remote controller 2252 is configured. The remote control 2252 can be a signal generator 2256 , a signal transmitter 2258 and an electrical circuit 2260 as described elsewhere herein.

In another embodiment of an application system 2300 , this in 35 is shown schematically, the remote control can be an authentication hardware or software 2312 for carrying out an authentication process with an application means 2304 is formed, the remote control 2302 for effecting activation of the controllable output mechanism 2316 an authenticated application means is configured, but not the controllable output mechanism of an unauthenticated application means. The remote control can turn a signal generator 2306 , a signal transmitter 2308 and an electrical circuit 2310 as generally described elsewhere, as well as an authentication component 2314 which may include hardware, firmware, or software for performing an authentication protocol with the remote controller 2302 is configured. In various embodiments of the remote control described here, the generated magnetic control signal may have a defined magnetic field strength or alternatively or additionally, a defined electric field strength. Depending on the intended application, the electromagnetic control signal may have signal characteristics sufficient to produce a change in the dimension of the controllable dispensing mechanism, a change in temperature of at least a portion of the controllable dispensing mechanism, a change in the design or configuration of the controllable dispensing mechanism Change in the orientation of the position of the controllable dispensing mechanism. The remote control may comprise an electromagnetic signal generator having an electromagnetic or electrical or magnetically polarized element or one or more permanent magnets or electrets.

36 schematically shows the steps of a method 2350 the application of an active substance in a human or an animal with the introduction of at least one active substance application agent into an in vivo environment of a human or an animal ( 2351 ). The drug delivery agent has at least one controllable dispensing mechanism and at least one deformable reservoir capable of storing a material to be applied. It is further provided with at least one outlet containing a quantity of the at least one active substance in the deformable reservoir (FIG. 2352 ), and sends a control signal to the drug delivery means disposed in the in vivo environment, the control signal having properties that can be received by the drug delivery agent and that is sufficient to activate the at least one delivery mechanism and is sufficient for the escape of a part of the at least one active substance from the at least one outlet ( 2353 ) to effect, step 2352 , The methods described herein with a control signal may be effected using a remote controller for generating and transmitting the control signal or using a microprocessor (also referred to herein as a processor) and a memory located in the drug delivery means itself. 37 schematically shows further variations of the method of 36 , For example, the method 2400 providing an electromagnetic control signal to the environment receiving the application agent. In this case, the application means has an electromagnetically responsive controllable dispensing mechanism and a reservoir containing an active substance which receives the active ingredient to be administered. The electromagnetic control signal has signal characteristics that can be picked up by the electromagnetically responsive controllable dispensing mechanism and that are sufficient to cause the dispensing of a portion of the material to be dispensed from the reservoir. Further steps may include generating and transmitting the electromagnetic control signal to the application means with the remote control as in 2406a shown. Alternatively, the method may include generating a first electromagnetic control signal sufficient to cause a portion of the at least one material to be applied to exit the deformable reservoir into the in vivo environment, as in US Pat 2406b shown. Or, the method includes generating a first electrical control signal having a frequency and a magnitude sufficient to cause the at least one controllable output mechanism to be heated 2406c shown. Alternatively, the method may include generating a first electromagnetic control signal having a frequency and magnitude sufficient to cool at least one controllable output mechanism as in 2406d a first electromagnetic field having a frequency and a magnitude sufficient to effect a design change of a molecular structure as in 2406e or to generate a first electromagnetic field having a frequency and strength sufficient to cause a volume change of a molecular structure drug, as in US Pat 2406f shown to produce.

38 schematically shows a method 2450 - 2456 the application of a drug (exemplified as a fluid in this figure) including pumping a fluid to be administered from a reservoir of an application agent to a downstream location with a first pump rate at the step 5452 and controlling the escape rate of the drug from a remotely emitted electromagnetic control signal at step 2454 , In some embodiments, the first pumping rate may be a constant pumping rate, in some embodiments, varying the rate of application of the active agent to the downstream location may be in response to a remote transmitting electromagnetic control signal. The first pumping rate is modifiable in response to a remote transmitting electromagnetic control signal, for example. The method may include controlling the output of the fluid by activating the controllable dispensing mechanism in the application agent through the telemetered electromagnetic control signal for activating the controllable dispensing mechanism, for example by heating the controllable dispensing mechanism or cooling the controllable dispensing mechanism. In some variations of this method, the controllable dispensing mechanism may include a change in at least one dimension in the controllable dispensing mechanism, a change in the orientation of the controllable dispensing mechanism, or a change in the design of the controllable dispensing mechanism.

In the process 2500 - 2510 from 39 For example, in some embodiments where the drug delivery agent has at least two deformable reservoirs each having at least one outlet and at least one controllable delivery mechanism, the at least two deformable reservoirs may include the same or different agents. The procedure ( 2502 . 2504 ), controlling the exit rate of the first drug to be delivered to an optionally downstream location in response to receiving a first control signal (in this example, the first control signal is exemplary electromagnetic) from a first controllable output mechanism ( 2506 . 2508 and controlling the output rate of a second or additional drug to be administered to an optionally downstream location in response to the received second or additional control signal (in this figure, the control signal is exemplary electromagnetic) by a second or additional controllable output mechanism. In some embodiments, the at least two electromagnetic control signals may be the same electromagnetic control signal. In other embodiments, the at least two electromagnetic control signals may be different. In some embodiments, the at least two electromagnetic control signals may include the same or different ones. In some embodiments, the at least two controllable output mechanisms may be the same controllable output mechanism, while in other embodiments the two controllable output mechanisms may each be different controllable output mechanisms or some of the at least two controllable output mechanisms are the same, while some are different. "Different" controllable output mechanisms may be controllable output mechanisms of different types or differently controllable output mechanisms of the same type. In other embodiments, the at least two agents to be administered may be different or the same. In yet another embodiment, the two drugs to be administered may form a therapeutic cocktail for preventing and treating a particular disease or condition. The at least two active substances to be administered can be administered under rules that are based sequentially, simultaneously or on different plans. The at least two drugs to be administered may be reactants which react in vivo or in a chamber prior to delivery in vivo.

40 schematically shows a method 2750 - 2758 with a number of alternative steps relating to the generation of the electrical control signal 2752 , The step 2756a reads generating an electromagnetic control signal and sending the electromagnetic control signal to the application means with a remote control. The step 2756b includes generating the electromagnetic control signal and transmitting the electromagnetic control signal to the application means with two or more remote controls. The step 2756c includes generating the electromagnetic control signal from a model-based calculation. The step 2765d includes generating the electromagnetic control signal based on a stored pattern. As another alternative, the step flows 2756e generating the electromagnetic control signal based on a feedback control scheme. For example, a feedback control scheme may be a variable feedback scheme. The step 2754 includes remotely transmitting the electromagnetic control signal to the application means having signal characteristics sufficient to activate the electromagnetically responsive controllable output mechanism in the application means to control delivery of a portion of the active agent from the reservoir to the in vivo environment.

Another extension of the in 40 The method shown may include the additional steps shown schematically in FIG 41 are shown (steps 2800 - 2806 Namely, receiving a signal corresponding to one or more parameters from the in vivo environment 2802 have been sensed and, based on this signal, generating the electromagnetic control signal having signal characteristics which contribute to the generation of a desired signal 2804 to be expected. In some embodiments, receiving the signal from the in vivo environment may include receiving signals from at least one sensor in the environment, while in the other embodiments, receiving the signal from the environment includes receiving signals from two or more sensors in the environment the environment has. Receiving the signal from the environment may, for example, receiving a measurement of the temperature or the con concentration or presence or absence of a chemical or biological substance within at least part of the environment.

at another variation of the method shown here the additional steps of receiving a feedback signal be present from the application agent. Based on the feedback signal An electromagnetic control signal is generated, the signal characteristics which are expected to control the output of a portion of the Drug from the reservoir or to produce a desired Signal. Receiving a signal from the drug delivery agent can receive signals from at least one sensor in the Having drug delivery agent, or, alternatively, the Receiving a signal from the application means receiving of signals from two or more sensors in the application means. For example, receiving the signal from the application means Receiving a signal that includes the activity the controllable output mechanism of the temperature, the amount that Quality or the degradation state or concentration of the fabricating agent in or around the application agent. In other embodiments, receiving the Signals from the application means include receiving a signal, indicating whether the reservoir needs refilling.

Another variation of the method shown here, as shown schematically in FIG 42 is shown (steps 2890 - 2896 ), the provision of particular steps may include receiving an input of one or more control parameters by the user 2894 and generating, based on the one or more controlled parameters, the generation of an electromagnetic control signal having expected signal characteristics for causing leakage of a portion of the active agent from the reservoir, as in US Pat 2894 , Further advances to the method include the steps of activating the controllable dispensing mechanism to effect heating or cooling or activating the controllable dispensing mechanism to produce a change in the configuration of the controllable dispensing mechanism. The steps of generating an electromagnetic control signal and remotely transmitting the electromagnetic control signal to the application means may be performed in accordance with instructions that are in the form of software, hardware or firmware. In some embodiments of the method, the steps of generating an electromagnetic control signal and remotely transmitting the electromagnetic control signal to the application means may be performed in accordance with instructions distributed among a plurality of controllers or transmitters.

Further Embodiments for controlling the controllable output mechanism shows the addition of an on / off mechanically operated switch one. This switch can be operated by any means and may include, but is not limited to, a pressure gauge holder include, which can be operated by the user. The user may wish to include the drug delivery device. or turn off if necessary.

Generating the electromagnetic control signal includes generating a static or quasi-static magnetic field, a static or quasi-static magnetic field, a radio frequency electromagnetic signal, an electromagnetic signal from microwaves, a millimeter-wave electromagnetic signal, an optical electromagnetic signal, or an ultraviolet electromagnetic signal. The generation of the electromagnetic control signal may be performed under hardware, firmware or firmware control or via the actuation of a circuit. 43A shows schematically an embodiment relating to a kit described herein. The kit has an insertion mechanism that is in 43A a syringe-like device 430 that is a drug delivery agent with a deformable reservoir described herein 431 , and may include an agent for application to an in vivo environment of a human or animal. The syringe or delivery mechanism may be a cylinder having a proximal end 434 and a distal end 435 , a cannula 436 , which is in communication with the distal end, and a piston 437 which is slidable through the proximal end with respect to the cylinder. The syringe or piston may have at least one cavity 438 comprise (in the figure, the piston is shown by way of example) for retaining the at least one active substance for supply to the at least one deformable reservoir 431 ,

According to one embodiment, the drug delivery agent may be in the cannula 436 be arranged together with at least one deformable reservoir 431 adapted for receiving and maintaining a drug subsequent to injection into a human or an animal, the deformable reservoir having at least one outlet through which the drug can exit the at least one deformable reservoir. At least one controllable dispensing mechanism 440 is operatively connected to the at least one outlet and capable of being activated to control delivery of the active agent from the at least one deformable reservoir. The kit can continue a remote control 441 which is capable of generating a control signal 442 sufficient to activate at least one controllable dispensing mechanism 440 , Alternatively, the remote control may be configured to generate commands to program the processor of the drug delivery device (eg, hardware, firmware, or software), thereby programming the function of the agent. The at least one cavity of the piston may further be prefilled with at least one active substance to be applied, or may be designed to receive the at least one material to be dispensed at the time of use.

One In vivo introduction of the drug delivery agent, as here has been described can be achieved in various ways be including a loading mechanism.

It will be up now 43B Referenced. An embodiment for inserting the drug delivery agent includes a deformable reservoir 431 with a cannula 436 (For example, a hypodermic needle) of the syringe and the drug to be applied 432 within a cavity of the cylinder or within a cavity 438 of the piston 437 one. For introducing the drug delivery agent with the controllable output mechanism 440 becomes the cannula 436 in the in vivo environment 430 used, such as transcutaneously in the peritoneal cavity. The piston 437 It is slidably moved through the barrel of the syringe where it presses on the drug delivery device to remove it from the cannula 437 in the nearby areas 450 to drive.

Following the disposition of the at least one portion of the deformable reservoir 431 in the in vivo environment 450 , the active ingredient may be 432 from the syringe into the inner cavity of the introduced deformable reservoir 431 where it is taken up by the reservoir. The reservoir deforms in vivo to receive the applied material and subsequently deliver the predetermined amount of the drug within the deformable reservoir. The deformable reservoir is scanned to maintain its contents of drug to be delivered. The application agent is taken from the cannula 436 separated and the cannula 436 can then from the in vivo environment 450 be withdrawn. The method and means as described herein can also be achieved using an automated device. For example, to provide consistent application of pressure to introduce the drug delivery agent and the drug to be administered, use may be made of a device which provides a mechanical mechanism for driving the piston or other piston-like element, which introduces the delivery agent into the in vivo environment by introducing the drug Active ingredient used in the deformable reservoir.

Of the automated mechanical mechanism may possibly To introduce the agent or the drug too gently or too slowly.

44A schematically shows an embodiment in which the application means in the in vivo environment 450 is introduced before receiving the drug to be delivered by means of a syringe (in this figure) or other means. 44B schematically shows an alternative embodiment in which the application agent in vivo 450 has been introduced and the active ingredient 432 then percutaneously to the agent via a needle 445 has been supplied, for example to the reservoir 432 refill.

An illustrative two-stage injection device that can be used for delivery of an application agent including a deformable reservoir and a drug is disclosed in U.S. Pat U.S. Patent No. 4,834,704 which is incorporated by reference. The devices, means and approaches of U.S. Patent No. 4,834,704 may be adapted to include a controllable output mechanism operatively connected to the at least one outlet. Although the two-stage means are illustrated for illustrative purposes, other apparatus and methods are known which may also be used to provide such functionality.

software may be used to perform a variation of the methods, such as they have been described here are used. Such software includes software for controlling the application of the active ingredient from a Application means, including commands to generate including an electromagnetic control signal Frequency components provided by at least one controllable output mechanism an application means are absorbable in an environment, wherein the application means comprises a deformable reservoir, the is able to absorb a material to be applied and store and with at least one outlet, the supply of the active ingredient by at least one controllable delivery mechanism is controllable. Commands for controlling the transmission of the electromagnetic Control signal to the application means with signal properties which are sufficient for activating the at least one controllable Output mechanism in the application means for controlling the application the active ingredient in the application agent.

The software may include commands for generating the electromagnetic control signal and commands for calculating the electromagnetic control signal nals based on a model. The instructions for generating the electromagnetic control signal may be instructions for generating the electromagnetic control signal based on a pattern stored in the data storage location or instructions for generating the electromagnetic control signal based on a feedback control algorithm. For example, the instructions for generating the electromagnetic control signal may include instructions for generating the electromagnetic control signal based on a variable feedback control algorithm. The software may include instructions for receiving a feedback signal corresponding to the one or more parameters sensed by the environment, and instructions for generating the electrical control signal based at least in part on the received feedback signal, wherein the electromagnetic control signal has signal characteristics expected to be Generating a desired feedback signal. Some embodiments of the software may include instructions for receiving a feedback signal from the application means and instructions for generating the electromagnetic control signal based at least in part on the received feedback signal. The electromagnetic control signal has a frequency composition and an amplitude expected to produce the desired feedback signal. In some embodiments, the software may include instructions for receiving user input of one or more control parameters and instructions for generating the electromagnetic control signal based at least in part on the one or more control parameters. In some embodiments, the software may include instructions for performing encryption of the electromagnetic control signal.

Of the Command may be provided to perform an authentication process between a remote control transmitting the electromagnetic control signal, and an application means with the controllable dispensing mechanism, which is used to activate the electromagnetic control signal. At least part of the electromagnetic generating commands Control signal and the command to control the transmission of the electromagnetic control signal are in one of a plurality of processors distribute way executable. Some embodiments the software may include channel allocation commands, which are configured to control the distribution of the control signal transmission channels for transmitting a plurality of control signals to a corresponding plurality of application means.

In terms of the hardware and / or software used in the control of the means and systems according to the embodiments described herein used and in particular for sensing, analyzing and the control aspects of such systems, the person skilled in the art will recognize that these have progressed to a point where little distinction has remained is between aspects of hardware and software implementations of the systems. The use of hardware and software is generally (but not always insofar as that in certain contexts the choice between hardware and software can become significant) is a design choice that faces the cost the efficiency or considerations of convenience of the implementation. The skilled person will recognize that There are different carriers through which the ones described here Processes and / or systems may be affected (for example Hardware, software and / or firmware) and that the preferred carrier in the context in which the process is used will vary. If a user, for example, the speed and accuracy As a goal, the user is responsible for a hardware and / or opt for a firmware carrier. If on the other hand flexibility that The goal is, the user can for a sole software implementation opt. Alternatively, the user may opt for a combination from hardware, software and / or corporate goods. They are therefore different Carrier possible through which the ones described here Processes can be effected. None of these is inherent the other superior in that as a carrier what can be used, a choice that depends on the context, in which the carrier is used and its particular Properties (eg speed, flexibility or predictability) by the user, which vary in each case can.

The foregoing detailed description has concerned various embodiments of the means and associated processes using methods through the use of block diagrams, flowcharts, and / or examples. As far as the block diagrams, flowcharts, and / or examples include one or more functions and / or operations, it will be understood by those skilled in the art that any function and / or operation within such diagrams, flow diagrams, or examples may be implemented both individually and collectively through a variety of hardware, software, corporate goods, or virtually any combination thereof. One embodiment, various portions of the subject matter described herein may be implemented via Application Specific Integrated Circuits (ASICs), Field Programmable Gate Arrays (FPGAs), Digital Signal Processors (DSPs), or other integrated formats. However, the skilled artisan recognizes that some aspects The embodiments disclosed herein may be implemented in whole or in part equivalently in conventional integrated circuits, as one or more computer programs running on one or more computers, such as one or more programs running on one or more computer systems, such as one or more Programs that run on one or more processors (for example, as one or more programs running on one or more microprocessors), as a company product or any combination thereof, and that the design of the circuit and / or the writing of the code for the Software and / or corporate goods are within the capabilities of those skilled in the art in light of this disclosure. In addition, it will be understood by those skilled in the art that certain mechanisms of the subject matter described herein are capable of being distributed as a program product in a variety of forms, and that an illustrative embodiment of the subject matter described herein is to be equally applied, regardless of the particular type of object the signal carrying medium that currently carries the spread. Examples of signal carrying media include, but are not limited to, writable type media such as floppy disks, ROM drives, CD ROMs, digital tape and computer memory, and transmission type media such as digital and analog communication links from TDM or IP based communication links (e.g., links carrying data bundled into packets).

in the General sense, the skilled artisan will recognize that different here described aspects or collectively in another area of Hardware, software, company goods or any combination thereof can be realized, this is collectively referred to as different types from "electrical circuit". As a result closes the term "electrical circuit" as used herein, without being limited to an electrical circuit with at least one discrete electrical circuit, an electrical Circuit with at least one integrated circuit, an electrical Circuit with at least one application-specific integrated Circuit, an electrical circuit that uses a general purpose computer configured by a computer program (for example, a general-purpose computer configured by a computer program that at least partially Processes and / or devices that are described here or a microprocessor through a computer program are configured, the at least partially processes and / or here represents described devices), an electrical circuit, which forms a storage unit (for example in the form of a Random access memory) and / or an electrical circuit that a communication unit forms (for example, a modem) Communication switch or an optical-electrical device).

Of the One skilled in the art will recognize that it is common within the art is, devices for detection or sensing, signal processing or devices for controlling the type described here and Manner and the subsequent customary use of the practice for Integrating such described devices and / or in fluidic treatment and / or delivery systems as described herein have been. That is, at least part of the devices and / or processes as described herein can be used in a fluidic system and / or a delivery system with an effort be integrated by experiments.

Of the One skilled in the art will recognize that the systems described herein or multiple storages that are volatile and not volatile memory, processors, such as microprocessors and digital signal processors, computer-aided or related Units such as operating systems, user interfaces, drives, Sensors, actuators, application programs, one or more interaction devices like data ports, control systems including feedback loops and a controller implementing actuators (eg, devices for measuring the osmosity, the pH, the pressure, the Temperature or chemical concentration, signal generators for generating electromagnetic control signals). A system can be implemented using any suitable available Components combined with common technical methods become.

The foregoing aspects describe different components included in or associated with different other components. It should be understood that the architectures shown are only examples, and that in fact many other architectures can be implemented while achieving the same functionality. In a conceptual sense, an array of components to accomplish the same function is effectively "associated" such that the desired functionality is achieved. Thus, any combination of any two components that achieve partial functionality may be understood to be "associated with" each other so that the desired functionality is achieved, regardless of the architectures or between components. Accordingly, any two components are associated with being considered "operably linked,""operablylinked," or "operably linked" to one another to achieve the desired function. Embodiments of an agent delivery agent including a deformable reservoir and associated controllable output have been described mechanisms. Methods of use and control of the agent have also been disclosed. In some embodiments, an agent delivery agent can be placed in a human or animal to controllably deliver at least one agent into the human or animal. The drug delivery agent may have a programmable mechanism for controlling release of the drug in the human or animal. In certain embodiments, a remote control may be used to program or control the drug delivery agent. Some embodiments are described herein in which a control signal of a magnetic field, an electric field or electromagnetism may be used.

• 1. Ein in einen Menschen oder ein Tier implantierbares Wirkstoffapplikationsmittel, mit wenigstens einem deformierbaren Reservoir, das zum Aufnehmen, Aufbewahren und Abgeben wenigstens eines Wirkstoff ausgebildet ist, mit wenigstens einem Auslass, durch den der wenigstens eine Wirkstoff aus dem wenigstens einen deformierbaren Reservoir austreten kann; und wenigstens einem steuerbaren Ausgabemechanismus, der operativ mit dem wenigstens einen Auslass zum Steuern der Applikation des wenigstens einen Teils des wenigstens einen Wirkstoffs aus dem wenigstens einen deformierbaren Reservoir verbunden ist.
• 2. Das Mittel nach der Lehre 1, wobei das wenigstens eine deformierbare Reservoir weiter wenigstens einen Einlassmechanismus zum Aufnehmen eines von Außen zugeführten Wirkstoffs nach Einbringung des Mittels in den Menschen oder das Tier aufweist.
• 3. Das Mittel nach der Lehre 1, wobei der wenigstens eine Abschnitt des wenigstens einen deformierbare Reservoirs innere oder äußere Flächen aufweist, die chemisch oder biologisch im wesentlich inert sind.
• 4. Das Mittel nach der Lehre 3, wobei das wenigstens eine deformierbare Reservoir eine äußere Fläche aufweist, die im Wesentlichen chemisch oder biologisch inert ist.
• 5. Das Mittel nach der Lehre 1, wobei der wenigstens eine Abschnitt des wenigstens eine deformierbare Reservoir ein nicht poröses elastomeres Material aufweist.
• 6. Das Mittel nach der Lehre 1, wobei der wenigstens eine Abschnitt des wenigstens einen deformierbaren Reservoirs ein längliches rohrförmiges Element ist.
• 7. Das Mittel nach der Lehre 1, wobei der wenigstens eine Abschnitt des wenigstens einen deformierbare Reservoirs ein gefaltetes Element ist.
• 8. Das Mittel nach der Lehre 1, wobei der wenigstens eine Abschnitt des wenigstens einen deformierbare Reservoirs volumetrisch expandierbar ist.
• 9. Das Mittel nach der Lehre 1, weiter mit einer RPID Schaltung.
• 10. Das Mittel nach der Lehre 1, ausgebildet für eine Injektion in den Menschen oder das Tier.
• 11. Das Mittel nach der Lehre 10, wobei der Mensch oder das Tier ein Mensch ist.
• 12. Das Mittel nach der Lehre 1, weiter mit wenigstens einem Sensor, wenigstens einem Zeitgeber, wenigstens einem Zähler.
• 13. Das Mittel nach der Lehre 1, wobei der wenigstens eine steuerbare Ausgabemechanismus auf den wenigstens einen Sensor, den wenigstens einen Zeitgeber, den wenigstens einen Zähler oder die wenigstens eine Fernsteuerung anspricht.
• 14. Das Mittel nach der Lehre 13, wobei der wenigstens eine Sensor zum Erkennen wenigstens eines Parameters des wenigstens einen Wirkstoffs in dem wenigstens einen deformierbaren Reservoir anspricht.
• 15. Das Mittel nach der Lehre 13, wobei der wenigstens eine Sensor an dem Mittel angeordnet ist.
• 16. Das Mittel nach der Lehre 13, wobei der wenigstens eine Sensor zur Anbringung entfernt von dem Mittel konfiguriert ist.
• 17. Das Mittel nach der Lehre 14, wobei der wenigstens eine Sensor zum Erkennen der Qualität oder des Abbauzustands des wenigstens eine Wirkstoffs in dem wenigstens einen deformierbare Reservoir.
• 18. Das Mittel nach der Lehre 14, wobei der wenigstens eine Sensor zum Erkennen der Menge des wenigstens einen Wirkstoffs in dem wenigstens einen deformierbare Reservoir konfiguriert ist.
• 19. Das Mittel nach der Lehre 14, wobei der wenigstens eine Sensor zum Erkennen der Temperaturen, des Drucks. Des pH-Werts, der Viskosität, der elektrischen Leitfähigkeit oder der optischen Dichte des wenigstens einen Wirkstoffs in der wenigstens eine deformierbare Reservoir ausgebildet ist.
• 20. Das Mittel nach der Lehre 13, wobei der wenigstens eine Sensor zum Erkennen wenigstens eines Parameter der außerhalb des wenigstens einen deformierbaren Reservoir befindlichen Umgebung konfiguriert ist.
• 21. Das Mittel nach der Lehre 20, wobei der wenigstens eine Sensor zum Erkennen der Temperaturen, des Drucks, des pH-Werts, der Viskosität, der elektrische Leitfähigkeit oder der optische Dichte der externen Umgebung ausgebildet ist.
• 22. Das Mittel nach der Lehre 20, wobei der wenigstens eine Sensor zum Erkennen des Vorhandenseins oder Nichtvorhandenseins eines bestimmten Moleküls oder Stoffs in der externen Umgebung ausgebildet ist.
• 23. Das Mittel nach der Lehre 20, wobei der wenigstens eine Sensor zum Erkennen der Konzentration eines spezifischen Moleküls oder Stoffs in der externen Umgebung konfiguriert ist.
• 24. Das Mittel nach der Lehre 1, weiter mit einer Hardware, Firmware oder Software, die zur Steuerung des wenigstens einen steuerbaren Ausgabemechanismus konfiguriert ist.
• 25. Das Mittel nach der Lehre 24, weiter mit wenigstens einer Steuerschaltung, die zum Steuern des wenigstens einen steuerbaren Ausgabemechanismus konfiguriert ist.
• 26. Das Mittel nach der Lehre 25, wobei die wenigstens eine Steuerschaltung zum Erzeugen und Übertragen eines elektromagnetischen Steuersignal zum Steuern des wenigstens einen steuerbaren Ausgabemechanismus ausgebildet ist.
• 27. Das Mittel nach der Lehre 26, weiter mit einem Speichermechanismus zum Speichern von Befehlen zum Erzeugen und Übertragen des elektromagnetischen Steuersignals.
• 28. Das Mittel nach der Lehre 1, weiter mit wenigstens einem Speicherort zum Aufzeichnen von Information.
• 29. Das Mittel nach der Lehre 28, wobei der Speicherort von einem externen Mittel lesbar ist.
• 30. Das Mittel nach der Lehre 28, wobei der wenigstens eine Speicherort zum Aufzeichnen von Information betreffend wenigstens des Sensors, Zählers, der Fernsteuerung oder des Zeitgebers konfiguriert ist.
• 31. Das Mittel nach der Lehre 28, wobei der wenigstens eine Speicherort zum Aufzeichnen von Information betreffend wenigstens eine s sensierten Zustands, eines Verlaufs oder einer Eigenschaft des Mittels konfiguriert ist.
• 32. Das Mittel nach der Lehre 28, wobei der wenigstens eine Speicherort zum Aufzeichnen von Information betreffend wenigstens des Datums, der Zeit und/oder der Menge des abgegebenen Wirkstoffs konfiguriert ist.
• 33. Das Mittel nach der Lehre 28, weiter mit einem Informationsübertragungsmechanismus zum Übertragen der von dem wenigstens einem elektronischen Speicherort gespeicherten Information konfiguriert ist.
• 34. Das Mittel nach der Lehre 33, wobei der Informationsübertragungsmechanismus zum Übertragen von Information in Antwort auf eine Anfrage konfiguriert ist.
• 35. Das Mittel nach der Lehre 33, wobei die Information codiert ist.
• 36. Das Mittel nach der Lehre 1, wobei der wenigstens eine steuerbare Ausgabemechanismus eine Mikropumpe aufweist.
• 37. Das Mittel nach der Lehre 36, wobei die Mikropumpe peristaltisch ist.
• 38. Das Mittel nach der Lehre 1, wobei der wenigstens eine steuerbare Ausgabemechanismus ein MEMS Mittel oder ein NEMS Mittel aufweist.
• 39. Das Mittel nach der Lehre 1, wobei der wenigstens eine steuerbare Ausgabemechanismus ein Einwegventil in Kommunikation mit dem wenigstens einen Auslass des wenigstens ein deformierbares Reservoirs aufweist.
• 40. Das Mittel nach der Lehre 1, wobei der wenigstens eine steuerbare Ausgabemechanismus wenigstens ein thermisch, magnetisch, elektrisch oder elektromagnetisch ansprechendes Material aufweist.
• 41. Das Mittel nach der Lehre 40, wobei der wenigstens eine thermisch, magnetisch, elektrisch oder elektromagnetisch ansprechende Wirkstoff ein Hydrogel, ein Polymer, eine Keramik, ein Dielektrikum, ein Metal, ein dauerhaft magnetisierbares Material, ein ferrofluidisches Material, ein ferromagnetisches Material, ein ferrimagnetisches Material, ein eisenhaltiges Material, ein eisenartiges Material, ein dielektrisches Material, ein ferroelektrisches Material, ein piezoelektrisches Material, ein diamagnetisches Material, ein paramagnetisches Material, ein metallisches Material oder ein antiferromagnetisches Material ist.
• 42. Das Mittel nach der Lehre 40, wobei das wenigstens eine thermisch, magnetisch, elektrisch oder elektromagnetisch ansprechende Material ein Polymer, eine Keramik, ein Dielektrikum, ein Ferrofluid oder ein Metal ist.
• 43. Das Mittel nach der Lehre 40, wobei das wenigstens eine thermisch, magnetisch, elektrisch oder elektromagnetisch ansprechende Material auf ein statisch oder quasi-statisch elektrisches Feld anspricht.
• 44. Das Mittel nach der Lehre 40, wobei das wenigstens eine thermisch, magnetisch, elektrisch oder elektromagnetisch ansprechende Material auf ein statisches oder quasi-statisches magnetisches Feld anspricht.
• 45. Das Mittel nach der Lehre 40, wobei das wenigstens eine thermisch, magnetisch, elektrisch oder elektromagnetisch ansprechende Material auf ein nichtionisierendes elektromagnetisches Signal anspricht.
• 46. Das Mittel nach der Lehre 40, wobei das wenigstens eine thermisch, magnetisch, elektrisch oder elektromagnetisch ansprechende Material auf ein elektromagnetisches Signal mit Radiofrequenz anspricht.
• 47. Das Mittel nach der Lehre 40, wobei das wenigstens eine thermisch, magnetisch, elektrisch oder elektromagnetisch ansprechende Material auf ein elektromagnetisches Signal im Mikrowellenbereich anspricht.
• 48. Das Mittel nach der Lehre 40, wobei der wenigstens eine thermisch, magnetisch, elektrisch oder elektromagnetisch ansprechende Wirkstoff auf ein elektromagnetisches Signal mit einer Millimeterwellenlänge anspricht.
• 49. Das Mittel nach der Lehre 40, wobei das wenigstens eine thermisch, magnetisch, elektrisch oder elektromagnetisch ansprechende Material auf ein optisches Signal anspricht.
• 50. Das Mittel nach der Lehre 40, wobei das wenigstens eine thermisch, magnetisch, elektrisch oder elektromagnetisch ansprechende Material auf ein akustisches Signal anspricht.
• 51. Das Mittel nach der Lehre 1, wobei der wenigstens eine steuerbare Ausgabemechanismus ein Formgedächtnismaterial aufweist.
• 52. Das Mittel nach der Lehre 51, wobei das Formgedächtnismaterial auf das Steuersignal durch Ändern seiner Form anspricht.
• 53. Das Mittel nach der Lehre 39, wobei das Einwegventil in Antwort auf das Steuersignal öffnet oder schließt.
• 54. Das Mittel nach der Lehre 1, weiter mit einer Körperstruktur zum Schaffen einer Abgrenzung gegen umgebendes in vivo Gewebe konfiguriert ist.
• 55. Das Mittel nach der Lehre 54, wobei das Wirkstoffapplikationsmittel zum Entfernen von der Körperstruktur, während die Körperstruktur in vivo verbleibt, konfiguriert ist.
• 56. Das Mittel nach der Lehre 54, wobei die Körperstruktur zum biologischen Abbau in einem Zeitraum konfiguriert ist.
• 57. Das Mittel nach der Lehre 54, wobei die Körperstruktur von einem biokompatiblem Material abbaubar ist.
• 58. Das Mittel nach der Lehre 54, wobei die Körperstruktur zum Abbau in Antwort auf ein externes Signal konfiguriert ist.
• 59. Das Mittel nach der Lehre 1, mit wenigstens zwei deformierbaren Reservoirs.
• 60. Das Mittel nach der Lehre 59 mit wenigstens zwei Wirkstoffen.
• 61. Das Mittel nach der Lehre 60, wobei die zwei oder mehr Wirkstoffe Reaktantien sind.
• 62. Das Mittel nach der Lehre 1, weiter mit einem Dekontaminationsmechanismus.
• 63. Das Mittel nach der Lehre 62, wobei der Dekontaminationsmechanismus UV Licht oder einen chemischen Dekontaminanten verwendet.
• 64. Das Mittel nach der Lehre 1, weiter mit einem Energiespeichermechanismus.
• 65. Das Mittel nach der Lehre 1, weiter mit einem Leistung aufnehmenden Mechanismus.
• 66. Das Mittel nach der Lehre 1, weiter mit einem Energie erzeugenden Mechanismus.
• 67. A Wirkstoffapplikationssystem mit wenigstens einem Wirkstoffapplikationsmittel, das in einen Menschen oder ein Tier implantierbar ist, mit: wenigstens einem deformierbaren Reservoir, das zum Aufnehmen, Aufbewahren und Abgeben wenigstens eines Wirkstoff, mit wenigstens eine Auslass, durch den der wenigstens eine Wirkstoff austreten kann, wenigstens einem deformierbaren Reservoir; wenigstens einem steuerbaren Ausgabemechanismus, der operativ mit dem wenigstens einen Auslass zur Steuerung der Applikation des wenigstens einen Teil des wenigstens einen Wirkstoffs aus dem wenigstens einen deformierbaren Reservoir; und wenigstens einer Fernsteuerung, die zum Erzeugen und Übertragen wenigstens eines Steuersignals an das wenigstens eine Wirkstoffapplikationsmittel ausgebildet ist, konfiguriert ist.
• 68. Das System nach der Lehre 67, wobei das wenigstens eine deformierbare Reservoir weiter wenigstens einen Einlassmechanismus zur Aufnahme eines von außen zugeführten Wirkstoffs aufweist.
• 69. Das System nach der Lehre 67, wobei der wenigstens ein Abschnitt des wenigstens einen deformierbaren Reservoirs innere oder äußere Flächen, die im Wesentlichen chemisch oder biologisch inert sind, aufweist.
• 70. Das Mittel nach der Lehre 69, wobei das wenigstens eine deformierbare Reservoir eine äußere Fläche, die im wesentlichen chemisch oder biologisch inert ist, aufweist.
• 71. Das System nach der Lehre 67, wobei der wenigstens eine Abschnitt des wenigstens einen deformierbaren Reservoirs ein nicht poröses, elastomeres Material aufweist.
• 72. Das System nach der Lehre 67, wobei der wenigstens eine Abschnitt des wenigstens einen deformierbaren Reservoirs ein längliches, rohrförmiges Element ist.
• 73. Das System nach der Lehre 67, wobei der wenigstens eine Abschnitt des wenigstens einen deformierbaren Reservoir ein gefaltetes Element aufweist.
• 74. Das System mach der Lehre 67, wobei der wenigstens eine Abschnitt des wenigstens einen deformierbaren Reservoirs volumetrisch expandierbar ist.
• 75. Das System nach der Lehre 67, wobei das wenigstens eine Wirkstoffapplikationsmittel eine RFID Schaltung aufweist.
• 76. Das System nach der Lehre 67, wobei das wenigstens eine Wirkstoffapplikationsmittel zur Injektion in einen Menschen oder ein Tier ausgebildet ist.
• 77. Das System nach der Lehre 76, wobei der Mensch oder das Tier ein Mensch ist.
• 78. Das System nach der Lehre 67, weiter mit wenigstens einem Sensor, wenigstens einem Zeitgeber und/oder wenigstens einem Zähler.
• 79. Das System nach der Lehre 78, wobei der wenigstens eine steuerbaren Ausgabemechanismus auf den wenigstens einen Sensor, den wenigstens einen Zeitgeber, den wenigstens einen Zähler oder die wenigstens eine Fernsteuerung anspricht.
• 80. Das System nach der Lehre 78, wobei der wenigstens eine Sensor an dem wenigstens einen Wirkstoffapplikationsmittel angeordnet ist.
• 81. Das System nach der Lehre 80, wobei der wenigstens eine Sensor zum Erkennen wenigstens eines Parameter des wenigstens einen Wirkstoffs in dem wenigstens einen deformierbare Reservoir vorgesehen ist.
• 82. Das System nach der Lehre 78, wobei der wenigstens eine Sensor für eine Anordnung entfernt von dem wenigstens einen Wirkstoffapplikationsmittel eingerichtet ist.
• 83. Das System nach der Lehre 81, wobei der wenigstens eine Sensor zum Erkennen den Qualitäts- oder Abbauzustand des wenigstens eines Wirkstoffs in dem wenigstens einen deformierbaren Reservoir ausgebildet ist.
• 84. Das System nach der Lehre 81, wobei der wenigstens eine Sensor zum Erkennen der Menge des wenigstens einen Wirkstoff in dem wenigstens einen deformierbaren Reservoir eingerichtet ist.
• 85. Das System nach der Lehre 81, wobei der wenigstens eine Sensor zum Erkennen der Temperatur, des Drucks, des pH-Werts, der Viskosität, der elektrischen Leitfähigkeit oder der optischen Dichte des wenigstens eine Wirkstoffs in dem wenigstens einen deformierbare Reservoir eingerichtet ist.
• 86. Das System nach der Lehre 82, wobei der wenigstens eine Sensor zum Erkennen wenigstens eines Parameter der zu dem wenigstens einen deformierbaren Reservoir externen Umgebung ausgebildet ist.
• 87. Das System nach der Lehre 86, wobei der wenigstens eine Sensor zum Erkennen der Temperatur, des Drucks, des pH-Werts, der Viskosität, der elektrischen Leitfähigkeit oder der optischen Dichte der äußeren Umgebung ausgebildet ist.
• 88. Das System nach der Lehre 86, wobei der wenigstens eine Sensor zum Erkennen des Vorhandenseins oder des Fehlens eines bestimmten Moleküls oder Wirkstoffs in einer externen Umgebung ausgebildet ist.
• 89. Das System nach der Lehre 86, wobei der wenigstens eine Sensor zum Erkennen der Konzentration eines bestimmten Moleküls oder Wirkstoffs in einer externen Umgebung konfiguriert ist.
• 90. Das System nach der Lehre 67, wobei das wenigstens eine Wirkstoffapplikationsmittel weiter eine Hardware, Firmware oder Software aufweist, die zur Steuerung des wenigstens einen steuerbaren Ausgabemechanismus ausgebildet ist.
• 91. Das System nach der Lehre 90, wobei der wenigstens eine Wirkstoffapplikationsmittel weiter wenigstens eine Steuerschaltung zum Aktivieren des wenigstens einen steuerbaren Ausgabemechanismus aufweist.
• 92. Das System nach der Lehre 91, wobei die wenigstens eine Steuerschaltung zum Erzeugen und Übertragen eines elektromagnetischen Steuersignals zum Steuern des steuerbaren Ausgabemechanismus ausgebildet ist.
• 93. Das System nach der Lehre 91, wobei das wenigstens eine Wirkstoffapplikationsmittel weiter wenigstens einen elektronischen Speichermechanismus zum Speichern von Befehlen zum Erzeugen und Übertragen eines elektromagnetischen Steuersignals aufweist.
• 94. Das System nach der Lehre 67, wobei das wenigstens eine Wirkstoffapplikationsmittel weiter wenigstens einen elektronische Speicherort zum Aufzeichnen von Information aufweist.
• 95. Das System nach der Lehre 94, wobei der wenigstens eine elektronische Speicherort zum Aufzeichnen von Information betreffend wenigstens eines Sensors, Zählers, einer Fernsteuerung oder eines Zeitgeber konfiguriert ist.
• 96. Das System nach der Lehre 94, wobei der wenigstens eine elektronische Speicherort zum Aufzeichnen von Information betreffend wenigstens eines zweiten Zustands, einer sensierten Bedingung, eines Verlaufs oder einer Eigenschaft des wenigstens eine Wirkstoffapplikationsmittel konfiguriert ist.
• 97. Das System nach der Lehre 94, wobei der wenigstens eine elektronische Speicherort zum Aufzeichnen von Information betreffend wenigstens des Datums, der Zeit oder der Menge des abgegebenen Wirkstoffs konfiguriert ist.
• 98. Das System nach der Lehre 94, wobei das wenigstens eine Wirkstoffapplikationsmittel weiter einen Informationsübertragungsmechanismus aufweist, der zum Übertragen von an dem wenigstens einen elektronische Speicherort gespeicherten Information eingerichtet ist.
• 99. Das System nach der Lehre 98, wobei der Informationsübertragungsmechanismus zum Übertragen von Information in Antwort auf eine Anfrage eingerichtet ist.
• 100. Das System nach der Lehre 98, wobei die Information codiert ist.
• 101. Das System nach der Lehre 67, wobei der wenigstens eine steuerbare Ausgabemechanismus eine Mikropumpe ist.
• 102. Das System nach der Lehre 101, wobei die Mikropumpe peristaltisch ist.
• 103. Das System nach der Lehre 67, wobei der wenigstens eine steuerbare Ausgabemechanismus ein MEMS Mittel oder ein NEMS Mittel ist.
• 104. Das System nach der Lehre 67, wobei der wenigstens eine steuerbare Ausgabemechanismus ein Einwegventil in Kommunikation mit dem wenigstens einen Ausgang des wenigstens einen deformierbaren Reservoirs aufweist.
• 105. Das System nach der Lehre 67, wobei der wenigstens eine steuerbare Ausgabemechanismus wenigstens ein thermisch, magnetisch, elektrisch oder elektromagnetisch ansprechendes Material aufweist.
• 106. Das System nach der Lehre 105, wobei das wenigstens eine thermisch, magnetisch, elektrisch oder elektromagnetisch ansprechenden Material ein Hydrogel, Polymer, eine Keramik, ein Dielektrikum, Metal, ein dauerhaft magnetisierbarer Material, ein ferro-fluidisches Material, ein Ferromagnetischer Material, ein ferrimagnetisches Material, ein eisenhaltiger Material, eisenartiger Material, ein dielektrisches Material, ein ferroelektrisches Material, ein piezoelektrisches Material, ein diamagnetisches Material, ein paramagnetisches Material, ein metallisches Material, oder antiferromagnetisches Material ist.
• 107. Das System nach der Lehre 105, wobei das wenigstens eine thermisch, magnetisch, elektrisch oder elektromagnetisch ansprechenden Material ein Polymer, eine Keramik, ein Dielektrikum, ein Ferrofluid oder ein Metal aufweist.
• 108. Das System nach der Lehre 105, wobei das wenigstens eine thermisch, magnetisch, elektrisch oder elektromagnetisch ansprechende Material auf ein statisches oder quasi-statisches elektrisches Feld anspricht.
• 109. Das System nach der Lehre 105, wobei das wenigstens eine thermisch, magnetisch, elektrisch oder elektromagnetisch ansprechende Material auf ein statisches oder quasi-statisches elektrisches Feld anspricht.
• 110. Das System nach der Lehre 105, wobei das wenigstens eine thermisch, magnetisch, elektrisch oder elektromagnetisch ansprechendes Material auf ein nicht ionisierendes elektrisches Signal anspricht.
• 111. Das System nach der Lehre 105, wobei das wenigstens eine thermisch, magnetisch, elektrisch oder elektromagnetisch ansprechenden Material auf ein elektrisches Radiofrequenzsignal anspricht.
• 112. Das System nach der Lehre 105, wobei das wenigstens eine thermisch, magnetisch, elektrisch oder elektromagnetisch ansprechendes Material auf ein elektromagnetisches Mikrowellensignalsignal anspricht.
• 113. Das System nach der Lehre 105, wobei das wenigstens eine thermisch, magnetisch, elektrisch oder elektromagnetisch ansprechende Material auf ein optisches Signal anspricht.
• 114. Das System nach der Lehre 105, wobei das wenigstens eine thermisch, magnetisch, elektrisch oder elektromagnetisch ansprechende Material auf ein elektrisches Signal im Millimeterwellenbereich anspricht.
• 115. Das System nach der Lehre 105, wobei das wenigstens eine thermisch, magnetisch, elektrisch oder elektromagnetisch ansprechenden Material auf ein akustisches Signal anspricht.
• 116. Das System nach der Lehre 105, wobei das wenigstens eine thermisch, magnetisch, elektrisch oder elektromagnetisch ansprechende Material ein Formgedächtnismaterial aufweist.
• 117. Das System nach der Lehre 116, wobei das Formgedächtnismaterial auf ein Steuersignal durch eine Formänderung anspricht.
• 118. Das System nach der Lehre 104, wobei das Einwegventil in Antwort auf ein Steuersignal öffnet oder schließt.
• 119. Das System nach der Lehre 67, weiter mit wenigstens eine Körperstruktur zum Schaffen einer Abgrenzung zwischen der wenigstens eine Wirkstoffapplikationsmittel und dem umgebenden in vivo Gewebe.
• 120. Das System nach der Lehre 119, wobei das wenigstens eine Wirkstoffapplikationsmittel zur Entfernung von der wenigstens eine Körperstruktur, während die wenigstens eine Körperstruktur in vivo verbleibt, ausgebildet ist.
• 121. Das System nach der Lehre 119, wobei die wenigstens eine Körperstruktur zum biologischen Abbau in einem Zeitraum konfiguriert ist.
• 122. Das System nach der Lehre 119, wobei die wenigstens eine Körperstruktur von einem biokompatiblem Material abbaubar ist.
• 123. Das System nach der Lehre 119, wobei die Körperstruktur zum Abbau in Antwort auf ein externes Signal konfiguriert ist.
• 124. Das System nach der Lehre 67, wobei das wenigstens eine Wirkstoffapplikationsmittel wenigstens zwei deformierbare Reservoirs aufweist.
• 125. Das System nach der Lehre 124, mit wenigstens zwei Wirkstoffen.
• 126. Das System nach der Lehre 125, wobei die wenigstens zwei Wirkstoffe Reaktantien sind.
• 127. Das System nach der Lehre 67, wobei das wenigstens eine Wirkstoffapplikationsmittel weiter wenigstens einen Dekontaminationsmechanismus aufweist.
• 128. Das System nach der Lehre 127, wobei der wenigstens eine Dekontaminationsmechanismus UV Licht oder ein chemisches Dekontaminat verwendet.
• 129. Das System nach der Lehre 67, wobei das wenigstens eine Wirkstoffapplikationsmittel weiter einen Energiespeichermechanismus aufweist.
• 130. Das System nach der Lehre 67, wobei das wenigstens eine Wirkstoffapplikationsmittel weiter einen Energie aufnehmenden Mechanismus aufweist.
• 131. Das System nach der Lehre 67, wobei das wenigstens eine Wirkstoffapplikationsmittel weiter einen Energie erzeugenden Mechanismus aufweist.
• 132. Das System nach der Lehre 67, wobei die wenigstens eine Fernsteuerung eine Hardware, Firmware und/oder Software beinhaltet, die zur Steuerung der Übertragung des wenigstens einen Steuersignals eingerichtet ist.
• 133. Das System nach der Lehre 67, wobei die wenigstens eine Fernsteuerung weiter einen Anzeigemechanismus zum Anzeigen der Information für eine Person beinhaltet.
• 134. Das System nach der Lehre 67, wobei das wenigstens eine Steuersignal Befehle, die zum Programmieren des wenigstens eine Wirkstoffapplikationsmittel konfiguriert sind, beinhaltet.
• 135. Das System nach der Lehre 67, wobei das wenigstens eine Steuersignal durch die wenigstens eine Fernsteuerung einem zeitlichen Plan folgend übertragen wird.
• 136. Das System nach der Lehre 67, wobei das wenigstens eine Steuersignal elektromagnetisch ist.
• 137. Das System nach der Lehre 67, wobei das wenigstens eine Steuersignal infrarot ist.
• 138. Das System nach der Lehre 67, wobei das wenigstens eine Steuersignal magnetisch ist.
• 139. Das System nach der Lehre 67, wobei das wenigstens eine Steuersignal Ultraschall ist.
• 140. Das System nach der Lehre 67, wobei das wenigstens eine Steuersignal ultraviolet ist.
• 141. Das System nach der Lehre 67, wobei das wenigstens eine Steuersignal akustisch ist.
• 142. Das System nach der Lehre 67, wobei das wenigstens eine Steuersignal sichtbar ist.
• 143. Das System nach der Lehre 67, wobei das wenigstens eine Steuersignal elektrisch ist.
• 144. Das System nach der Lehre 132, wobei die Hardware, Firmware oder Software der wenigstens eine Fernsteuerung einen Speichermechanismus zum Speichern von Befehlen aufweist.
• 145. Das System nach der Lehre 144, wobei der Speichermechanismus nicht-flüchtig ist.
• 146. Das System nach der Lehre 144, wobei die Hardware, Firmware und/oder Software der wenigstens einen Fernsteuerung weiter Befehle zum Aufnehmen eines Eingans von einem oder mehreren Steuerparametern aufweist.
• 147. Das System nach der Lehre 146, wobei die Hardware, Firmware und/oder Software der wenigstens eine Fernsteuerung weiter Befehle zum Erzeugen des wenigstens einen Steuersignals basierend auf einem oder mehreren Steuerparameter aufweist.
• 148. Das System nach der Lehre 132, wobei die Hardware, Firmware und/oder Software der wenigstens einen Fernsteuerung weiter Befehle zum Durchführen einer Verschlüsselung des wenigstens einen Steuersignals aufweist.
• 149. Das System nach der Lehre 132, wobei die Hardware, Firmware und/oder Software der wenigstens einen Fernsteuerung weiter Befehle zum Durchführen eines Authentifizierungs vorgangs zwischen der wenigstens einen Fernsteuerung und dem wenigstens eine Wirkstoffapplikationsmittel beinhaltet.
• 150. Das System nach der Lehre 132, wobei die Hardware, Firmware und/oder Software der wenigstens einen Fernsteuerung weiter Befehle zum Durchführen eines Abfragevorgangs zwischen der wenigstens einen Fernsteuerung und dem wenigstens einen Wirkstoffapplikationsmittel aufweist.
• 151. Das System nach der Lehre 67, wobei der wenigstens eine Wirkstoff ein Fluid ist.
• 152. Das System nach der Lehre 67, wobei der wenigstens eine Wirkstoff partikelförmig ist.
• 153. Ein Wirkstoffapplikationskit, mit: wenigstens einem Applikationsmechanismus; wenigstens einem in einem Menschen oder einem Tier implantierbaren Wirkstoffapplikationsmittel, das aufweist: wenigstens ein zum Aufnehmen, Aufbewahren und gesteuertem Abgeben wenigstens eines Wirkstoffs ausgebildetes deformierbares Reservoir mit wenigstens einem Auslass, durch den der wenigstens eine Wirkstoff aus dem wenigstens einen deformierbaren Reservoir abgegeben werden kann; und wenigstens einem steuerbaren Ausgabemechanismus der operativ mit dem wenigstens einen Auslass verbunden ist und zum Steuern der Ausgabe des wenigstens einen Wirkstoff aus dem wenigstens einen deformierbaren Reservoir konfiguriert ist.
• 154. Das Kit nach der Lehre 153, weiter mit wenigstens einer Fernsteuerung, die zum Erzeugen und Übertragen wenigstens eines Steuersignals zu dem wenigstens einen implantierbaren Wirkstoffapplikationsmittel konfiguriert ist.
• 155. Das Kit nach der Lehre 153, weiter mit wenigstens einem zuzuführenden Wirkstoff.
• 156. Das Kit nach der Lehre 153, wobei das wenigstens eine Wirkstoffapplikationsmittel weiter wenigstens eine Einlassmechanismus zum Aufnehmen einer externen Applikation wenigstens eines Wirkstoffs.
• 157. Das Kit nach der Lehre 153, wobei wenigstens ein Teil des wenigstens einen deformierbaren Reservoirs weiter innere oder äußere Flächen aufweist, die chemisch oder biologisch im Wesentlichen inert sind.
• 158. Das Kit nach der Lehre 153, wobei wenigstens ein Teil des wenigstens eines deformierbaren Reservoirs ein nicht poröses elastomeres Material ist.
• 159. Das Kit nach der Lehre 153, wobei wenigstens ein Teil des wenigstens einen deformierbaren Reservoirs ein längliches rohrförmiges Element ist.
• 160. Das Kit nach der Lehre 153, wobei wenigstens ein Teil des wenigstens einen deformierbaren Reservoirs ein gefaltetes Element aufweist.
• 161. Das Kit nach der Lehre 153, wobei wenigstens ein Abschnitt des wenigstens einen deformierbaren Reservoirs volumetrisch expandierbar ist.
• 162. Das Kit nach der Lehre 153, wobei das wenigstens eine einbringbare Wirkstoffapplikationsmittel eine RFID Schaltung aufweist.
• 163. Das Kit nach der Lehre 153, wobei das wenigstens eine einbringbare Wirkstoffapplikationsmittel zur Injektion in den Menschen oder das Tier ausgebildet ist.
• 164. Das Kit nach der Lehre 153, wobei das wenigstens eine einbringbare Wirkstoffapplikationsmittel weiter wenigstens einen Sensor, wenigstens einen Zeitgeber oder wenigstens einen Zähler aufweist.
• 165. Das Kit nach der Lehre 164, wobei der wenigstens eine steuerbaren Ausgabemechanismus auf den wenigstens einen Sensor, den wenigstens einen Zeitgeber, den wenigstens einen Zähler oder wenigstens eine Fernsteuerung anspricht.
• 166. Das Kit nach der Lehre 164, wobei der wenigstens eine Sensor an dem wenigstens einen einbringbare Wirkstoffapplikationsmittel angeordnet ist.
• 167. Das Kit nach der Lehre 166, wobei der wenigstens eine Sensor zum Erkennen wenigstens eines Parameters des wenigstens einen Wirkstoffs in dem wenigstens einen deformierbare Reservoir ausgebildet ist.
• 168. Das Kit nach der Lehre 164, weiter mit wenigstens einem Sensor, der zur Anordnung distal von dem wenigstens einen Wirkstoffapplikationsmittel ausgebildet ist.
• 169. Das Kit nach der Lehre 167, wobei der wenigstens eine Sensor zum Erkennen eines Qualitäts- oder Abbauzustands des wenigstens einen Wirkstoffs in dem wenigstens einen deformierbaren Reservoir ausgebildet ist.
• 170. Das Kit nach der Lehre 167, wobei der wenigstens eine Sensor zum Erkennen der Menge des wenigstens einen Wirkstoffs in dem wenigstens einen deformierbaren Reservoir ausgebildet ist.
• 171. Das Kit nach der Lehre 167, wobei der wenigstens eine Sensor zum Erkennen der Temperatur, des Drucks, des pH-Wert, der Viskosität, der elektrischen Leitfähigkeit oder der optischen Dichte des wenigstens einen Wirkstoffs in der wenigstens eines deformierbares Reservoir ausgebildet ist.
• 172. Das Kit nach der Lehre 168, wobei der wenigstens eine Sensor zum Erkennen wenigstens eines Parameter der Umgebung extern zu dem wenigstens einen deformierbare Reservoir ausgebildet ist.
• 173. Das Kit nach der Lehre 172, wobei der wenigstens eine Sensor zum Erkennen der Temperatur, des Drucks, des pH-Werts, der Viskosität, der elektrischen Leitfähigkeit oder der optische Dichte der externen Umgebung ausgebildet ist
• 174. Das Kit nach der Lehre 172, wobei der wenigstens eine Sensor zum Erkennen des Vorhandensein oder Nichtvorhandenseins eines bestimmten Moleküls oder Stoffs in der externen Umgebung.
• 175. Das Kit nach der Lehre 172, wobei der wenigstens eine Sensor zum Erkennen der Konzentration eines bestimmten Moleküls oder Stoffs in der externen Umgebung ausgebildet ist.
• 176. Das Kit nach der Lehre 153, wobei der wenigstens eine implantierbare Wirkstoffapplikationsmittel weiter eine Hardware, Firmware und/oder Software aufweist, die zum Steuern des wenigstens einen steuerbaren Ausgabemechanismus ausgebildet ist.
• 177. Das Kit nach der Lehre 176, wobei das wenigstens eine implantierbare Wirkstoffapplikationsmittel weiter wenigstens eine Steuerschaltung aufweist, die zum Aktivieren des wenigstens einen steuerbaren Ausgabemechanismus ausgebildet ist.
• 178. Das Kit nach der Lehre 177, wobei die wenigstens eine Steuerschaltung zum Erzeugen und Übertragen eines elektromagnetischen Steuersignals, das zum Steuern des wenigstens einen steuerbaren Ausgabemechanismus eingerichtet ist, ausgebildet ist.
• 179. Das Kit nach der Lehre 177, wobei das wenigstens eine implantierbare Wirkstoffapplikationsmittel weiter einen elektronischen Speichermechanismus zum Speichern von Befehlen zum Erzeugen und Übertragen des elektromagnetischen Steuersignals aufweist.
• 180. Das Kit nach der Lehre 177, wobei das wenigstens eine implantierbare Wirkstoffapplikationsmittel weiter wenigstens einen elektronische Speicherort zum Aufzeichnen von Information aufweist.
• 181. Das Kit nach der Lehre 180, wobei der wenigstens eine elektronische Speicherort zum Aufzeichnen von Information betreffend eines Sensors, eines Zählers, einer Fernsteuerung oder eines Zeitgeber ausgebildet ist.
• 182. Das Kit nach der Lehre 180, wobei der wenigstens eine elektronische Speicherort zum Aufzeichnen von Information betreffend wenigstens eines sensierten Zustands, Verlaufs oder Eigenschaft des wenigstens einen implantierbaren Wirkstoffapplikationsmittels eingerichtet ist.
• 183. Das Kit nach der Lehre 180, wobei der wenigstens eine elektronische Speicherort zum Aufzeichnen von Information betreffend wenigstens des Datums, der Zeit und der Menge des abgegebenen Wirkstoffs konfiguriert ist.
• 184. Das Kit nach der Lehre 180, wobei das wenigstens eine implantierbare Wirkstoffapplikationsmittel weiter einen Informationsübertragungsmechanismus aufweist, der zum Übertragen von an dem wenigstens einen elektronische Speicherort aufgezeichneter Information eingerichtet ist.
• 185. Das Kit nach der Lehre 184, wobei der Informationsübertragungsmechanismus zum Übertragen von Information auf eine Anfrage hin ausgebildet ist.
• 186. Das Kit nach der Lehre 184, wobei die Information verschlüsselt ist.
• 187. Das Kit nach der Lehre 153, wobei der wenigstens einen steuerbaren Ausgabemechanismus eine Mikropumpe aufweist.
• 188. Das Kit nach der Lehre 187, wobei die Mikropumpe peristaltisch ist.
• 189. Das Kit nach der Lehre 153, wobei der wenigstens eine steuerbare Ausgabemechanismus ein MEMS Mittel oder ein NEMS Mittel aufweist.
• 190. Das Kit nach der Lehre 153, wobei der wenigstens eine steuerbare Ausgabemechanismus ein Einwegventil in Kommunikation mit dem wenigstens einen Auslass des wenigstens einen deformierbaren Reservoirs aufweist.
• 191. Das Kit nach der Lehre 153, wobei der wenigstens einen steuerbaren Ausgabemechanismus wenigstens ein thermisch, magnetisch, elektrisch oder elektromagnetisch ansprechendes Material aufweist.
• 192. Das Kit nach der Lehre 191, wobei das wenigstens eine thermisch, magnetisch, elektrisch oder elektromagnetisch ansprechende Material ein Hydrogel, Polymer, ein Keramik, Dielektrikum, Metal, dauerhaft magnetisierbares Material, ein Ferrofluid, ein ferromagnetisches Material, ein ferrimagnetisches Material, ein eisenhaltiges Material, ein eisenartiges Material, ein ferrisches Material, ein dielektrisches Material, ein ferroelektrisches Material, ein piezoelektrisches Material, ein diamagnetisches Material, ein paramagnetisches Material, ein metallisches Material oder ein antiferromagnetisches Material aufweist.
• 193. Das Kit nach der Lehre 191, wobei das wenigstens eine thermisch, magnetisch, elektrisch oder elektromagnetisch ansprechende Material ein Polymer, eine Keramik, ein Dielektrikum, ein Ferrofluid oder ein Metal aufweist.
• 194. Das Kit nach der Lehre 191, wobei das wenigstens eine thermisch, magnetisch, elektrisch oder elektromagnetisch ansprechende Material auf ein statisches oder quasi-statisches elektrisches Feld anspricht.
• 195. Das Kit nach der Lehre 191, wobei das wenigstens eine thermisch, magnetisch, elektrisch oder elektromagnetisch ansprechenden Material auf ein statisches oder quasi-statisches magnetisches Feld anspricht.
• 196. Das Kit nach der Lehre 191, wobei das wenigstens eine thermisch, magnetisch, elektrisch oder elektromagnetisch ansprechende Material auf ein nicht-ionisierendes elektromagnetisches Signal anspricht.
• 197. Das Kit nach der Lehre 191, wobei das wenigstens eine thermisch, magnetisch, elektrisch oder elektromagnetisch ansprechende Material auf ein elektromagnetisches Signal im Radiofrequenzbereich anspricht.
• 198. Das Kit nach der Lehre 191, wobei das wenigstens eine thermisch, magnetisch, elektrisch oder elektromagnetisch ansprechenden Material auf ein elektromagnetisches Mikrowellensignal anspricht.
• 199. Das Kit nach der Lehre 191, wobei das wenigstens eine thermisch, magnetisch, elektrisch oder elektromagnetisch ansprechende Material auf ein optisches Signal anspricht.
• 200. Das Kit nach der Lehre 191, wobei das wenigstens eine thermisch, magnetisch, elektrisch oder elektromagnetisch ansprechende Material auf ein elektromagnetisches Millimeterwellen-Signal anspricht.
• 201. Das Kit nach der Lehre 191, wobei der wenigstens eine thermisch, magnetisch, elektrisch oder elektromagnetisch ansprechenden Wirkstoff auf ein akustisches Signal anspricht.
• 202. Das Kit nach der Lehre 191, wobei das wenigstens eine thermisch, magnetisch, elektrisch oder elektromagnetisch ansprechende Material ein Formgedächtnismaterial ist.
• 203. Das Kit nach der Lehre 202, wobei das Formgedächtnismaterial auf ein Steuersignal durch Ändern seiner Form anspricht.
• 204. Das Kit nach der Lehre 190, wobei das Einwegventil in Antwort auf ein Steuersignal öffnet oder schließt.
• 205. Das Kit nach der Lehre 153, weiter mit wenigstens eine Körperstruktur zum Schaffen einer Abgrenzung zwischen der wenigstens eine Wirkstoffapplikationsmittel und dem umgebenden in vivo Gewebe.
• 206. Das Kit nach der Lehre 205, wobei das wenigstens eine implantierbare Wirkstoffapplikationsmittel zur Entfernung von der wenigstens eine Körperstruktur, während die wenigstens eine Körperstruktur in vivo verbleibt, ausgebildet ist.
• 207. Das Kit nach der Lehre 205, wobei die wenigstens eine Körperstruktur zum biologischen Abbau entsprechend einem Zeitintervall ausgebildet ist.
• 208. Das Kit nach der Lehre 205, wobei die wenigstens eine Körperstruktur durch ein biokompatibles Material abbaubar ist.
• 209. Das Kit nach der Lehre 205, wobei die Körperstruktur zum Abbau in Antwort auf ein externes Signal abbaubar ist.
• 210. Das Kit nach der Lehre 153, wobei das wenigstens eine implantierbare Wirkstoffapplikationsmittel wenigstens zwei deformierbare Reservoirs aufweist.
• 211. Das Kit nach der Lehre 210, mit wenigstens zwei Wirkstoffen.
• 212. Das Kit nach der Lehre 211, wobei die wenigstens zwei Wirkstoffe Reaktantien sind.
• 213. Das Kit nach der Lehre 153, wobei das wenigstens eine implantierbare Wirkstoffapplikationsmittel weiter wenigstens einen Dekontaminationsmechanismus aufweist.
• 214. Das Kit nach der Lehre 213, wobei der wenigstens eine Dekontaminationsmechanismus die Verwendung von UV Licht oder eines chemischen Dekontaminanten beinhaltet.
• 215. Das Kit nach der Lehre 153, wobei das wenigstens eine implantierbare Wirkstoffapplikationsmittel weiter einen Energiespeichermechanismus aufweist.
• 216. Das Kit nach der Lehre 153, wobei der wenigstens eine implantierbare Wirkstoffapplikationsmittel weiter einen Energie aufnehmenden Mechanismus aufweist.
• 217. Das Kit nach der Lehre 153, wobei der wenigstens eine implantierbare Wirkstoffapplikationsmittel weiter eine Energie erzeugenden Mechanismus aufweist.
• 218. Das Kit nach der Lehre 154, wobei die wenigstens eine Fernsteuerung eine Hardware, Firmware und/oder Software aufweist, die zur Steuerung der Übertragung des wenigstens eines Steuersignals ausgebildet ist.
• 219. Das Kit nach der Lehre 218, wobei die wenigstens eine Fernsteuerung weiter einen Displaymechanismus zum Darstellen der Information für eine Person aufweist.
• 220. Das Kit nach der Lehre 218, wobei das wenigstens eine Steuersignal Befehle aufweist, die zum Programmieren des wenigstens eine implantierbare Wirkstoffapplikationsmittel konfiguriert sind.
• 221. Das Kit nach der Lehre 218, wobei das wenigstens eine Steuersignal durch die wenigstens eine Fernsteuerung entsprechend einem zeitlichen Plan übertragen wird.
• 222. Das Kit nach der Lehre 184, wobei die wenigstens eine Fernsteuerung wenigstens eine Hardware, Firmware oder Software aufweist, die zum Empfangen von von dem Informationsübertragungsmechanismus übertragener Information eingerichtet ist.
• 223. Das Kit nach der Lehre 218, wobei das wenigstens eine Steuersignal elektromagnetisch ist.
• 224. Das Kit nach der Lehre 218, wobei das wenigstens eine Steuersignal infrarot ist.
• 225. Das Kit nach der Lehre 218, wobei das wenigstens eine Steuersignal magnetisch ist.
• 226. Das Kit nach der Lehre 218, wobei das wenigstens eine Steuersignal Ultraschall ist.
• 227. Das Kit nach der Lehre 218, wobei das wenigstens eine Steuersignal ultraviolet ist.
• 228. Das Kit nach der Lehre 218, wobei das wenigstens eine Steuersignal akustisch ist.
• 229. Das Kit nach der Lehre 218, wobei das wenigstens eine Steuersignal optisch ist.
• 230. Das Kit nach der Lehre 218, wobei die Hardware, Firmware und/oder Software der wenigstens einen Fernsteuerung einen Speichermechanismus zum Speichern von Befehlen aufweist.
• 231. Das Kit nach der Lehre 230, wobei der Speichermechanismus nicht flüchtig ist.
• 232. Das Kit nach der Lehre 218, wobei die Hardware, Firmware und/oder Software der wenigstens einen Fernsteuerung weiter Befehle zum Aufnehmen eines oder Steuerparameter aufweist.
• 233. Das Kit nach der Lehre 232, wobei der wenigstens eine of Hardware, Firmware oder Software der wenigstens einen Fernsteuerung weiter Befehle zum Erzeugen des wenigstens einen Steuersignals basierend auf einem oder mehreren Steuerparametern aufweist.
• 234. Das Kit nach der Lehre 218, wobei das wenigstens eine Steuersignal elektromagnetisch ist.
• 235. Das Kit nach der Lehre 218, wobei die Hardware, Firmware oder Software der wenigstens einen Fernsteuerung weiter Befehle zum Durchführen einer Verschlüsselung des wenigstens eine Steuersignals aufweist.
• 236. Das Kit nach der Lehre 218, wobei der Hardware, Firmware und/Software der wenigstens eine Fernsteuerung weiter Befehle zum Durchführen eines Authentifizierungsvorgangs zwischen der wenigstens eine Fernsteuerung und der wenigstens eine implantierbare Wirkstoffapplikationsmittel.
• 237. Das Kit nach der Lehre 218, wobei die Hardware, Firmware und/oder Software der wenigstens eine Fernsteuerung weiter Befehle zum Durchführen eines Abfragevorgangs zwischen der wenigstens eine Fernsteuerung und der wenigstens eine implantierbare Wirkstoffapplikationsmittel.
• 238. Das Kit nach der Lehre 155, wobei der wenigstens eine zuzuführende Wirkstoff wenigstens einen therapeutischen Wirkstoff aufweist.
• 239. Das Kit nach der Lehre 238, wobei der wenigstens eine therapeutische Wirkstoff eine therapeutisch wirksame Menge oder Konzentration wenigstens eines Nährstoffs, Nutrazeutikums, Hormons, Wachstumsfaktors, eines Anti-Infektionsmittels, einer Medikation, einer therapeutischen Verbindung, eines Enzym, eines genetisches Materials, eines Impfstoffs, Vitamins, Neurotransmitters, Zytokins, zell-signalisierenden Wirkstoffs, ein pro- oder anti-apoptotischer Wirkstoffs, eines bildgebenden Wirkstoffs, eines Labelingwirkstoffs, eines diagnostischen Wirkstoffs, eines Nanomaterials, eines Inhibitors oder Blockers oder einer Komponente daraus sein.
• 240. Das Kit nach der Lehre 155, wobei der wenigstens eine zuzuführende Wirkstoff ein Fluid ist.
• 241. Das Kit nach der Lehre 238, wobei der wenigstens eine therapeutische Wirkstoff eine immunogene Menge wenigstens eines Impfstoffs aufweist.
• 242. Das Kit nach der Lehre 241, wobei der wenigstens eine Impfstoff wenigstens einen HIV-I Impfstoff aufweist.
• 243. Das Kit nach der Lehre 241, wobei der wenigstens eine Impfstoff wenigstens einen Masern-Impfstoff aufweist.
• 244. Das Kit nach der Lehre 241, wobei der wenigstens eine Impfstoff wenigstens einen Influenza Impfstoff aufweist.
• 245. Das Kit nach der Lehre 241, wobei der wenigstens eine Impfstoff wenigstens einen Hepatitis-Impfstoff aufweist.
• 246. Das Kit nach der Lehre 242, wobei der wenigstens eine HIV-I Impfstoff eine Untereinheit von gp120 aufweist.
• 247. Das Kit nach der Lehre 239, wobei der wenigstens eine therapeutische Wirkstoff eine therapeutisch wirksame Menge wenigstens eines anti-infiziösen Wirkstoffs aufweist.
• 248. Das Kit nach der Lehre 247, wobei der wenigstens eine anti-inektiöse Wirkstoff wenigstens einen anti-viralen Wirkstoff aufweist.
• 249. Das Kit nach der Lehre 247, wobei der wenigstens eine anti-infektiöse Wirkstoff wenigstens einen anti-mikrobiellen Wirkstoff aufweist.
• 250. Das Kit nach der Lehre 239, wobei der wenigstens eine therapeutische Wirkstoff eine therapeutisch wirksame Menge wenigstens eines anti-neoplastischen Wirkstoffs aufweist.
• 251. Das Kit nach der Lehre 248, wobei der wenigstens eine anti-virale Wirkstoff aus der Gruppe, die anti-virale Protease, einen viralen Fusionsinhibitor, einen Integraseinhibitor, einen Umkehrtranskriptase-Inhibitor (entweder nukleotid oder nicht-nukleotid), ein pharmazeutisch akzeptables Derivativ von diesen oder eine Kombination daraus ausgewählt ist.
• 252. Das Kit nach der Lehre 239, wobei der wenigstens eine therapeutische Wirkstoff eine therapeutisch wirksame Menge wenigstens eines Wirkstoff zur Behandlung der Malaria aufweist.
• 253. Das Kit nach der Lehre 252, wobei der wenigstens eine Wirkstoff zur Behandlung der Malaria aus der Gruppe mit Chloroquin, Sulfadoxin-Pyrimethamine, Mefloquin, Atovaquein-Proguanil, Chinin, Doxycycline, Artemisinderivativen, Primaquin, einem pharmazeutisch akzeptablem Salz daraus oder eine Kombination daraus ausgewählt ist.
• 254. Das Kit nach der Lehre 239, wobei der wenigstens eine therapeutische Wirkstoff eine therapeutisch wirksame Menge von wenigstens einem Wirkstoff zur Behandlung der Tuberkulose aufweist.
• 255. Das Kit nach der Lehre 239, wobei der wenigstens eine therapeutische Wirkstoff eine therapeutisch wirksame Menge von wenigstens einem Wirkstoff zur Behandlung von Lieshmaniasis aufweist.
• 256. Das Kit nach der Lehre 239, wobei der wenigstens eine therapeutische Wirkstoff eine therapeutisch wirksame Menge von wenigstens einem Wirkstoff zur Behandlung von Cholera aufweist.
• 257. Das Kit nach der Lehre 239, wobei der wenigstens eine therapeutische Wirkstoff eine therapeutisch wirksame Menge von wenigstens einem Wirkstoff zur Behandlung von Maser aufweist.
• 258. Das Kit nach der Lehre 239, wobei der wenigstens eine therapeutische Wirkstoff eine therapeutisch wirksame Menge von wenigstens einem Wirkstoff zur Behandlung von Diphtherie aufweist.
• 259. Das Kit nach der Lehre 239, wobei der wenigstens eine therapeutische Wirkstoff eine therapeutisch wirksame Menge wenigstens einem Wirkstoffs zur Behandlung von Krebs aufweist.
• 260. Das Kit nach der Lehre 239, wobei der wenigstens eine therapeutische Wirkstoff eine therapeutisch wirksame Menge von wenigstens einem Wirkstoff zur Behandlung einer Autoimmunerkrankung aufweist.
• 261. Das Kit nach der Lehre 239, wobei der wenigstens eine therapeutische Wirkstoff eine therapeutisch wirksame Menge von wenigstens einem Wirkstoff zur Behandlung von Hepatitis C aufweist.
• 262. Das Kit nach der Lehre 261, wobei der wenigstens eine therapeutische Wirkstoff eine therapeutisch wirksame Menge von pegyliertem Interferon alfa-2a, Ribavirin, Telaprevir, einem a pharmazeutisch akzeptablem Salz daraus oder Kombinationen dieser aufweist.
• 263. Das Kit nach der Lehre 239, wobei der wenigstens eine therapeutische Wirkstoff eine therapeutisch wirksame Menge von wenigstens einem Anti-Sucht-Wirkstoff aufweist.
• 264. Das Kit nach der Lehre 239, wobei der wenigstens eine therapeutische Wirkstoff eine immunogen wirksame Menge von wenigstens einem Impfstoffadjuvans aufweist.
• 265. Das Kit nach der Lehre 153, wobei der wenigstens eine Einbringungsmechanismus eine Spritze ist.
• 266. Ein Verfahren zum Applizieren wenigstens eines Wirkstoffs zu einem Menschen oder Tier, mit: Einbringen wenigstens eines Wirkstoffapplikationsmittel in eine in vivo Umgebung des Menschen oder des Tiers, wobei das wenigstens eine Wirkstoffapplikationsmittel wenigstens ein deformierbares Reservoir, das zum Aufnehmen, Aufbewahren und gesteuertem Abgeben des wenigstens einen Wirkstoffs ausgebildet ist und wenigstens eine Auslass und wenigstens einen steuerbare Ausgabemechanismus, der operativ mit dem wenigstens einen Auslass verbunden ist; aufweist, und Applizieren einer Menge des wenigstens einen Wirkstoff in das wenigstens einen deformierbaren Reservoir; wobei der wenigstens einen steuerbaren Ausgabemechanismus den wenigstens einen Wirkstoff in Antwort auf das wenigstens eine Steuersignal abgibt, aufweist.
• 267. Das Verfahren nach der Lehre 266, wobei das wenigstens eine deformierbare Reservoir weiter wenigstens einen Einlassmechanismus zum Aufnehmen eines von außen zugeführten Wirkstoffs aufweist.
• 268. Das Verfahren nach der Lehre 266, wobei wenigstens ein Teil des wenigstens einen deformierbaren Reservoirs weiter innere und äußere Flächen, die chemisch oder biologisch im Wesentlichen inert sind, aufweist.
• 269. Das Verfahren nach der Lehre 266, wobei wenigstens ein Teil des wenigstens einen deformierbaren Reservoirs aus einem nicht-porösen Material besteht.
• 270. Das Verfahren nach der Lehre 266, wobei wenigstens ein Teil des wenigstens einen deformierbaren Reservoirs ein längliches rohrförmiges Element ist.
• 271. Das Verfahren nach der Lehre 266, wobei wenigstens ein Teil des wenigstens einen deformierbaren Reservoirs ein gefaltetes Element aufweist.
• 272. Das Verfahren nach der Lehre 266, wobei wenigstens ein Teil des wenigstens einen deformierbaren Reservoirs volumetrisch expandierbar ist.
• 273. Das Verfahren nach der Lehre 266, wobei das wenigstens eine Wirkstoffapplikationsmittel eine RFID Schaltung aufweist.
• 274. Das Verfahren nach der Lehre 266, wobei das wenigstens eine Wirkstoffapplikationsmittel zur Injektion in den Menschen oder das Tier konfiguriert ist.
• 275. Das Verfahren nach der Lehre 274, wobei der Mensch oder das Tier ein Mensch ist.
• 276. Das Verfahren nach der Lehre 266, wobei das wenigstens eine Wirkstoffapplikationsmittel weiter wenigstens einen Sensor, wenigstens einen Zeitgeber oder wenigstens einen Zähler aufweist.
• 277. Das Verfahren nach der Lehre 276, wobei der wenigstens einen steuerbaren Ausgabemechanismus auf den wenigstens einen Sensor, den wenigstens einen Zeitgeber, den wenigstens einen Zähler oder die wenigstens eine Fernsteuerung anspricht.
• 278. Das Verfahren nach der Lehre 276, wobei der wenigstens eine Sensor an dem wenigstens einen Wirkstoffapplikationsmittel angeordnet ist.
• 279. Das Verfahren nach der Lehre 278, wobei der wenigstens eine Sensor zum Erkennen wenigstens eines Parameter des wenigstens einen Wirkstoffs in dem wenigstens einen deformierbaren Reservoir ausgebildet ist.
• 280. Das Verfahren nach der Lehre 278, wobei der wenigstens eine Sensor zum Erkennen den Qualitäts- oder Abbauzustand des wenigstens eine Wirkstoff in dem wenigstens einen deformierbare Reservoir ausgebildet ist.
• 281. Das Verfahren nach der Lehre 278, wobei der wenigstens eine Sensor zum Erkennen der Menge des wenigstens einen Wirkstoffs in dem wenigstens einen deformierbaren Reservoir ausgebildet ist.
• 282. Das Verfahren nach der Lehre 278, wobei der wenigstens eine Sensor zum Erkennen der Temperatur, des Drucks, des pH-Werts, der Viskosität, der elektrischen Leitfähigkeit oder der optischen Dichte des wenigstens einen Wirkstoffs in der wenigstens eines deformierbares Reservoir ausgebildet ist.
• 283. Das Verfahren nach der Lehre 266, wobei das wenigstens eine Wirkstoffapplikationsmittel weiter wenigstens einen Sensor aufweist, der zur Anordnung entfernt von dem wenigstens einen Wirkstoffapplikationsmittel angeordnet ist.
• 284. Das Verfahren nach Lehre 283, wobei der wenigstens eine Sensor zum Erkennen wenigstens eines Parameter der Umgebung extern zu dem wenigstens einen deformierbare Reservoir ausgebildet ist.
• 285. Das Verfahren nach der Lehre 284, wobei der wenigstens eine Sensor zum Erkennen der Temperatur, des Drucks, des pH-Werts, der Viskosität, der elektrischen Leitfähigkeit oder der optische Dichte der externen Umgebung ausgebildet ist
• 286. Das Verfahren nach der Lehre 284, wobei der wenigstens eine Sensor zum Erkennen des Vorhandensein oder Nichtvorhandenseins eines bestimmten Moleküls oder Stoffs in der externen Umgebung.
• 287. Das Verfahren nach der Lehre 284, wobei der wenigstens eine Sensor zum Erkennen der Konzentration eines bestimmten Moleküls oder Stoffs in der externen Umgebung ausgebildet ist.
• 288. Das Verfahren nach der Lehre 266, wobei der wenigstens eine implantierbare Wirkstoffapplikationsmittel weiter eine Hardware, Firmware und/oder Software aufweist, die zum Steuern des wenigstens einen steuerbaren Ausgabemechanismus ausgebildet ist.
• 289. Das Verfahren nach der Lehre 288, wobei das wenigstens eine implantierbare Wirkstoffapplikationsmittel weiter wenigstens eine Steuerschaltung aufweist, die zum Aktivieren des wenigstens einen steuerbaren Ausgabemechanismus ausgebildet ist.
• 290. Das Verfahren nach der Lehre 289, wobei die wenigstens eine Steuerschaltung zum Erzeugen und Übertragen eines elektromagnetischen Steuersignals, das zum Steuern des wenigstens einen steuerbaren Ausgabemechanismus eingerichtet ist, ausgebildet ist.
• 291. Das Verfahren nach der Lehre 290, wobei das wenigstens eine implantierbare Wirkstoffapplikationsmittel weiter einen elektronischen Speichermechanismus zum Speichern von Befehlen zum Erzeugen und Übertragen des elektromagnetischen Steuersignals aufweist.
• 292. Das Verfahren nach der Lehre 266, wobei das wenigstens eine implantierbare Wirkstoffapplikationsmittel weiter wenigstens einen elektronische Speicherort zum Aufzeichnen von Information aufweist.
• 293. Das Verfahren nach der Lehre 292, wobei der wenigstens eine elektronische Speicherort zum Aufzeichnen von Information betreffend eines Sensors, eines Zählers, einer Fernsteuerung oder eines Zeitgeber ausgebildet ist.
• 294. Das Verfahrne nach der Lehre 292, wobei der wenigstens eine elektronische Speicherort zum Aufzeichnen von Information betreffend wenigstens eines sensierten Zustands, Verlaufs oder Eigenschaft des wenigstens einen implantierbaren Wirkstoffapplikationsmittels eingerichtet ist.
• 295. Das Verfahren nach der Lehre 292, wobei der wenigstens eine elektronische Speicherort zum Aufzeichnen von Information betreffend wenigstens des Datums, der Zeit und der Menge des abgegebenen Wirkstoffs konfiguriert ist.
• 296. Das Verfahren nach der Lehre 292, wobei das wenigstens eine implantierbare Wirkstoffapplikationsmittel weiter einen Informationsübertragungsmechanismus aufweist, der zum Übertragen von an dem wenigstens einen elektronische Speicherort aufgezeichneter Information eingerichtet ist.
• 297. Das Verfahren nach der Lehre 266, wobei der wenigstens einen steuerbaren Ausgabemechanismus eine Mikropumpe aufweist.
• 298. Das Verfahren nach der Lehre 297, wobei die Mikropumpe peristaltisch ist.
• 299. Das Verfahren nach der Lehre 266, wobei der wenigstens einen steuerbaren Ausgabemechanismus ein MEMS Mittel oder ein NEMS Mittel aufweist.
• 300. Das Verfahren nach der Lehre 266, wobei der wenigstens einen steuerbare Ausgabemechanismus ein Einwegventil in Kommunikation mit dem wenigstens eine Auslass des wenigstens einen deformierbaren Reservoir aufweist.
• 301. Das Verfahren nach der Lehre 266, wobei der wenigstens einen steuerbaren Ausgabemechanismus wenigstens ein thermisch, magnetisch, elektrisch oder elektromagnetisch ansprechenden Material aufweist.
• 302. Das Verfahren nach der Lehre 301, wobei das wenigstens eine thermisch, magnetisch, elektrisch oder elektromagnetisch ansprechende Material ein Hydrogel, Polymer, eine Keramik, Dielektrikum, ein Metal, ein dauerhaft magnetisierbares Material, ein Ferrofluid, ein ferromagnetisches Material, ein ferrimagnetisches Material, ein eisenhaltiges Material, en eisenartiges Material, ein ferrische Material, ein dielektrisches Material, ein Ferroelektrisches Material, ein piezoelektrisches Material, ein diamagnetisches Material, ein paramagnetisches Material, ein metallisches Material oder ein antiferromagnetisches Material aufweist.
• 303. Das Verfahren nach der Lehre 301, wobei das wenigstens eine thermisch, magnetisch, elektrisch oder elektromagnetisch ansprechende Material ein Polymer, eine Keramik, ein Dielektrikum, ein Ferrofluid oder ein Metal aufweist.
• 304. Das Verfahren nach der Lehre 301, wobei das wenigstens eine thermisch, magnetisch, elektrisch oder elektromagnetisch ansprechende Material auf ein statisches oder quasi-statisches elektrisches Feld anspricht.
• 305. Das Verfahren nach der Lehre 301, wobei das wenigstens eine thermisch, magnetisch, elektrisch oder elektromagnetisch ansprechende Material auf ein nicht-ionisierendes elektromagnetisches Signal anspricht.
• 306. Das Verfahren nach der Lehre 301, wobei das wenigstens eine thermisch, magnetisch, elektrisch oder elektromagnetisch ansprechende Material auf ein elektromagnetisches Signal im Radiofrequenzbereich anspricht.
• 307. Das Verfahren nach der Lehre 301, wobei das wenigstens eine thermisch, magnetisch, elektrisch oder elektromagnetisch ansprechenden Material auf ein elektromagnetisches Mikrowellensignal anspricht.
• 308. Das Verfahren nach der Lehre 301, wobei das wenigstens eine thermisch, magnetisch, elektrisch oder elektromagnetisch ansprechende Material auf ein optisches Signal anspricht.
• 309. Das Verfahren nach der Lehre 301, wobei das wenigstens eine thermisch, magnetisch, elektrisch oder elektromagnetisch ansprechende Material auf ein elektromagnetisches Millimeterwellen-Signal anspricht.
• 310. Das Verfahren nach der Lehre 301, wobei der wenigstens eine thermisch, magnetisch, elektrisch oder elektromagnetisch ansprechenden Wirkstoff auf ein akustisches Signal anspricht.
• 311. Das Verfahren nach der Lehre 266, wobei der wenigstens eine steuerbare Ausgabemechanismus ein Formgedächtnismaterial aufweist.
• 312. Das Verfahren nach der Lehre 311, wobei die wenigstens eine steuerbare Ausgabe Formgedächtnismaterial auf ein Steuersignal durch Ändern seiner Form anspricht.
• 313. Das Verfahren nach der Lehre 300, wobei das Einwegventil in Antwort auf ein Steuersignal öffnet oder schließt.
• 314. Das Verfahren nach der Lehre 266, weiter mit wenigstens eine Körperstruktur zum Schaffen einer Abgrenzung zwischen der wenigstens eine Wirkstoffapplikationsmittel und dem umgebendes in vivo Gewebe.
• 315. Das Verfahren nach der Lehre 314, wobei das wenigstens eine implantierbare Wirkstoffapplikationsmittel zur Entfernung von der wenigstens eine Körperstruktur, während die wenigstens eine Körperstruktur in vivo verbleibt, ausgebildet ist.
• 316. Das Verfahren nach der Lehre 314, wobei die wenigstens eine Körperstruktur zum biologischen Abbau entsprechend einem Zeitinterval ausgebildet ist.
• 317. Das Verfahren nach der Lehre 314, wobei die wenigstens eine Körperstruktur durch ein biokompatibles Material abbaubar ist.
• 318. Das Verfahren nach der Lehre 314, wobei die Körperstruktur zum Abbau in Antwort auf ein externes Signal abbaubar ist.
• 319. Das Verfahren nach der Lehre 266, wobei das wenigstens eine implantierbare Wirkstoffapplikationsmittel wenigstens zwei deformierbare Reservoirs aufweist.
• 320. Das Verfahren nach der Lehre 319, wobei die wenigstens zwei deformierbaren Reservoirs wenigstens zwei Wirkstoffe aufnehmen.
• 321. Das Verfahren nach der Lehre 320, wobei die wenigstens zwei Wirkstoffe Reaktantien sind.
• 322. Das Verfahren nach der Lehre 266, wobei das wenigstens eine implantierbare Wirkstoffapplikationsmittel weiter wenigstens einen Dekontaminationsmechanismus aufweist.
• 323. Das Verfahren nach der Lehre 322, wobei der wenigstens eine Dekontaminationsmechanismus die Verwendung von UV Licht oder eines chemischen Dekontaminanten beinhaltet.
• 324. Das Verfahren nach der Lehre 266, wobei das wenigstens eine implantierbare Wirkstoffapplikationsmittel weiter einen Energiespeichermechanismus aufweist.
• 325. Das Verfahren nach der Lehre 266, wobei der wenigstens eine implantierbare Wirkstoffapplikationsmittel weiter einen Energie aufnehmenden Mechanismus aufweist.
• 326. Das Verfahren nach der Lehre 266, wobei der wenigstens eine implantierbare Wirkstoffapplikationsmittel weiter eine Energie erzeugenden Mechanismus aufweist.
• 327. Das Verfahren nach der Lehre 266, wobei das wenigstens eine Steuersignal von wenigstens einer Fernsteuerung erzeugt wird.
• 328. Das Verfahren nach der Lehre 327, wobei die wenigstens eine Fernsteuerung eine Hardware, Firmware und/oder Software aufweist, die zur Steuerung der Übertragung des wenigstens eines Steuersignals ausgebildet ist.
• 329. Das Kit nach der Lehre 327, wobei die wenigstens eine Fernsteuerung eine Hardware, Firmware und/oder Software aufweist, die zum Empfang der Übertragung von Information von dem Informationsübertragungsmechanismus ausgebildet ist.
• 330. Das Kit nach der Lehre 329, wobei die wenigstens eine Fernsteuerung weiter einen Displaymechanismus zum Darstellen der Information für eine Person aufweist.
• 331. Das Verfahren nach der Lehre 327, wobei das wenigstens eine Steuersignal Befehle aufweist, die zum Programmieren des wenigstens eine Wirkstoffapplikationsmittel konfiguriert sind.
• 332. Das Verfahren nach der Lehre 327, wobei das wenigstens eine Steuersignal von der wenigstens eine Fernsteuerung einem Zeitplan folgende übertragen wird.
• 333. Das Verfahren nach der Lehre 266, wobei das wenigstens eine Steuersignal elektromagnetisch ist.
• 334. Das Verfahren nach der Lehre 266, wobei das wenigstens eine Steuersignal infrarot ist.
• 335. Das Verfahren nach der Lehre 266, wobei das wenigstens eine Steuersignal magnetisch ist.
• 336. Das Verfahren nach der Lehre 266, wobei das wenigstens eine Steuersignal Ultraschall ist.
• 337. Das Verfahren nach der Lehre 266, wobei das wenigstens eine Steuersignal ultraviolet ist.
• 338. Das Verfahren nach der Lehre 266, wobei das wenigstens eine Steuersignal akustisch ist.
• 339. Das Verfahren nach der Lehre 266, wobei das wenigstens eine Steuersignal optisch ist.
• 340. Das Verfahren nach der Lehre 328, wobei die Hardware, Firmware und/oder Software der wenigstens einen Fernsteuerung einen Speichermechanismus zum Speichern von Befehlen aufweist.
• 341. Das Verfahren nach der Lehre 340, wobei der Speichermechanismus nicht flüchtig ist.
• 342. Das Verfahren nach der Lehre 328, wobei die Hardware, Firmware und/oder Software der wenigstens einen Fernsteuerung weiter Befehle zum Aufnehmen eines oder Steuerparameter aufweist.
• 343. Das Verfahren nach der Lehre 342, wobei die Hardware, Firmware und/oder Software der wenigstens einen Fernsteuerung weiter Befehle zum Erzeugen des wenigstens einen Steuersignals basierend auf einem oder mehreren Steuerparametern aufweist.
• 344. Das Verfahren nach der Lehre 328, wobei die Hardware, Firmware oder Software der wenigstens einen Fernsteuerung weiter Befehle zum Durchführen einer Verschlüsselung des wenigstens eine Steuersignals aufweist.
• 345. Das Verfahren nach der Lehre 32, wobei die Hardware, Firmware und/oder Software der wenigstens eine Fernsteuerung weiter Befehle zum Durchführen eines Authentifizierungsvorgangs zwischen der wenigstens eine Fernsteuerung und der wenigstens eine implantierbare Wirkstoffapplikationsmittel.
• 346. Das Verfahren nach der Lehre 328, wobei die Hardware, Firmware und/oder Software der wenigstens eine Fernsteuerung weiter Befehle zum Durchführen eines Abfragevorgangs zwischen der wenigstens eine Fernsteuerung und der wenigstens eine implantierbare Wirkstoffapplikationsmittel.
• 347. Das Verfahren nach der Lehre 266, wobei der wenigstens eine zuzuführende Wirkstoff wenigstens einen therapeutischen Wirkstoff aufweist.
• 348. Das Verfahren nach der Lehre 347, wobei der wenigstens eine therapeutische Wirkstoff eine therapeutisch wirksame Menge oder Konzentration wenigstens eines Nährstoffs, Nutrazeutikums, Hormons, Wachstumsfaktors, eines Anti-Infektionsmittels, einer Medikation, einer therapeutischen Verbindung, eines Enzym, eines genetisches Materials, eines Impfstoffs, Vitamins, Neurotransmitters, Zytokins, zell-signalisierenden Wirkstoffs, ein pro- oder anti-apoptotischer Wirkstoffs, eines bildgebenden Wirkstoffs, eines Labelingwirkstoffs, eines diagnostischen Wirkstoffs, eines Nanomaterials, eines Inhibitors oder Blockers oder einer Komponente daraus sein.
• 349. Das Verfahren nach der Lehre 266, wobei der wenigstens eine zuzuführende Wirkstoff ein Fluid ist.
• 350. Das Verfahren nach der Lehre 348, wobei der wenigstens eine therapeutische Wirkstoff eine immunogene Menge wenigstens eines Impfstoffs aufweist.
• 351. Das Verfahren nach der Lehre 350, wobei der wenigstens eine Impfstoff wenigstens einen HIV-I Impfstoff aufweist.
• 352. Das Verfahren nach der Lehre 350, wobei der wenigstens eine Impfstoff wenigstens einen Masern-Impfstoff aufweist.
• 353. Das Verfahren nach der Lehre 350, wobei der wenigstens eine Impfstoff wenigstens einen Influenza Impfstoff aufweist.
• 354. Das Verfahren nach der Lehre 350, wobei der wenigstens eine Impfstoff wenigstens einen Hepatitis-Impfstoff aufweist.
• 355. Das Verfahren nach der Lehre 341, wobei der wenigstens eine HIV-I Impfstoff eine Untereinheit von gp120 aufweist.
• 356. Das Verfahren nach der Lehre 338, wobei der wenigstens eine therapeutische Wirkstoff eine therapeutisch wirksame Menge wenigstens eines anti-infiziösen Wirkstoffs aufweist.
• 357. Das Verfahren nach der Lehre 356, wobei der wenigstens eine anti-inektiöse Wirkstoff wenigstens einen anti-viralen Wirkstoff aufweist.
• 358. Das Verfahren nach der Lehre 356, wobei der wenigstens eine anti-infektiöse Wirkstoff wenigstens einen anti-mikrobiellen Wirkstoff aufweist.
• 359. Das Verfahren nach der Lehre 348, wobei der wenigstens eine therapeutische Wirkstoff eine therapeutisch wirksame Menge wenigstens eines anti-neoplastischen Wirkstoffs aufweist.
• 360. Das Verfahren nach der Lehre 357, wobei der wenigstens eine antiviral Wirkstoff wenigstens einen Anti-HIV-1 Wirkstoff aufweist.
• 361. Das Verfahren nach der Lehre 360, wobei der anti-HIV-1 Wirkstoff aus der Gruppe, die anti-virale Protease, einen viralen Fusionsinhibitor, einen Integraseinhibitor, einen Umkehrtranskriptase-Inhibitor (entweder nukleotid oder nicht-nukleotid), ein pharmazeutisch akzeptables Derivativ von diesen oder eine Kombination daraus ausgewählt ist.
• 362. Das Verfahren nach der Lehre 348, wobei der wenigstens eine therapeutische Wirkstoff eine therapeutisch wirksame Menge wenigstens eines Wirkstoff zur Behandlung der Malaria aufweist.
• 363. Das Verfahren nach der Lehre 362, wobei der wenigstens eine Wirkstoff zur Behandlung der Malaria aus der Gruppe mit Chloroquin, Sulfadoxin-Pyrimethamine, Mefloquin, Atovaquein-Proguanil, Chinin, Doxycycline, Artemisinderivativen, Primaquin, einem pharmazeutisch akzeptablem Salz daraus oder eine Kombination daraus ausgewählt ist.
• 364. Das Verfahren nach der Lehre 348, wobei der wenigstens eine therapeutische Wirkstoff eine therapeutisch wirksame Menge of wenigstens einem Wirkstoff zur Behandlung der Tuberkulose aufweist.
• 365. Das Verfahren nach der Lehre 348, wobei der wenigstens eine therapeutische Wirkstoff eine therapeutisch wirksame Menge von wenigstens einem Wirkstoff zur Behandlung von Lieshmaniasis aufweist.
• 366. Das Verfahren nach der Lehre 348, wobei der wenigstens eine therapeutische Wirkstoff eine therapeutisch wirksame Menge von wenigstens einem Wirkstoff zur Behandlung von Cholera aufweist.
• 367. Das Verfahren nach der Lehre 348, wobei der wenigstens eine therapeutische Wirkstoff eine therapeutisch wirksame Menge von wenigstens einem Wirkstoff zur Behandlung von Maser aufweist.
• 368. Das Verfahren nach der Lehre 348, wobei der wenigstens eine therapeutische Wirkstoff eine therapeutisch wirksame Menge von wenigstens einem Wirkstoff zur Behandlung von Diphtherie aufweist.
• 369. Das Verfahren nach der Lehre 348, wobei der wenigstens eine therapeutische Wirkstoff eine therapeutisch wirksame Menge wenigstens einem Wirkstoffs zur Behandlung von Krebs aufweist.
• 370. Das Verfahren nach der Lehre 348, wobei der wenigstens eine therapeutische Wirkstoff eine therapeutisch wirksame Menge von wenigstens einem Wirkstoff zur Behandlung einer Autoimmunerkrankung aufweist.
• 371. Das Verfahren nach der Lehre 348, wobei der wenigstens eine therapeutische Wirkstoff eine therapeutisch wirksame Menge von wenigstens einem Wirkstoff zur Behandlung von Hepatitis C aufweist.
• 372. Das Verfahren nach der Lehre 348, wobei der wenigstens eine therapeutische Wirkstoff eine therapeutisch wirksame Menge von pegyliertem Interferon alfa-2a, Ribavirin, Telaprevir, einem a pharmazeutisch akzeptablem Salz daraus oder Kombinationen dieser aufweist.
• 373. Das Verfahren nach der Lehre 348, wobei der wenigstens eine therapeutische Wirkstoff eine immunogen wirksame Menge von wenigstens einem Impfstoffadjuvans aufweist.
• 374. Das Verfahren nach der Lehre 348, wobei der wenigstens eine therapeutische Wirkstoff eine therapeutisch wirksame Menge von wenigstens einem gegen eine Sucht wirkenden Wirkstoff aufweist.
• 375. Das Verfahren nach der Lehre 266, wobei das Tier ein Säugetier ist.
• 376. Das Verfahren nach der Lehre 375, wobei das Säugetier ein Vieh ist.
• 377. Das Verfahren nach der Lehre 375, wobei das Säugetier ein Mensch ist.
• 378. Das Verfahren nach der Lehre 375, wobei das Säugetier ein Haustier ist.
• 379. Das Verfahren nach der Lehre 266, wobei das wenigstens eine Wirkstoffapplikationsmittel in den Menschen oder das Tier injiziert ist.
• 380. Das Verfahren nach der Lehre 266, weiter mit dem Schritt des Entfernens des wenigstens einen Wirkstoffs aus dem wenigstens eine Wirkstoffapplikationsmittel in vivo.
• 381. Ein Verfahren zum Applizieren wenigstens eines therapeutischen Wirkstoffs zu einem Menschen oder einem Tier, mit: Einbringen eines Wirkstoffapplikationsmittels in eine in vivo Umgebung eines Menschen oder eines Tieres; wobei das Wirkstoffapplikationsmittel mit wenigstens einem deformierbaren Reservoir, das zum Aufnehmen, Beherbergen und Abgeben wenigstens eines Wirkstoff ausgebildet ist, mit wenigstens einem Auslass, durch den der wenigstens eine Wirkstoff aus dem wenigstens einen deformierbaren Reservoir austreten kann; und wenigstens einem steuerbaren Ausgabemechanismus, der operativ mit dem wenigstens einen Auslass zum Steuern der Applikation des wenigstens einen Teils des wenigstens einen Wirkstoffs aus dem wenigstens einen deformierbaren Reservoir verbunden ist; und Übertragen eines elektromagnetischen Steuersignals um den wenigstens einen steuerbaren Ausgabemechanismus ausreichend zu veranlassen, einen Teil des wenigstens eine therapeutische Wirkstoffs aus dem wenigstens eine deformierbare Reservoir freizusetzen.
• 382. Ein Verfahren zum Applizieren eines Wirkstoffs zu einem Menschen oder Tier, mit: Definieren eines deformierbaren Wirkstoffreservoirs in dem Menschen oder dem Tier; Einbringen einer Menge des Wirkstoffs in das deformierbare Wirkstoffreservoir durch Injektion und Bewirken eines wählbaren Steuerung der Freisetzung des Wirkstoffs aus dem deformierbaren Wirkstoffreservoir.

Examples of aspects of the subject matter described herein will become apparent from the following numbered teachings:

• A drug delivery device implantable in a human or animal, comprising at least one deformable reservoir adapted to receive, store, and dispense at least one drug having at least one outlet through which the at least one drug may emerge from the at least one deformable reservoir ; and at least one controllable dispensing mechanism operatively connected to the at least one outlet for controlling application of the at least one portion of the at least one active agent from the at least one deformable reservoir.
• 2. The means of doctrine 1, wherein the at least one deformable reservoir further comprises at least one inlet mechanism for receiving an externally supplied drug after the agent has been introduced into the human or animal.
• 3. The agent of teaching 1, wherein the at least one portion of the at least one deformable reservoir has inner or outer surfaces that are substantially chemically or biologically inert.
• 4. The means of teaching 3, wherein the at least one deformable reservoir has an outer surface that is substantially chemically or biologically inert.
• 5. The means of teaching 1, wherein the at least a portion of the at least one deformable reservoir comprises a non-porous elastomeric material.
• 6. The means of teaching 1, wherein the at least a portion of the at least one deformable reservoir is an elongated tubular member.
• 7. The means of teaching 1, wherein the at least one portion of the at least one deformable reservoir is a folded member.
• 8. The means of teaching 1, wherein the at least a portion of the at least one deformable reservoir is volumetrically expandable.
• 9. The means of teaching 1, further with an RPID circuit.
• 10. The composition according to the teaching 1, designed for injection into the human or the animal.
• 11. The means of doctrine 10, wherein the human or the animal is a human.
• 12. The means according to the teaching 1, further comprising at least one sensor, at least one timer, at least one counter.
• 13. The means of teaching 1, wherein the at least one controllable dispensing mechanism is responsive to the at least one sensor, the at least one timer, the at least one counter, or the at least one remote controller.
• 14. The means of teaching 13, wherein the at least one sensor is responsive to detecting at least one parameter of the at least one drug in the at least one deformable reservoir.
• 15. The means according to the teaching 13, wherein the at least one sensor is arranged on the means.
• 16. The means of gauge 13, wherein the at least one sensor is configured for attachment remote from the means.
• 17. The means of gauge 14, wherein the at least one sensor detects the quality or degradation state of the at least one drug in the at least one deformable reservoir.
• 18. The means of gauge 14, wherein the at least one sensor is configured to detect the amount of the at least one drug in the at least one deformable reservoir.
• 19. The means according to the teaching 14, wherein the at least one sensor for detecting the temperatures, the pressure of the pH, the viscosity, the electrical conductivity or the optical density of the at least one active substance in the at least one deformable reservoir is formed.
• 20. The means of teaching 13, wherein the at least one sensor is configured to detect at least one parameter of the environment external to the at least one deformable reservoir.
• 21. The means according to the teaching 20, wherein the at least one sensor for detecting the temperatures, the pressure, the pH, the viscosity, the electrical conductivity or the optical density of the external environment is formed.
• 22. The means according to the teaching 20, wherein the at least one sensor for detecting the presence of the absence or absence of a particular molecule or substance in the external environment.
• 23. The means of teaching 20, wherein the at least one sensor is configured to detect the concentration of a specific molecule or substance in the external environment.
• 24. The means of teaching 1, further comprising hardware, firmware or software configured to control the at least one controllable output mechanism.
• 25. The means of teaching 24, further comprising at least one control circuit configured to control the at least one controllable output mechanism.
• 26. The means according to the teaching 25, wherein the at least one control circuit is designed to generate and transmit an electromagnetic control signal for controlling the at least one controllable output mechanism.
• 27. The means of teaching 26, further comprising a storage mechanism for storing instructions for generating and transmitting the electromagnetic control signal.
• 28. The means of teaching 1, further comprising at least one storage location for recording information.
• 29. The means of teaching 28, wherein the storage location is readable by an external means.
• 30. The means of teaching 28, wherein the at least one storage location is configured to record information regarding at least the sensor, counter, remote control, or timer.
• 31. The means of teaching 28, wherein the at least one storage location is configured to record information regarding at least one sensed condition, a history, or a property of the agent.
• 32. The means of teaching 28, wherein the at least one storage location is configured to record information regarding at least the date, time, and / or amount of drug delivered.
• 33. The means of teaching 28, further configured with an information transfer mechanism for transferring the information stored by the at least one electronic storage location.
• 34. The means of teaching 33, wherein the information transfer mechanism is configured to transfer information in response to a request.
• 35. The means of doctrine 33, wherein the information is coded.
• 36. The means of teaching 1, wherein the at least one controllable dispensing mechanism comprises a micropump.
• 37. The agent according to the teaching 36, wherein the micropump is peristaltic.
• 38. The means of teaching 1, wherein the at least one controllable dispensing mechanism comprises a MEMS agent or an NEMS agent.
• 39. The means of teaching 1, wherein the at least one controllable dispensing mechanism comprises a one-way valve in communication with the at least one outlet of the at least one deformable reservoir.
• 40. The means of teaching 1, wherein the at least one controllable dispensing mechanism comprises at least one thermally, magnetically, electrically or electromagnetically responsive material.
• 41. The agent according to the teaching 40, wherein the at least one thermally, magnetically, electrically or electromagnetically responsive active substance is a hydrogel, a polymer, a ceramic, a dielectric, a metal, a permanently magnetizable material, a ferrofluidic material, a ferromagnetic material, a ferrimagnetic material, an iron-containing material, an iron-like material, a dielectric material, a ferroelectric material, a piezoelectric material, a diamagnetic material, a paramagnetic material, a metallic material or an antiferromagnetic material.
• 42. The means of teaching 40, wherein the at least one thermally, magnetically, electrically, or electromagnetically responsive material is a polymer, a ceramic, a dielectric, a ferrofluid, or a metal.
• 43. The means of teaching 40, wherein the at least one thermally, magnetically, electrically, or electromagnetically responsive material is responsive to a static or quasi-static electric field.
• 44. The means of teaching 40, wherein the at least one thermally, magnetically, electrically, or electromagnetically responsive material is responsive to a static or quasi-static magnetic field.
• 45. The means of teaching 40, wherein the at least one thermally, magnetically, electrically, or electromagnetically responsive material is responsive to a non-ionizing electromagnetic signal.
• 46. The means of teaching 40, wherein the at least one thermally, magnetically, electrically, or electromagnetically responsive material is responsive to a radio frequency electromagnetic signal.
• 47. The means of teaching 40, wherein the at least one thermally, magnetically, electrically, or electromagnetically responsive material is responsive to an electromagnetic signal in the microwave range.
• 48. The agent according to the teaching 40, wherein the at least one thermally, magnetically, electrically or electromagnetically responsive active substance to an electromagnetic signal with a Milli meter wavelength responds.
• 49. The means of teaching 40, wherein the at least one thermally, magnetically, electrically, or electromagnetically responsive material is responsive to an optical signal.
• 50. The means of teaching 40, wherein the at least one thermally, magnetically, electrically, or electromagnetically responsive material is responsive to an acoustic signal.
• 51. The means of teaching 1, wherein the at least one controllable dispensing mechanism comprises a shape memory material.
• 52. The means of gauge 51, wherein the shape memory material is responsive to the control signal by changing its shape.
• 53. The means of teaching 39, wherein the one-way valve opens or closes in response to the control signal.
• 54. The device of teaching 1, further configured with a body structure to create a boundary against surrounding in vivo tissue.
• 55. The means of teaching 54, wherein the drug delivery agent is configured to be removed from the body structure while the body structure remains in vivo.
• 56. The means of teaching 54, wherein the body structure is configured for biodegradation in a period of time.
• 57. The means of teaching 54, wherein the body structure is degradable by a biocompatible material.
• 58. The means of teaching 54, wherein the body structure is configured for disassembly in response to an external signal.
• 59. The agent according to the teaching 1, with at least two deformable reservoirs.
• 60. The agent according to the teaching 59 with at least two active ingredients.
• 61. The agent of the teaching 60, wherein the two or more agents are reactants.
• 62. The agent according to the teaching 1, further with a decontamination mechanism.
• 63. The agent of gauge 62, wherein the decontamination mechanism uses UV light or a chemical decontaminant.
• 64. The means according to the teaching 1, further with an energy storage mechanism.
• 65. The means according to doctrine 1, further with a performance-absorbing mechanism.
• 66. The means according to the teaching 1, further with an energy-generating mechanism.
• 67. A drug delivery system comprising at least one drug delivery agent implantable in a human or animal comprising: at least one deformable reservoir adapted to receive, store and deliver at least one drug having at least one outlet through which the at least one drug may emerge at least one deformable reservoir; at least one controllable dispensing mechanism operatively associated with the at least one outlet for controlling application of the at least one portion of the at least one active agent from the at least one deformable reservoir; and at least one remote control configured to generate and transmit at least one control signal to the at least one drug delivery device.
• 68. The system of clause 67, wherein the at least one deformable reservoir further comprises at least one inlet mechanism for receiving an externally supplied drug.
• 69. The system of clause 67, wherein the at least a portion of the at least one deformable reservoir has inner or outer surfaces that are substantially chemically or biologically inert.
• 70. The means of gauge 69, wherein the at least one deformable reservoir has an outer surface that is substantially chemically or biologically inert.
• 71. The system of clause 67, wherein the at least a portion of the at least one deformable reservoir comprises a non-porous, elastomeric material.
• 72. The system of gauge 67, wherein the at least a portion of the at least one deformable reservoir is an elongated tubular member.
• 73. The system of gauge 67, wherein the at least one portion of the at least one deformable reservoir comprises a folded member.
• 74. The system of doctrine 67, wherein the at least a portion of the at least one deformable reservoir is volumetrically expandable.
• 75. The system of clause 67, wherein the at least one drug delivery agent comprises an RFID circuit.
• 76. The system of clause 67, wherein the at least one drug delivery agent is for injection into a human or animal.
• 77. The system of Doctrine 76, wherein the human or the animal is a human.
• 78. The system according to the teaching 67, further comprising at least one sensor, at least one timer and / or at least one counter.
• 79. The system of clause 78, wherein the at least one controllable dispensing mechanism is responsive to the at least one sensor, the at least one timer, the at least one counter, or the at least one remote controller.
• 80. The system of teaching 78, wherein the at least one sensor on the at least one Active agent application agent is arranged.
• 81. The system of teaching 80, wherein the at least one sensor is provided for detecting at least one parameter of the at least one drug in the at least one deformable reservoir.
• 82. The system of clause 78, wherein the at least one sensor is arranged for an assembly remote from the at least one drug delivery agent.
• 83. The system of clause 81, wherein the at least one sensor is configured to detect the quality or degradation state of the at least one drug in the at least one deformable reservoir.
• 84. The system of clause 81, wherein the at least one sensor is configured to detect the amount of the at least one drug in the at least one deformable reservoir.
• 85. The system of clause 81, wherein the at least one sensor is configured to detect the temperature, pressure, pH, viscosity, electrical conductivity or optical density of the at least one drug in the at least one deformable reservoir.
• 86. The system of clause 82, wherein the at least one sensor is configured to detect at least one parameter of the environment external to the at least one deformable reservoir.
• 87. The system of clause 86, wherein the at least one sensor is configured to detect temperature, pressure, pH, viscosity, electrical conductivity, or optical density of the external environment.
• 88. The system of clause 86, wherein the at least one sensor is configured to detect the presence or absence of a particular molecule or drug in an external environment.
• 89. The system of clause 86, wherein the at least one sensor is configured to detect the concentration of a particular molecule or drug in an external environment.
• 90. The system of clause 67, wherein the at least one drug delivery agent further comprises hardware, firmware, or software configured to control the at least one controllable delivery mechanism.
• 91. The system of teaching 90, wherein the at least one drug delivery agent further comprises at least one control circuit for activating the at least one controllable delivery mechanism.
• 92. The system of clause 91, wherein the at least one control circuit is configured to generate and transmit an electromagnetic control signal to control the controllable output mechanism.
• 93. The system of clause 91, wherein the at least one drug delivery agent further comprises at least one electronic storage mechanism for storing instructions for generating and transmitting an electromagnetic control signal.
• 94. The system of teaching 67, wherein the at least one drug delivery agent further comprises at least one electronic storage location for recording information.
• 95. The system of clause 94, wherein the at least one electronic storage location is configured to record information regarding at least one of a sensor, counter, remote control, or timer.
• 96. The system of clause 94, wherein the at least one electronic storage location is configured to record information regarding at least one of a second condition, a sensed condition, a history, or a property of the at least one drug delivery agent.
• 97. The system of clause 94, wherein the at least one electronic storage location is configured to record information regarding at least the date, time or amount of drug delivered.
• 98. The system of clause 94, wherein the at least one drug delivery agent further comprises an information transfer mechanism configured to transfer information stored at the at least one electronic storage location.
• 99. The system of doctrine 98, wherein the information transfer mechanism is arranged to transfer information in response to a request.
• 100. The system of gauge 98, wherein the information is encoded.
• 101. The system of clause 67, wherein the at least one controllable dispensing mechanism is a micropump.
• 102. The system according to the teaching 101, wherein the micropump is peristaltic.
• 103. The system of clause 67, wherein the at least one controllable output mechanism is a MEMS agent or an NEMS agent.
• 104. The system of clause 67, wherein the at least one controllable dispensing mechanism includes a one-way valve in communication with the at least one outlet of the at least one deformable reservoir.
• 105. The system of clause 67, wherein the at least one controllable output mechanism comprises at least one thermally, magnetically, electrically or electromagnetically responsive material.
• 106. The system according to the teaching 105, wherein the at least one thermal, magnetic, elek a hydrogel, polymer, a ceramic, a dielectric, metal, a permanently magnetizable material, a ferro-fluidic material, a ferromagnetic material, a ferrimagnetic material, an iron-containing material, iron-like material, a dielectric material, a ferroelectric Material, a piezoelectric material, a diamagnetic material, a paramagnetic material, a metallic material, or antiferromagnetic material.
• 107. The system of clause 105, wherein the at least one thermally, magnetically, electrically, or electromagnetically responsive material comprises a polymer, a ceramic, a dielectric, a ferrofluid, or a metal.
• 108. The system of gauge 105, wherein the at least one thermally, magnetically, electrically, or electromagnetically responsive material is responsive to a static or quasi-static electric field.
• 109. The system of gauge 105, wherein the at least one thermally, magnetically, electrically or electromagnetically responsive material is responsive to a static or quasi-static electric field.
• 110. The system of gauge 105, wherein the at least one thermally, magnetically, electrically or electromagnetically responsive material is responsive to a non-ionizing electrical signal.
• 111. The system of gauge 105, wherein the at least one thermally, magnetically, electrically, or electromagnetically responsive material is responsive to a radio frequency electrical signal.
• 112. The system of gauge 105, wherein the at least one thermally, magnetically, electrically, or electromagnetically responsive material is responsive to a microwave electromagnetic signal.
• 113. The system of gauge 105, wherein the at least one thermally, magnetically, electrically, or electromagnetically responsive material is responsive to an optical signal.
• 114. The system of gauge 105, wherein the at least one thermally, magnetically, electrically, or electromagnetically responsive material is responsive to an electrical signal in the millimeter-wave range.
• 115. The system of gauge 105, wherein the at least one thermally, magnetically, electrically, or electromagnetically responsive material is responsive to an audible signal.
• 116. The system of claim 105, wherein the at least one thermally, magnetically, electrically or electromagnetically responsive material comprises a shape memory material.
• 117. The system of claim 116, wherein the shape memory material is responsive to a control signal by a shape change.
• 118. The system of gauge 104, wherein the one-way valve opens or closes in response to a control signal.
• 119. The system of claim 67, further comprising at least one body structure to provide a demarcation between the at least one drug delivery agent and the surrounding in vivo tissue.
• 120. The system of claim 119, wherein the at least one drug delivery agent is adapted to be removed from the at least one body structure while the at least one body structure remains in vivo.
• 121. The system of claim 119, wherein the at least one body structure is configured for biodegradation in a period of time.
• 122. The system of claim 119, wherein the at least one body structure is degradable by a biocompatible material.
• 123. The system of gauge 119, wherein the body structure is configured for degradation in response to an external signal.
• 124. The system of clause 67, wherein the at least one drug delivery agent comprises at least two deformable reservoirs.
• 125. The system of the teaching 124, with at least two active ingredients.
• 126. The system of claim 125, wherein the at least two drugs are reactants.
• 127. The system of teaching 67, wherein the at least one drug delivery agent further comprises at least one decontamination mechanism.
• 128. The system of claim 127, wherein the at least one decontamination mechanism uses UV light or a chemical decontaminate.
• 129. The system of clause 67, wherein the at least one drug delivery agent further comprises an energy storage mechanism.
• 130. The system of clause 67, wherein the at least one drug delivery agent further comprises an energy absorbing mechanism.
• 131. The system of clause 67, wherein the at least one drug delivery agent further comprises an energy producing mechanism.
• 132. The system of clause 67, wherein the at least one remote control includes hardware, firmware, and / or software configured to control the transmission of the at least one control signal.
• 133. The system of clause 67, wherein the at least one remote control further includes a display mechanism for displaying the information to a person.
• 134. The system of teaching 67, wherein the at least one control signal includes instructions related to Programming the at least one drug delivery means are configured includes.
• 135. The system of clause 67, wherein the at least one control signal is transmitted by the at least one remote controller following a time schedule.
• 136. The system of clause 67, wherein the at least one control signal is electromagnetic.
• 137. The system of clause 67, wherein the at least one control signal is infrared.
• 138. The system of clause 67, wherein the at least one control signal is magnetic.
• 139. The system of clause 67, wherein the at least one control signal is ultrasound.
• 140. The system of clause 67, wherein the at least one control signal is ultraviolet.
• 141. The system of clause 67, wherein the at least one control signal is audible.
• 142. The system of clause 67, wherein the at least one control signal is visible.
• 143. The system of clause 67, wherein the at least one control signal is electrical.
• 144. The system of clause 132, wherein the hardware, firmware, or software of the at least one remote controller includes a storage mechanism for storing instructions.
• 145. The system of the teaching 144, wherein the storage mechanism is non-volatile.
• 146. The system of clause 144, wherein the hardware, firmware and / or software of the at least one remote control further comprises instructions for receiving an input of one or more control parameters.
• 147. The system of teaching 146, wherein the hardware, firmware and / or software of the at least one remote control further comprises instructions for generating the at least one control signal based on one or more control parameters.
• 148. The system of clause 132, wherein the hardware, firmware and / or software of the at least one remote control further comprises instructions for performing encryption of the at least one control signal.
• 149. The system of clause 132, wherein the hardware, firmware, and / or software of the at least one remote control further includes instructions for performing an authentication process between the at least one remote controller and the at least one drug delivery agent.
• 150. The system of clause 132, wherein the hardware, firmware and / or software of the at least one remote control further comprises instructions for performing a polling operation between the at least one remote control and the at least one drug delivery device.
• 151. The system of teaching 67, wherein the at least one drug is a fluid.
• 152. The system of teaching 67, wherein the at least one drug is particulate.
• 153. A drug delivery kit comprising: at least one delivery mechanism; at least one drug-delivery agent implantable in a human or animal, comprising: at least one deformable reservoir adapted to receive, store, and control delivery of at least one drug having at least one outlet through which the at least one drug may be delivered from the at least one deformable reservoir; and at least one controllable dispensing mechanism operatively connected to the at least one outlet and configured to control the dispensing of the at least one active agent from the at least one deformable reservoir.
• 154. The kit of claim 153, further comprising at least one remote controller configured to generate and transmit at least one control signal to the at least one implantable drug delivery device.
• 155. The kit according to the teaching 153, further with at least one active ingredient to be supplied.
• 156. The kit of claim 153, wherein the at least one drug delivery agent further comprises at least one inlet mechanism for receiving an external application of at least one drug.
• 157. The kit of claim 153, wherein at least a portion of the at least one deformable reservoir further comprises inner or outer surfaces that are substantially inert chemically or biologically.
• 158. The kit of claim 153, wherein at least a portion of the at least one deformable reservoir is a non-porous elastomeric material.
• 159. The kit of claim 153, wherein at least a portion of the at least one deformable reservoir is an elongated tubular member.
• 160. The kit of claim 153, wherein at least a portion of the at least one deformable reservoir comprises a folded member.
• 161. The kit of claim 153, wherein at least a portion of the at least one deformable reservoir is volumetrically expandable.
• 162. The kit of claim 153, wherein the at least one injectable drug delivery agent comprises an RFID circuit.
• 163. The kit of claim 153, wherein the at least one injectable drug delivery agent is for injection into the human or animal.
• 164. The kit of teaching 153, wherein the at least one insertable drug delivery means further comprises at least one sensor, at least one timer or at least one counter.
• 165. The kit of claim 164, wherein the at least one controllable dispensing mechanism is responsive to the at least one sensor, the at least one timer, the at least one counter, or at least one remote controller.
• 166. The kit of claim 164, wherein the at least one sensor is disposed on the at least one injectable drug delivery agent.
• 167. The kit of claim 166, wherein the at least one sensor is configured to detect at least one parameter of the at least one drug in the at least one deformable reservoir.
• 168. The kit of claim 164, further comprising at least one sensor configured to be located distally of the at least one drug delivery device.
• 169. The kit of claim 167, wherein the at least one sensor is configured to detect a quality or degradation state of the at least one drug in the at least one deformable reservoir.
• 170. The kit of claim 167, wherein the at least one sensor is configured to detect the amount of the at least one drug in the at least one deformable reservoir.
• 171. The kit of claim 167, wherein the at least one sensor is configured to detect the temperature, pressure, pH, viscosity, electrical conductivity, or optical density of the at least one drug in the at least one deformable reservoir.
• 172. The kit of claim 168, wherein the at least one sensor is configured to detect at least one parameter of the environment external to the at least one deformable reservoir.
• 173. The kit of teaching 172, wherein the at least one sensor is configured to detect temperature, pressure, pH, viscosity, electrical conductivity or optical density of the external environment
• 174. The kit of claim 172, wherein the at least one sensor is for detecting the presence or absence of a particular molecule or substance in the external environment.
• 175. The kit of claim 172, wherein the at least one sensor is configured to detect the concentration of a particular molecule or substance in the external environment.
• 176. The kit of clause 153, wherein the at least one implantable drug delivery agent further comprises hardware, firmware, and / or software configured to control the at least one controllable delivery mechanism.
• 177. The kit of claim 176, wherein the at least one implantable drug delivery agent further comprises at least one control circuit configured to activate the at least one controllable delivery mechanism.
• 178. The kit of claim 177, wherein the at least one control circuit is configured to generate and transmit an electromagnetic control signal configured to control the at least one controllable output mechanism.
• 179. The kit of claim 177, wherein the at least one implantable drug delivery agent further comprises an electronic storage mechanism for storing instructions for generating and transmitting the electromagnetic control signal.
• 180. The kit of claim 177, wherein the at least one implantable drug delivery agent further comprises at least one electronic storage location for recording information.
• 181. The kit of claim 180, wherein the at least one electronic storage location is configured to record information regarding a sensor, a counter, a remote control, or a timer.
• 182. The kit of clause 180, wherein the at least one electronic storage location is configured to record information regarding at least one sensed condition, history or property of the at least one implantable drug delivery agent.
• 183. The kit of teaching 180, wherein the at least one electronic storage location is configured to record information regarding at least the date, time, and amount of drug delivered.
• 184. The kit of claim 180, wherein the at least one implantable drug delivery agent further comprises an information transfer mechanism configured to transfer information recorded at the at least one electronic storage location.
• 185. The kit of claim 184, wherein the information transfer mechanism is configured to transmit information upon a request.
• 186. The kit of teaching 184, wherein the information is encrypted.
• 187. The kit of claim 153, wherein the at least one controllable dispensing mechanism comprises a micropump.
• 188. The kit of teaching 187, wherein the micropump is peristaltic.
• 189. The kit according to the teaching 153, wherein the we at least one controllable output mechanism comprises a MEMS agent or an NEMS agent.
• 190. The kit of claim 153, wherein the at least one controllable dispensing mechanism includes a one-way valve in communication with the at least one outlet of the at least one deformable reservoir.
• 191. The kit of claim 153, wherein the at least one controllable dispensing mechanism comprises at least one thermally, magnetically, electrically or electromagnetically responsive material.
• 192. The kit of claim 191, wherein the at least one thermally, magnetically, electrically, or electromagnetically responsive material is a hydrogel, polymer, ceramic, dielectric, metal, permanently magnetizable material, ferrofluid, ferromagnetic material, ferrimagnetic material An iron-containing material, an iron-like material, a ferromagnetic material, a dielectric material, a ferroelectric material, a piezoelectric material, a diamagnetic material, a paramagnetic material, a metallic material or an antiferromagnetic material.
• 193. The kit of claim 191, wherein the at least one thermally, magnetically, electrically, or electromagnetically responsive material comprises a polymer, a ceramic, a dielectric, a ferrofluid, or a metal.
• 194. The kit of claim 191, wherein the at least one thermally, magnetically, electrically or electromagnetically responsive material is responsive to a static or quasi-static electric field.
• 195. The kit of claim 191, wherein the at least one thermally, magnetically, electrically or electromagnetically responsive material is responsive to a static or quasi-static magnetic field.
• 196. The kit of claim 191, wherein the at least one thermally, magnetically, electrically, or electromagnetically responsive material is responsive to a non-ionizing electromagnetic signal.
• 197. The kit of claim 191, wherein the at least one thermally, magnetically, electrically or electromagnetically responsive material is responsive to an electromagnetic signal in the radio frequency range.
• 198. The kit of claim 191, wherein the at least one thermally, magnetically, electrically, or electromagnetically responsive material is responsive to an electromagnetic microwave signal.
• 199. The kit of claim 191, wherein the at least one thermally, magnetically, electrically, or electromagnetically responsive material is responsive to an optical signal.
• 200. The kit of claim 191, wherein the at least one thermally, magnetically, electrically, or electromagnetically responsive material is responsive to a millimeter wave electromagnetic signal.
• 201. The kit of claim 191, wherein the at least one thermally, magnetically, electrically or electromagnetically responsive drug is responsive to an audible signal.
• 202. The kit of claim 191, wherein the at least one thermally, magnetically, electrically or electromagnetically responsive material is a shape memory material.
• 203. The kit of claim 202, wherein the shape memory material is responsive to a control signal by changing its shape.
• 204. The kit of teaching 190, wherein the one-way valve opens or closes in response to a control signal.
• 205. The kit of claim 153, further comprising at least one body structure to provide a demarcation between the at least one drug delivery agent and the surrounding in vivo tissue.
• 206. The kit of claim 205, wherein the at least one implantable drug delivery agent is adapted to be removed from the at least one body structure while the at least one body structure remains in vivo.
• 207. The kit of teaching 205, wherein the at least one body structure is adapted for biodegradation according to a time interval.
• 208. The kit of claim 205, wherein the at least one body structure is degradable by a biocompatible material.
• 209. The kit of teaching 205, wherein the body structure is degradable for degradation in response to an external signal.
• 210. The kit of claim 153, wherein the at least one implantable drug delivery agent comprises at least two deformable reservoirs.
• 211. The kit according to the teaching 210, with at least two active substances.
• 212. The kit of teaching 211, wherein the at least two drugs are reactants.
• 213. The kit of claim 153, wherein the at least one implantable drug delivery agent further comprises at least one decontamination mechanism.
• 214. The kit of teaching 213, wherein the at least one decontamination mechanism includes the use of UV light or a chemical decontaminant.
• 215. The kit of claim 153, wherein the at least one implantable drug delivery agent further comprises an energy storage mechanism.
• 216. The kit according to the teaching 153, wherein the at least one implantable Wirkstoffapplikati Onsmittel further has an energy absorbing mechanism.
• 217. The kit of clause 153, wherein the at least one implantable drug delivery agent further comprises an energy producing mechanism.
• 218. The kit of teaching 154, wherein the at least one remote controller includes hardware, firmware, and / or software configured to control the transmission of the at least one control signal.
• 219. The kit of teaching 218, wherein the at least one remote control further comprises a display mechanism for presenting the information to a person.
• 220. The kit of claim 218, wherein the at least one control signal comprises instructions configured to program the at least one implantable drug delivery device.
• 221. The kit of teaching 218, wherein the at least one control signal is transmitted by the at least one remote controller according to a time schedule.
• 222. The kit of claim 184, wherein the at least one remote controller includes at least one of hardware, firmware, or software configured to receive information transmitted by the information transfer mechanism.
• 223. The kit of teaching 218, wherein the at least one control signal is electromagnetic.
• 224. The kit of teaching 218, wherein the at least one control signal is infrared.
• 225. The kit of claim 218, wherein the at least one control signal is magnetic.
• 226. The kit of teaching 218, wherein the at least one control signal is ultrasound.
• 227. The kit of teaching 218, wherein the at least one control signal is ultraviolet.
• 228. The kit of teaching 218, wherein the at least one control signal is acoustic.
• 229. The kit of teaching 218, wherein the at least one control signal is optical.
• 230. The kit of claim 218, wherein the hardware, firmware, and / or software of the at least one remote controller includes a storage mechanism for storing instructions.
• 231. The kit of clause 230, wherein the storage mechanism is non-volatile.
• 232. The kit of teaching 218, wherein the hardware, firmware, and / or software of the at least one remote control further comprises instructions for receiving one or control parameters.
• 233. The kit of clause 232, wherein the at least one of hardware, firmware, or software of the at least one remote control further comprises instructions for generating the at least one control signal based on one or more control parameters.
• 234. The kit of teaching 218, wherein the at least one control signal is electromagnetic.
• 235. The kit of teaching 218, wherein the hardware, firmware or software of the at least one remote control further comprises instructions for performing encryption of the at least one control signal.
• 236. The kit of teaching 218, wherein the hardware, firmware, and / software of the at least one remote controller further commands to perform an authentication operation between the at least one remote controller and the at least one implantable drug delivery device.
• 237. The kit of claim 218, wherein the hardware, firmware, and / or software of the at least one remote control further comprises instructions for performing a query operation between the at least one remote controller and the at least one implantable drug delivery device.
• 238. The kit of claim 155, wherein the at least one drug to be delivered comprises at least one therapeutic agent.
• 239. The kit of clause 238, wherein the at least one therapeutic agent comprises a therapeutically effective amount or concentration of at least one nutrient, nutraceutical, hormone, growth factor, anti-infective agent, medication, therapeutic compound, enzyme, genetic material, a vaccine, vitamin, neurotransmitter, cytokine, cell-signaling agent, a pro- or anti-apoptotic agent, an imaging agent, a labeling agent, a diagnostic agent, a nanomaterial, an inhibitor or blocker, or a component thereof.
• 240. The kit of claim 155, wherein the at least one drug to be delivered is a fluid.
• 241. The kit of clause 238, wherein the at least one therapeutic agent comprises an immunogenic amount of at least one vaccine.
• 242. The kit of clause 241, wherein the at least one vaccine comprises at least one HIV-I vaccine.
• 243. The kit of clause 241, wherein the at least one vaccine comprises at least one measles vaccine.
• 244. The kit of teaching 241, wherein the at least one vaccine comprises at least one influenza vaccine.
• 245. The kit of clause 241, wherein the at least one vaccine comprises at least one hepatitis vaccine.
• 246. The kit of clause 242, wherein the at least one HIV-1 vaccine has a subunit of gp120.
• 247. The kit according to the teaching 239, wherein the we at least one therapeutic agent has a therapeutically effective amount of at least one anti-infective agent.
• 248. The kit of teaching 247, wherein the at least one anti-infective agent comprises at least one anti-viral agent.
• 249. The kit of teaching 247, wherein the at least one anti-infective agent comprises at least one anti-microbial agent.
• 250. The kit of clause 239, wherein the at least one therapeutic agent comprises a therapeutically effective amount of at least one anti-neoplastic agent.
• 251. The kit of clause 248, wherein the at least one anti-viral drug from the group, the anti-viral protease, a viral fusion inhibitor, an integrase inhibitor, a reverse transcriptase inhibitor (either nucleotide or non-nucleotide), is a pharmaceutically acceptable Derivative of these or a combination thereof is selected.
• 252. The kit of clause 239, wherein the at least one therapeutic agent comprises a therapeutically effective amount of at least one agent for the treatment of malaria.
• 253. The kit of clause 252, wherein the at least one antimalarial drug is selected from the group consisting of chloroquine, sulfadoxine pyrimethamine, mefloquine, atovaquine proguanil, quinine, doxycycline, artemisin derivatives, primaquine, a pharmaceutically acceptable salt thereof or a combination thereof selected from this.
• 254. The kit of claim 239, wherein the at least one therapeutic agent comprises a therapeutically effective amount of at least one agent for the treatment of tuberculosis.
• 255. The kit of clause 239, wherein the at least one therapeutic agent comprises a therapeutically effective amount of at least one drug for the treatment of lyshmaniasis.
• 256. The kit of clause 239, wherein the at least one therapeutic agent comprises a therapeutically effective amount of at least one drug for the treatment of cholera.
• 257. The kit of clause 239, wherein the at least one therapeutic agent comprises a therapeutically effective amount of at least one maser treating agent.
• 258. The kit of clause 239, wherein the at least one therapeutic agent comprises a therapeutically effective amount of at least one drug for the treatment of diphtheria.
• 259. The kit of clause 239, wherein the at least one therapeutic agent comprises a therapeutically effective amount of at least one drug for the treatment of cancer.
• 260. The kit of clause 239, wherein the at least one therapeutic agent comprises a therapeutically effective amount of at least one agent for treating an autoimmune disease.
• 261. The kit of clause 239, wherein the at least one therapeutic agent comprises a therapeutically effective amount of at least one drug for the treatment of hepatitis C.
• 262. The kit of clause 261, wherein the at least one therapeutic agent comprises a therapeutically effective amount of pegylated interferon alfa-2a, ribavirin, telaprevir, a pharmaceutically acceptable salt thereof, or combinations thereof.
• 263. The kit of clause 239, wherein the at least one therapeutic agent comprises a therapeutically effective amount of at least one anti-addictive agent.
• 264. The kit of clause 239, wherein the at least one therapeutic agent comprises an immunogenically effective amount of at least one vaccine adjuvant.
• 265. The kit of claim 153, wherein the at least one delivery mechanism is a syringe.
• 266. A method for applying at least one drug to a human or animal, comprising: introducing at least one drug delivery agent into an in vivo environment of the human or animal, wherein the at least one drug delivery agent comprises at least one deformable reservoir adapted for receiving, storing, and controlled delivery the at least one active agent is formed and at least one outlet and at least one controllable dispensing mechanism operatively connected to the at least one outlet; and applying an amount of the at least one active agent to the at least one deformable reservoir; wherein the at least one controllable dispensing mechanism dispenses the at least one active ingredient in response to the at least one control signal.
• 267. The method of claim 266, wherein the at least one deformable reservoir further comprises at least one inlet mechanism for receiving an externally supplied drug.
• 268. The method of gauge 266, wherein at least a portion of the at least one deformable reservoir further includes inner and outer surfaces that are substantially chemically or biologically inert.
• 269. The method of gauge 266, wherein at least a portion of the at least one deformable reservoir is made of a non-porous material.
• 270. The method of teaching 266, wherein at least a portion of the at least one defor mable reservoir is an elongate tubular member.
• 271. The method of gauge 266, wherein at least a portion of the at least one deformable reservoir comprises a folded element.
• 272. The method of gauge 266, wherein at least a portion of the at least one deformable reservoir is volumetrically expandable.
• 273. The method of clause 266, wherein the at least one drug delivery agent comprises an RFID circuit.
• 274. The method of clause 266, wherein the at least one drug delivery agent is configured for injection into the human or animal.
• 275. The method of teaching 274, wherein the human or the animal is a human.
• 276. The method of teaching 266, wherein the at least one drug delivery agent further comprises at least one sensor, at least one timer, or at least one counter.
• 277. The method of teaching 276, wherein the at least one controllable dispensing mechanism is responsive to the at least one sensor, the at least one timer, the at least one counter, or the at least one remote controller.
• 278. The method of teaching 276, wherein the at least one sensor is disposed on the at least one drug delivery agent.
• 279. The method of teaching 278, wherein the at least one sensor is configured to detect at least one parameter of the at least one drug in the at least one deformable reservoir.
• 280. The method of teaching 278, wherein the at least one sensor is configured to detect the quality or degradation state of the at least one active agent in the at least one deformable reservoir.
• 281. The method of gauge 278, wherein the at least one sensor is configured to detect the amount of the at least one drug in the at least one deformable reservoir.
• 282. The method of teaching 278, wherein the at least one sensor is configured to detect the temperature, pressure, pH, viscosity, electrical conductivity or optical density of the at least one drug in the at least one deformable reservoir.
• 283. The method of clause 266, wherein the at least one drug delivery agent further comprises at least one sensor disposed for disposition away from the at least one drug delivery agent.
• 284. The method of teaching 283, wherein the at least one sensor is configured to detect at least one parameter of the environment external to the at least one deformable reservoir.
• 285. The method of teaching 284, wherein the at least one sensor is configured to detect temperature, pressure, pH, viscosity, electrical conductivity, or optical density of the external environment
• 286. The method of teaching 284, wherein the at least one sensor is for detecting the presence or absence of a particular molecule or substance in the external environment.
• 287. The method of teaching 284, wherein the at least one sensor is configured to detect the concentration of a particular molecule or substance in the external environment.
• 288. The method of teaching 266, wherein the at least one implantable drug delivery agent further comprises hardware, firmware, and / or software configured to control the at least one controllable delivery mechanism.
• 289. The method of teaching 288, wherein the at least one implantable drug delivery agent further comprises at least one control circuit configured to activate the at least one controllable delivery mechanism.
• 290. The method of teaching 289, wherein the at least one control circuit is configured to generate and transmit an electromagnetic control signal configured to control the at least one controllable output mechanism.
• 291. The method of teaching 290, wherein the at least one implantable drug delivery agent further comprises an electronic storage mechanism for storing instructions for generating and transmitting the electromagnetic control signal.
• 292. The method of clause 266, wherein the at least one implantable drug delivery agent further comprises at least one electronic storage location for recording information.
• 293. The method of teaching 292, wherein the at least one electronic storage location is configured to record information regarding a sensor, a counter, a remote control, or a timer.
• 294. The method of doctrine 292, wherein the at least one electronic storage location is configured to record information regarding at least one sensed condition, history, or property of the at least one implantable drug delivery agent.
• 295. The method of teaching 292, wherein the at least one electronic storage location is configured to record information regarding at least the date, time, and amount of drug delivered.
• 296. The method of teaching 292, wherein the at least one implantable drug delivery agent further comprises an information transfer mechanism configured to transfer information recorded at the at least one electronic storage location.
• 297. The method of clause 266, wherein the at least one controllable dispensing mechanism comprises a micropump.
• 298. The method of teaching 297, wherein the micropump is peristaltic.
• 299. The method of clause 266, wherein the at least one controllable dispensing mechanism comprises a MEMS agent or an NEMS agent.
• 300. The method of teaching 266, wherein the at least one controllable dispensing mechanism includes a one-way valve in communication with the at least one outlet of the at least one deformable reservoir.
• 301. The method of teaching 266, wherein the at least one controllable dispensing mechanism comprises at least one thermally, magnetically, electrically, or electromagnetically responsive material.
• 302. The method of clause 301, wherein the at least one thermally, magnetically, electrically, or electromagnetically responsive material is a hydrogel, polymer, ceramic, dielectric, metal, permanently magnetizable material, ferrofluid, ferromagnetic material, ferrimagnetic material , an iron-containing material, an iron-like material, a ferromagnetic material, a dielectric material, a ferroelectric material, a piezoelectric material, a diamagnetic material, a paramagnetic material, a metallic material, or an antiferromagnetic material.
• 303. The method of clause 301, wherein the at least one thermally, magnetically, electrically, or electromagnetically responsive material comprises a polymer, a ceramic, a dielectric, a ferrofluid, or a metal.
• 304. The method of clause 301, wherein the at least one thermally, magnetically, electrically or electromagnetically responsive material is responsive to a static or quasi-static electric field.
• 305. The method of clause 301, wherein the at least one thermally, magnetically, electrically, or electromagnetically responsive material is responsive to a non-ionizing electromagnetic signal.
• 306. The method of clause 301, wherein the at least one thermally, magnetically, electrically, or electromagnetically responsive material is responsive to an electromagnetic signal in the radio frequency range.
• 307. The method of clause 301, wherein the at least one thermally, magnetically, electrically, or electromagnetically responsive material is responsive to an electromagnetic microwave signal.
• 308. The method of clause 301, wherein the at least one thermally, magnetically, electrically, or electromagnetically responsive material is responsive to an optical signal.
• 309. The method of clause 301, wherein the at least one thermally, magnetically, electrically or electromagnetically responsive material is responsive to a millimeter wave electromagnetic signal.
• 310. The method of clause 301, wherein the at least one thermally, magnetically, electrically or electromagnetically responsive drug is responsive to an audible signal.
• 311. The method of clause 266, wherein the at least one controllable dispensing mechanism comprises a shape memory material.
• 312. The method of teaching 311, wherein the at least one controllable output responds to shape memory material to a control signal by changing its shape.
• 313. The method of clause 300, wherein the one-way valve opens or closes in response to a control signal.
• 314. The method of claim 266, further comprising at least one body structure to provide a demarcation between the at least one drug delivery agent and the surrounding in vivo tissue.
• 315. The method of teaching 314, wherein the at least one implantable drug delivery agent is adapted to be removed from the at least one body structure while the at least one body structure remains in vivo.
• 316. The method of teaching 314, wherein the at least one body structure is biodegraded in accordance with a time interval.
• 317. The method of teaching 314, wherein the at least one body structure is degradable by a biocompatible material.
• 318. The method of teaching 314, wherein the body structure is degradable for degradation in response to an external signal.
• 319. The method of claim 266, wherein the at least one implantable drug delivery agent comprises at least two deformable reservoirs.
• 320. The method of doctrine 319, wherein the at least two deformable reservoirs receive at least two drugs.
• 321. The method of clause 320, wherein the at least two drugs are reactants.
• 322. The method of clause 266, wherein the at least one implantable drug delivery agent further comprises at least one decontamination mechanism.
• 323. The method of clause 322, wherein the at least one decontamination mechanism includes the use of UV light or a chemical decontaminant.
• 324. The method of clause 266, wherein the at least one implantable drug delivery agent further comprises an energy storage mechanism.
• 325. The method of clause 266, wherein the at least one implantable drug delivery agent further comprises an energy absorbing mechanism.
• 326. The method of clause 266, wherein the at least one implantable drug delivery agent further comprises an energy producing mechanism.
• 327. The method of doctrine 266, wherein the at least one control signal is generated by at least one remote controller.
• 328. The method of teaching 327, wherein the at least one remote controller includes hardware, firmware and / or software configured to control the transmission of the at least one control signal.
• 329. The kit of clause 327, wherein the at least one remote control comprises hardware, firmware, and / or software configured to receive the transmission of information from the information transfer mechanism.
• 330. The kit of clause 329, wherein the at least one remote control further comprises a display mechanism for presenting the information to a person.
• 331. The method of clause 327, wherein the at least one control signal comprises instructions configured to program the at least one drug delivery agent.
• 332. The method of clause 327, wherein the at least one control signal is transmitted from the at least one remote controller following a schedule.
• 333. The method of gauge 266, wherein the at least one control signal is electromagnetic.
• 334. The method of doctrine 266, wherein the at least one control signal is infrared.
• 335. The method of doctrine 266, wherein the at least one control signal is magnetic.
• 336. The method of clause 266, wherein the at least one control signal is ultrasound.
• 337. The method of clause 266, wherein the at least one control signal is ultraviolet.
• 338. The method of teaching 266, wherein the at least one control signal is acoustic.
• 339. The method of doctrine 266, wherein the at least one control signal is optical.
• 340. The method of teaching 328, wherein the hardware, firmware, and / or software of the at least one remote controller includes a storage mechanism for storing instructions.
• 341. The method of teaching 340, wherein the storage mechanism is non-volatile.
• 342. The method of teaching 328, wherein the hardware, firmware, and / or software of the at least one remote control further comprises instructions for receiving one or control parameters.
• 343. The method of teaching 342, wherein the hardware, firmware and / or software of the at least one remote control further comprises instructions for generating the at least one control signal based on one or more control parameters.
• 344. The method of clause 328, wherein the hardware, firmware or software of the at least one remote control further comprises instructions for performing encryption of the at least one control signal.
• 345. The method of clause 32, wherein the hardware, firmware, and / or software of the at least one remote controller further commands to perform an authentication operation between the at least one remote controller and the at least one implantable drug delivery device.
• 346. The method of teaching 328, wherein the hardware, firmware, and / or software of the at least one remote control further commands to perform a query operation between the at least one remote controller and the at least one implantable drug delivery device.
• 347. The method of claim 266, wherein the at least one drug to be delivered comprises at least one therapeutic agent.
• 348. The method of teaching 347, wherein the at least one therapeutic agent comprises a therapeutically effective amount or concentration of at least one nutrient, nutraceutical, hormone, growth factor, an anti-infective agent, a medication, a therapeutic compound, an enzyme, a genetic material, a vaccine, vitamin, neurotransmitter, cytokine, cell-signaling agent, a pro- or anti-apoptotic agent, an imaging agent, a labeling agent, a diagnostic agent, a nanomaterial, an inhibitor or blocker, or a component thereof.
• 349. The method of claim 266, wherein the at least one drug to be delivered is a fluid.
• 350. The method of teaching 348, wherein the at least one therapeutic agent has an immunogenic amount of at least one vaccine.
• 351. The method of claim 350, wherein the at least one vaccine comprises at least one HIV-I vaccine.
• 352. The method of teaching 350, wherein the at least one vaccine comprises at least one measles vaccine.
• 353. The method of teaching 350, wherein the at least one vaccine comprises at least one influenza vaccine.
• 354. The method of teaching 350, wherein the at least one vaccine comprises at least one hepatitis vaccine.
• 355. The method of teaching 341, wherein the at least one HIV-I vaccine has a subunit of gp120.
• 356. The method of teaching 338, wherein the at least one therapeutic agent comprises a therapeutically effective amount of at least one anti-infective agent.
• 357. The method of teaching 356, wherein the at least one anti-infective agent comprises at least one anti-viral agent.
• 358. The method of claim 356, wherein the at least one anti-infective agent comprises at least one anti-microbial agent.
• 359. The method of teaching 348, wherein the at least one therapeutic agent comprises a therapeutically effective amount of at least one anti-neoplastic agent.
• 360. The method of teaching 357, wherein the at least one antiviral agent comprises at least one anti-HIV-1 active agent.
• 361. The method of teaching 360, wherein the anti-HIV-1 active agent of the group, the anti-viral protease, a viral fusion inhibitor, an integrase inhibitor, a reverse transcriptase inhibitor (either nucleotide or non-nucleotide), a pharmaceutically acceptable Derivative of these or a combination thereof is selected.
• 362. The method of teaching 348, wherein the at least one therapeutic agent comprises a therapeutically effective amount of at least one agent for the treatment of malaria.
• 363. The method of teaching 362, wherein the at least one antimalarial drug is selected from the group consisting of chloroquine, sulfadoxine pyrimethamine, mefloquine, atovaquine proguanil, quinine, doxycycline, artemisin derivatives, primaquine, a pharmaceutically acceptable salt thereof, or a combination thereof selected from this.
• 364. The method of teaching 348, wherein the at least one therapeutic agent comprises a therapeutically effective amount of at least one agent for the treatment of tuberculosis.
• 365. The method of teaching 348, wherein the at least one therapeutic agent comprises a therapeutically effective amount of at least one drug for the treatment of lishmaniasis.
• 366. The method of teaching 348, wherein the at least one therapeutic agent comprises a therapeutically effective amount of at least one drug for the treatment of cholera.
• 367. The method of teaching 348, wherein the at least one therapeutic agent comprises a therapeutically effective amount of at least one maser-treating agent.
• 368. The method of teaching 348, wherein the at least one therapeutic agent comprises a therapeutically effective amount of at least one drug for the treatment of diphtheria.
• 369. The method of teaching 348, wherein the at least one therapeutic agent comprises a therapeutically effective amount of at least one drug for the treatment of cancer.
• 370. The method of teaching 348, wherein the at least one therapeutic agent comprises a therapeutically effective amount of at least one agent for the treatment of an autoimmune disease.
• 371. The method of teaching 348, wherein the at least one therapeutic agent comprises a therapeutically effective amount of at least one drug for the treatment of hepatitis C.
• 372. The method of teaching 348, wherein the at least one therapeutic agent comprises a therapeutically effective amount of pegylated interferon alpha-2a, ribavirin, telaprevir, a pharmaceutically acceptable salt thereof, or combinations thereof.
• 373. The method of teaching 348, wherein the at least one therapeutic agent comprises an immunogenically effective amount of at least one vaccine adjuvant.
• 374. The method of teaching 348, wherein the at least one therapeutic agent comprises a therapeutically effective amount of at least one drug-inducing agent.
• 375. The method of teaching 266, wherein the animal is a mammal.
• 376. The method of teaching 375, wherein the mammal is a livestock.
• 377. The method of teaching 375, wherein the mammal is a human.
• 378. The method of teaching 375, wherein the mammal is a pet.
• 379. The method of doctrine 266, wherein the at least one drug delivery agent is injected into the human or animal.
• 380. The method of teaching 266, further comprising the step of removing the at least one drug from the at least one drug delivery agent in vivo.
• 381. A method of administering at least one therapeutic agent to a human or animal, comprising: introducing an agent delivery agent into an in vivo environment of a human or animal; wherein the drug delivery agent is provided with at least one deformable reservoir configured to receive, accomodate, and deliver at least one active agent having at least one outlet through which the at least one active agent may exit the at least one deformable reservoir; and at least one controllable dispensing mechanism operatively connected to the at least one outlet for controlling application of the at least one portion of the at least one active agent from the at least one deformable reservoir; and transmitting an electromagnetic control signal to cause the at least one controllable dispensing mechanism to release a portion of the at least one therapeutic agent from the at least one deformable reservoir sufficiently.
• 382. A method of applying a drug to a human or animal, comprising: defining a deformable drug reservoir in the human or animal; Introducing an amount of the drug into the deformable drug reservoir by injection and effecting selectable control of drug release from the deformable drug reservoir.

Even though certain aspects of the subject matter shown here and It will be understood by those skilled in the art based on these teachings that changes and modifications can be performed without departing from here and its broader aspects. The appended claims include all within their scope such changes and modifications within the true scope and thought of the subject matter described herein. It is further understood that the invention is covered by the attached Claims is defined.

It is understood by those skilled in the art that here and in particular used in the appended claims in general terms be understood as "open" terms (for example, the term "having" should be interpreted are considered "having, but not limited to," the term "with" should be interpreted as "at least with", the term "includes" interprets should be included, but not limited on ", etc.). It goes without saying for the skilled person that if a specified number of a specified Conclusion referral such an intention explicitly in has been specified in the claim, and in the absence of such Back reference no such intention exists. For example may help to understand the following claims, the use of introductory phrases the "at least a "or" one or more "for insertion the claim backlogs. The use of such However, phrases should not be understood to implicate that the introduction of the claim back the indefinite articles "a" a certain one Claim limited to the listed backlogs, to inventions involving only such a relationship, even if the same claim is the introductory question or more "or" at least one "or has an indefinite article, the same applies to the use of certain articles used for insertion a claim backlog. Next should, though a specific number of claim backlinks expressly is given, the skilled artisan recognize that such a reference typically interpreted as at least the specified Number. Further, in cases where a phrase such as "at least one of A, B and C "," at least one of A, B or C "or" a [point] starts from the group consisting of A, B and C "is used, in general Such a construction is meant in the sense that the skilled person the convention understands (for example, each of these could State phrases, but not be limited to systems that A alone, B alone, C alone, A and B together, A and C together, B and C together or A; B and C together). It goes on for a person skilled in the art, that each connection word or each Phrase that specifies two or more alternative expressions whether in the description, in the claims and in the drawings, understands itself as possibilities of inclusion one of these expressions, including one of these Concepts, the other of concepts or both. The phrase "A or B "understands that it's the possibilities as well from "A" or "B" or "A and B ".

Even though here various aspects and embodiments disclosed Other aspects will be apparent to those skilled in the art and embodiments. The different aspects and Embodiments as described herein dionen the illustration and are not intended to be limiting, the true scope of protection and the basic idea emerge from the following claims.

SUMMARY

embodiment a drug delivery agent having a deformable reservoir and an associated controllable dispensing mechanism described. Method of use and control of the agent will be further disclosed. According to some embodiments can be a drug delivery agent in a human or a Animal be placed to at least one active ingredient in humans or to deliver the animal controllably. The drug delivery agent can provide a programmable mechanism for controlling the delivery of the Contain material in humans or the animal. At selected Embodiments may use a remote control are used to program or control the drug delivery agent. Some embodiments will be described in which a magnetic field, an electric field or an electromagnetic Control signal can be used.

QUOTES INCLUDE IN THE DESCRIPTION

This list The documents listed by the applicant have been automated generated and is solely for better information recorded by the reader. The list is not part of the German Patent or utility model application. The DPMA takes over no liability for any errors or omissions.

Cited patent literature

• - US 6615074 [0003]
• - US 6655035 [0003]
• - US 6768246 [0003]
• US 2004/0182704 [0082]
• - US 6663821 [0082]
• US 6607553 [0083]
• US 2004/0106914 [0085]
• US 2004/0015154 [0085]
• - US 6935165 [0090, 0125]
• US 2004/0007051 [0090, 0125]
• US 2005/0208469 [0090, 0125]
• US 6146103 [0109]
• - US 6802489 [0109]
• - US 4834704 [0145, 0145]

Cited non-patent literature

• "Liver-Targeted Drug Delivery Using HepDirect® Prodrugs," Erion et al., Journal of Pharmacology and Experimental Therapeutics Fast Forward, JPET 312: 554-560, 2005 (claiming a date of first publication of Aug. 31, 2004) [0055]
• - "LEAPT: lectin-directed enzyme activated prodrug therapy", Robinson et al., PNAS October 5, 2004 vol. 101, No. 40, 14527-14532 [0055]
• - http://www.pnas.org/cgi/content/full/101/40/14527 [0055]
• - ISA-51 [0063]
• - ISA-720 [0063]
• Low, L., Seetharaman, S., He, K., Madou, MJ, 2000, "Microactuators Towards Microvalves for Responsive Controlled Drug Delivery", Sens. Actuators B 67, 149-160 [0082]
• "Responsive Drug Delivery Systems" Sapna Deo, Patricia Eisenhardt, Elizabeth Moschou, Serban Peteu, Leonidas Bachas, Marc Madou, Sylvia Daunert, Analytical Chemistry, 2003, 75 (9) 206A-213A [0082]
• Madou, MJ, Florkey, J., 2000, "From batch to continuous manufacturing of microbiomedical agent", Chem. Rev. 100, 2679-2692; [0082]
• - Beebe, DJ, Moore, JS, Bauer, JM, Vu, Q., Liu, RH, Devadoss, C, Jo, B., 2000, "Functional hydrogel structures for autonomous flow control inside microfluidic channels", Nature 404, 588 -590 [0082]
• - Neto, et al, "Optical, Magnetic and Dielectric Properties of Non-Liquid Crystalline Elastomers Doped with Magnetic Colloids"; Brazilian Journal of Physics; which bears the date of March 2005; Pp. 184-189; Volume 35, Number 1 [0083]
• Agarwal et al., "Magnetic-driven temperature-controlled microfluidic actuators"; Pp. 1-5 [0083]
• - _papers / OralPresentations / C2.pdf [0083]
• "Easy-to-Hake Nano Sensors: Tiny electron-based detectors could provide simple tests for cancer or bioterror drugs." By Kevin Bullis [0090]
• - http: //www.technologyreview.eom/Nanotech/18127/ [0090]
• Gruner, G., "Carbon Nanotube Transistors for Biosensing Applications"; Anal. Bioanal. Chem. (2006) 384: 322-335 [0090]
• - Gabriel, JC, Mat. Res. Soc. Symp. Proc, (2003) Vol. 776, Q.12.7.1-12.7.7 [0090]
• - tools and techniques as the expert from Electrodynamics of Continuous Media, 2nd Edition, by LD Landau, EM Lifshitz and LP Pitaevskii, Elsevier Butterworth-Heinemann, Oxford, particularly but not exclusively S. 1-13- and 199-222 [ 0098]
• - The ARRL Handbook for Radio Communications 2006, R. Dean Straw, Editor, published by ARRL, Newington, CT. [0099]
• Krauss et al., "Fluid pumped by magnetic stress", which bears the date of 1 July 2004, pp. 1-3 [0109]
• - http://arxiv.org/PS_cache/physics/pdf/0405/0405025.pdf [0109]
• - "Easy-to-Hake Nano Sensors: Tiny electron-based detectors could provide simple tests for cancer or bioterror drugs." By Kevin Bullis [0125]
• - http://www.technologyreview.com/Nanotech/18127/ [0125]
• Gruner, G., "Carbon Nanotube Transistors for Biosensing Applications"; Anal. Bioanal. Chem. (2006) 384: 322-335 [0125]
• - Gabriel, JC, Mat. Res. Soc. Symp. Proc, (2003) Vol. 776, Q.12.7.1-12.7.7 [0125]

Claims (62)

An implantable in a human or animal Drug delivery device, with at least one deformable Reservoir for recording, storing and dispensing at least an active ingredient is formed, with at least one outlet, through the at least one active ingredient of the at least one deformable Reservoir can escape; and at least one controllable output mechanism, operatively associated with the at least one outlet for controlling the delivery the at least part of the at least one active substance from the at least one deformable reservoir is connected. The device of claim 1 configured for injection into a human or an animal. The device of claim 1 or claim 2, wherein the at least one deformable reservoir further at least an inlet mechanism for receiving one from outside supplied drug after insertion of the device in the human or the animal. The device according to one of the preceding claims, continue with an RPID circuit. The device according to one of the preceding claims, where the human or the animal is a human. The device according to one of the preceding claims, further with at least one sensor, at least one timer, at least one counter. The apparatus of claim 6, wherein the at least a controllable dispensing mechanism on the at least one sensor, the at least one timer, the at least one counter or the at least one remote control responds. The device according to claim 6 or claim 7, wherein the at least one sensor on the at least one drug delivery device is arranged. The apparatus of claim 6, wherein the at least a sensor for detecting the amount of the at least one active substance in which at least one deformable reservoir is configured. The device according to one of the preceding claims, Continue with any hardware, firmware or software required for control the at least one controllable output mechanism is configured. The device according to one of the preceding claims, with at least one control circuit for activating the at least a controllable output mechanism is configured. The device according to one of the preceding claims, further with at least one storage location for recording information. The apparatus of claim 12, wherein the at least one a storage location for recording information regarding at least of the sensor, counter, remote control or timer is configured. The device according to one of the preceding claims, wherein the at least one controllable output mechanism is a MEMS Device or a NEMS device. The device according to one of the preceding claims, wherein the at least one controllable dispensing mechanism is at least a thermally, magnetically, electrically or electromagnetically appealing Material has. A drug delivery system with at least one device according to one of the preceding claims and at least one Remote control for generating and transmitting at least a control signal to the at least one drug delivery device is formed. The system of claim 16, wherein said at least an output mechanism to which at least one remote control responds. The system of claim 16 or 17, wherein the at least a remote control at least one hardware, firmware or software having to control the transmission of at least a control signal is formed. The system according to any one of claims 16 to 18, wherein the at least one control signal includes instructions that for programming the at least one drug delivery device are configured. A drug delivery kit with at least one Insertion mechanism and at least one device after one of claims 1 to 14. The kit of claim 20, further comprising at least a remote control for generating and transmitting at least a control signal to the at least one implantable drug delivery device is configured. The kit of claim 21, wherein the at least one remote control comprises hardware, firmware, and / or software necessary for controlling the Transmission of the at least one control signal is formed. The kit according to any one of claims 20 to 22, further with at least one active ingredient to be administered. The kit of claim 23, wherein said at least one the active substance to be applied is a fluid. The kit of claim 23 or claim 24 wherein the at least one active substance to be administered at least a therapeutic Means is. The kit of claim 25, wherein said at least one therapeutic agent is an immunogenic amount of at least one vaccine having. The kit of claim 25 or 26, wherein said at least a therapeutic agent is a therapeutically effective amount at least an anti-infective agent. The kit of claim 27, wherein the at least one anti-infective agent at least one anti-viral Active substance. The kit of claim 27 or 28, wherein said at least an anti-infective agent at least one anti-microbial Active substance. The kit according to any one of claims 25 to 29, wherein the at least one therapeutic agent is a therapeutic effective amount of at least one agent for the treatment of malaria having. The kit according to any one of claims 25 to 29, wherein the at least one therapeutic agent is a therapeutic effective amount of at least one tuberculosis treatment agent having. The kit according to any one of claims 25 to 29, wherein the at least one therapeutic agent is a therapeutic effective amount of at least one agent for the treatment of leishmaniasis having. The kit according to any one of claims 25 to 29, wherein the at least one therapeutic agent is a therapeutic effective amount of at least one agent for the treatment of cholera having. The kit according to any one of claims 25 to 29, wherein the at least one therapeutic agent is a therapeutic effective amount of at least one agent for the treatment of diphtheria having. The kit according to any one of claims 20 to 34, wherein the at least one delivery mechanism is a syringe is. A method for feeding at least one Active substance to a human or animal, with: introducing at least a drug delivery device in an in vivo environment of the human or the animal, wherein the at least one drug delivery device at least one deformable reservoir for holding, storing and controlled dispensing of the at least one active ingredient is and at least one outlet and at least one controllable Dispensing mechanism operative with the at least one outlet connected is; and supplying an amount of the at least an agent in the at least one deformable reservoir; wherein the at least one controllable dispensing mechanism comprises the at least one Delivers active substance in response to the at least one control signal, having. The method of claim 36, wherein the introducing injecting at least one drug delivery device into an in vivo environment in the human or animal. The method of claim 6 or claim 37, wherein the at least one deformable reservoir further at least an inlet mechanism for receiving one from outside having supplied active ingredient. The method of claim 36 or 37, wherein said at least one drug delivery device an RFID circuit having. The method according to one of the claims 36 to 40, wherein the human or the animal is a human. The method according to one of the claims 36 to 40, wherein the at least one drug delivery device at least one sensor, at least one timer or has at least one counter. The method according to one of the claims 36 to 41, wherein the at least one sensor on the at least one Active substance application device is arranged. The method according to one of the claims 36 to 43, wherein the at least one sensor for detecting at least a parameter of the at least one active substance in the at least a deformable reservoir is formed. The method of any one of claims 36 to 43, wherein the at least one implantable drug delivery device further comprises hardware, firmware, and / or software useful for controlling NEN of at least one controllable output mechanism is formed. The method according to one of the claims 36 to 44, wherein the at least one implantable drug delivery device at least one electronic storage location for recording of information. The method according to one of the claims 36-45, wherein the at least one controllable dispensing mechanism a MEMS device or a NEMS device. The method according to one of the claims 36-46, wherein the at least one controllable dispensing mechanism at least one thermal, magnetic, electrical or electromagnetic has attractive material. The method according to one of the claims 36 to 47, wherein the at least one control signal of the least a remote control is provided. The method of claim 48, wherein the at least a remote control has hardware, firmware and / or software, for controlling the transmission of the at least one Control signal is formed. The method according to one of the claims 36 to 49, wherein the at least one active ingredient is a fluid. The method according to one of the claims 36 to 50, wherein the at least one drug to be supplied at least one therapeutic agent. The method of claim 51, wherein the at least a therapeutic agent comprises an immunogenic amount of at least one Having vaccine. The method of claim 51, wherein the at least a therapeutic agent is a therapeutically effective amount has at least one anti-infective agent. The method of claim 53, wherein the at least an anti-inactive agent at least one anti-viral Having means. The method of claim 55, wherein the at least an anti-infective agent at least one anti-microbial Having means. The method of claim 53, wherein the at least a therapeutic agent is a therapeutically effective amount at least one agent for the treatment of malaria. The method of claim 53, wherein the at least a therapeutic agent includes a therapeutically effective An amount of at least one agent for treating tuberculosis. The method of claim 53, wherein the at least a therapeutic agent is a therapeutically effective amount of at least one agent for the treatment of leishmaniasis. The method of claim 53, wherein the at least a therapeutic agent is a therapeutically effective amount of at least one means of treating cholera. The method according to one of the claims 36-59, wherein the animal is a mammal. A method according to any one of the claims 36 to 60, with transmission of an electromagnetic control signal, that is sufficient to provide the at least one controllable dispensing mechanism to cause part of the at least one therapeutic Release drug from the at least one deformable reservoir. A method for delivering a drug a human or animal, comprising: defining a deformable drug reservoir in the human or the animal; Introducing an amount of the active ingredient into the deformable drug reservoir by injection and effect a selectable control of the release of the drug from the deformable drug reservoir.